Tumors or cancer of the LUNG.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A malignant epithelial tumor with a glandular organization.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A cell line derived from cultured tumor cells.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
Quinazolines are heterocyclic aromatic organic compounds consisting of a benzene ring fused to a pyrazine ring, which are synthesized and used as intermediates in pharmaceuticals, particularly in the production of various drugs such as antimalarials, antihypertensives, and antitumor agents.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Neuropeptide and gut hormone that helps regulate GASTRIC ACID secretion and motor function. Once released from nerves in the antrum of the STOMACH, the neuropeptide stimulates release of GASTRIN from the GASTRIN-SECRETING CELLS.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
Pathological processes involving any part of the LUNG.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A tetradecapeptide originally obtained from the skins of toads Bombina bombina and B. variegata. It is also an endogenous neurotransmitter in many animals including mammals. Bombesin affects vascular and other smooth muscle, gastric secretion, and renal circulation and function.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Tumors or cancer of the LIVER.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Cell surface proteins that bind bombesin or closely related peptides with high affinity and trigger intracellular changes influencing the behavior of cells. Gastrin- releasing peptide (GRP); GRP 18-27 (neuromedin C), and neuromedin B are endogenous ligands of bombesin receptors in mammals.
DNA present in neoplastic tissue.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.
Antibodies produced by a single clone of cells.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Transplantation between animals of different species.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
The excision of lung tissue including partial or total lung lobectomy.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
An organoplatinum compound that possesses antineoplastic activity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
The transference of either one or both of the lungs from one human or animal to another.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Tumors or cancer of the BRONCHI.
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
Established cell cultures that have the potential to propagate indefinitely.
Elements of limited time intervals, contributing to particular results or situations.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of DOPA to DOPAMINE. It is of clinical importance in the treatment of Parkinson's disease.
An autoimmune disease characterized by weakness and fatigability of proximal muscles, particularly of the pelvic girdle, lower extremities, trunk, and shoulder girdle. There is relative sparing of extraocular and bulbar muscles. CARCINOMA, SMALL CELL of the lung is a frequently associated condition, although other malignancies and autoimmune diseases may be associated. Muscular weakness results from impaired impulse transmission at the NEUROMUSCULAR JUNCTION. Presynaptic calcium channel dysfunction leads to a reduced amount of acetylcholine being released in response to stimulation of the nerve. (From Adams et al., Principles of Neurology, 6th ed, pp 1471)
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Tumors or cancer of the human BREAST.
RNA present in neoplastic tissue.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
A group of acidic proteins that are major components of SECRETORY GRANULES in the endocrine and neuroendocrine cells. They play important roles in the aggregation, packaging, sorting, and processing of secretory protein prior to secretion. They are cleaved to release biologically active peptides. There are various types of granins, usually classified by their sources.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
A type I keratin found associated with KERATIN-7 in ductal epithelia and gastrointestinal epithelia.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
Tumors or cancer of the THYROID GLAND.
A sarcoma characterized by the presence of small cells, cells measuring 9-14 micrometers with a faint or indistinct rim of cytoplasm and an oval-to-elongated nucleus with relatively dense chromatin. (From Segen, Dictionary of Modern Medicine, 1992)
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
Tumors or cancer of the ESOPHAGUS.
Inbred BALB/c mice are a strain of laboratory mice that have been selectively bred to be genetically identical to each other, making them useful for scientific research and experiments due to their consistent genetic background and predictable responses to various stimuli or treatments.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Tumors or cancer of the NASOPHARYNX.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
A type of chromogranin which was first isolated from CHROMAFFIN CELLS of the ADRENAL MEDULLA but is also found in other tissues and in many species including human, bovine, rat, mouse, and others. It is an acidic protein with 431 to 445 amino acid residues. It contains fragments that inhibit vasoconstriction or release of hormones and neurotransmitter, while other fragments exert antimicrobial actions.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Agents that inhibit PROTEIN KINASES.
Cerebellar degeneration associated with a remote neoplasm. Clinical manifestations include progressive limb and GAIT ATAXIA; DYSARTHRIA; and NYSTAGMUS, PATHOLOGIC. The histologic type of the associated neoplasm is usually carcinoma or lymphoma. Pathologically the cerebellar cortex and subcortical nuclei demonstrate diffuse degenerative changes. Anti-Purkinje cell antibodies (anti-Yo) are found in the serum of approximately 50% of affected individuals. (Adams et al., Principles of Neurology, 6th ed, p686)
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the URINARY BLADDER.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
A condition of HYPONATREMIA and renal salt loss attributed to overexpansion of BODY FLUIDS resulting from sustained release of ANTIDIURETIC HORMONES which stimulates renal resorption of water. It is characterized by normal KIDNEY function, high urine OSMOLALITY, low serum osmolality, and neurological dysfunction. Etiologies include ADH-producing neoplasms, injuries or diseases involving the HYPOTHALAMUS, the PITUITARY GLAND, and the LUNG. This syndrome can also be drug-induced.
A system of NEURONS that has the specialized function to produce and secrete HORMONES, and that constitutes, in whole or in part, an ENDOCRINE SYSTEM or organ.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Inhaling and exhaling the smoke of burning TOBACCO.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
A MARVEL domain-containing protein found in the presynaptic vesicles of NEURONS and NEUROENDOCRINE CELLS. It is commonly used as an immunocytochemical marker for neuroendocrine differentiation.
Specialized NEURONS that produce hormones, such as NEUROPEPTIDES or BIOGENIC AMINES. They generally are in the NERVOUS SYSTEM, such as HYPOTHALAMUS, but can be found in other organs or systems. These neurons contain dense neurosecretory granules and PROPROTEIN CONVERTASES allowing the rapidly release of NEUROHORMONES into the blood circulation upon stimulation.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
The action of a drug in promoting or enhancing the effectiveness of another drug.
Endoscopic examination, therapy or surgery of the bronchi.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
Family of retrovirus-associated DNA sequences (myc) originally isolated from an avian myelocytomatosis virus. The proto-oncogene myc (c-myc) codes for a nuclear protein which is involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Truncation of the first exon, which appears to regulate c-myc expression, is crucial for tumorigenicity. The human c-myc gene is located at 8q24 on the long arm of chromosome 8.
A carcinoma thought to be derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
Biochemical identification of mutational changes in a nucleotide sequence.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
Tumors or cancer of the SKIN.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Deoxycytidine is a nucleoside consisting of the pentose sugar deoxyribose linked to the nitrogenous base cytosine, which plays a crucial role in DNA replication and repair processes within cells.
Treatment that combines chemotherapy with radiotherapy.
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Degenerative or inflammatory conditions affecting the central or peripheral nervous system that develop in association with a systemic neoplasm without direct invasion by tumor. They may be associated with circulating antibodies that react with the affected neural tissue. (Intern Med 1996 Dec;35(12):925-9)
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
A diffuse or multifocal peripheral neuropathy related to the remote effects of a neoplasm, most often carcinoma or lymphoma. Pathologically, there are inflammatory changes in peripheral nerves. The most common clinical presentation is a symmetric distal mixed sensorimotor polyneuropathy. (Adams et al., Principles of Neurology, 6th ed, p1334)
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Tumors or cancer of the COLON.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
Cells with the capacity to take up and decarboxylate the amine precursors DIHYDROXYPHENYLALANINE or 5-HYDROXYTRYPTOPHAN. This is a property of endocrine cells of neural and non-neural origin. APUDOMA is a general term collectively applied to tumors associated with APUD cells.
The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI.
A mixture of six synthetic oligopeptides, each containing MELPHALAN. It is used as a broad-spectrum antineoplastic due to its alkylating and antimetabolic actions but, is toxic to bone marrow, gastrointestinal system and vasculature.
Tumors or cancer of the STOMACH.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
Leukopenia is a condition characterized by an abnormally low white blood cell count (less than 4,000 cells per microliter of blood) in peripheral blood, increasing the risk of infection due to decreased immune defense.
Tumors or cancer of the MOUTH.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Actual loss of portion of a chromosome.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Measurement of the amount of air that the lungs may contain at various points in the respiratory cycle.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
A paraneoplastic syndrome marked by degeneration of neurons in the LIMBIC SYSTEM. Clinical features include HALLUCINATIONS, loss of EPISODIC MEMORY; ANOSMIA; AGEUSIA; TEMPORAL LOBE EPILEPSY; DEMENTIA; and affective disturbance (depression). Circulating anti-neuronal antibodies (e.g., anti-Hu; anti-Yo; anti-Ri; and anti-Ma2) and small cell lung carcinomas or testicular carcinoma are frequently associated with this syndrome.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)

Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. (1/7523)

The association of p53 abnormalities with the prognosis of patients with non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial. Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC. p53 mutations were detected in 49 of 103 (48%) tumors. Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5-8. Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression was only 69%. p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P<0.001). Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P=0.243 in null mutations). These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.  (+info)

Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. (2/7523)

OBJECTIVE: To determine the sensitivity, specificity, and accuracy of positron emission tomography with 2-fluorine-18-fluorodeoxyglucose (PET-FDG) in the preoperative staging (N and M staging) of patients with lung cancer. The authors wanted to compare the efficacy of PET scanning with currently used computed tomography (CT) scanning. MATERIALS AND METHODS: Results of whole-body PET-FDG imaging and CT scans were compared with histologic findings for the presence or absence of lymph node disease or metastatic sites. Sampling of mediastinal lymph nodes was performed using mediastinoscopy or thoracotomy. RESULTS: PET-FDG imaging was significantly more sensitive, specific, and accurate for detecting N disease than CT. PET changed N staging in 35% and M staging in 11% of patients. CT scans helped in accurate anatomic localization of 6/57 PET lymph node abnormalities. CONCLUSION: PET-FDG is a reliable method for preoperative staging of patients with lung cancer and would help to optimize management of these patients. Accurate lymph node staging of lung cancer may be ideally performed by simultaneous review of PET and CT scans.  (+info)

Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. (3/7523)

Tissue factor (TF) is an initiator of the extrinsic cascade of blood coagulation. Although recent studies have revealed a relationship between metastatic properties and TF expression in some neoplastic cells, the significance of TF in lung cancer, especially in non-small-cell lung cancer (NSCLC), is still unclear. In this study, TF was detected in NSCLC cell lines by functional study, Western blot analysis and immunocytochemical staining. TF levels in eight NSCLC cell lines were also quantitated by enzyme-linked immunosorbent assay (ELISA), and TF expression was evaluated in 55 specimens of surgically resected NSCLCs. NSCLC cell lines derived from metastatic lesions produced high levels of TF (48.3+/-23.5 ng 10(-6) cells, mean +/- s.e.m.), whereas those derived from primary lesions produced low levels of TF (0.2+/-0.1 ng 10(-6) cells). Immunohistochemical studies disclosed significantly stronger staining for TF in cells from NSCLC patients with metastasis than in those without metastasis. Among the 28 patients with metastasis, ten were strongly positive, 16 were moderately positive and two were negative for TF. In contrast, among the 27 patients without metastasis, only two were strongly positive, 18 were moderately positive and seven were negative for TF. Therefore, malignant cells from patients with lung cancer produce various levels of TF, and TF may play an important role in the metastatic process.  (+info)

Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast. (4/7523)

Lung cancer is now the number one cause of cancer death for both men and women. An age-adjusted analysis over the past 25 years shows that in women specifically, lung cancer incidence is on the rise. It is estimated that 10-20 genetic events including the alteration of oncogenes and tumor suppressor genes will have occurred by the time a lung tumor becomes clinically evident. In an effort to identify regions containing novel cancer genes, chromosome 18p11, a band not previously implicated in disease, was examined for loss of heterozygosity (LOH). In this study, 50 matched normal and NSCLC tumor samples were examined using six 18p11 and one 18q12.3 PCR-based polymorphic markers. In addition, LOH was examined in 29 glioblastoma pairs and 14 paired breast carcinomas. This analysis has revealed potentially two regions of LOH in 18p11 in up to 38% of the tumor samples examined. The regions of LOH identified included a 2 cm area between markers D18S59 and D18S476, and a more proximal, 25 cm region of intermediate frequency between D18S452 and D18S453. These results provide evidence for the presence of one or more potential tumor suppressor genes on the short arm of chromosome 18 which may be involved in NSCLC, brain tumors and possibly breast carcinomas as well.  (+info)

Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. (5/7523)

BACKGROUND: Conventional cytologic analysis of sputum is an insensitive test for the diagnosis of non-small-cell lung cancer (NSCLC). We have recently demonstrated that polymerase chain reaction (PCR)-based molecular methods are more sensitive than cytologic analysis in diagnosing bladder cancer. In this study, we examined whether molecular assays could identify cancer cells in bronchoalveolar lavage (BAL) fluid. METHODS: Tumor-specific oncogene mutations, CpG-island methylation status, and microsatellite alterations in the DNA of cells in BAL fluid from 50 consecutive patients with resectable (stages I through IIIa) NSCLC were assessed by use of four PCR-based techniques. RESULTS: Of 50 tumors, 28 contained a p53 mutation, and the identical mutation was detected with a plaque hybridization assay in the BAL fluid of 39% (11 of 28) of the corresponding patients. Eight of 19 adenocarcinomas contained a K-ras mutation, and the identical mutation was detected with a mutation ligation assay in the BAL fluid of 50% (four of eight) of the corresponding patients. The p16 gene was methylated in 19 of 50 tumors, and methylated p16 alleles were detected in the BAL fluid of 63% (12 of 19) of the corresponding patients. Microsatellite instability in at least one marker was detected with a panel of 15 markers frequently altered in NSCLC in 23 of 50 tumors; the identical alteration was detected in the BAL fluid of 14% (three of 22) of the corresponding patients. When all four techniques were used, mutations or microsatellite instability was detected in the paired BAL fluid of 23 (53%) of the 43 patients with tumors carrying a genetic alteration. CONCLUSION: Although still limited by sensitivity, molecular diagnostic strategies can detect the presence of neoplastic cells in the proximal airway of patients with surgically resectable NSCLC.  (+info)

Trimodality therapy in stage III non-small cell lung cancer: prediction of recurrence by assessment of p185neu. (6/7523)

In a trimodality treatment approach for stage III non-small cell lung cancer the prognostic impact of pretherapeutic p185neu assessment was evaluated. Fifty-four patients were admitted to chemotherapy followed by twice-daily radiation with concomittant low-dose chemotherapy and subsequent surgery. Immunohistochemical assessment of p185neu expression was performed in paraffin-embedded mediastinal lymph node metastases, by mediastinoscopy biopsy prior to therapy. Paraffin-embedded biopsies of mediastinal lymph node metastases were available in 33 cases. Seven out of eight patients with positive p185neu staining developed distant metastases, in contrast to seven out of 25 negative cases. Expression of p185neu in mediastinal lymph node metastases was a significant predictor for progression-free survival (p=0.047) and resulted mainly from significant differences in metastases-free survival (p185neu-positive versus p185neu-negative: median, 11 versus 19 months; 2- and 3-yr rates, 13% and 0% versus 40% and 32%; p=0.04). On the basis of these preliminary results it was concluded that further evaluation of p185neu expression in trials on neoadjuvant and adjuvant therapy is warranted. When the prognostic impact of p185neu in such trials with larger patient numbers is confirmed, this may contribute to the identification of stratification variables for future treatment approaches of non-small cell lung cancer.  (+info)

Combined modality therapy of lung cancer. (7/7523)

Combined modality therapy for lung cancer was first demonstrated to be successful in limited-stage small cell lung cancer. Concurrent administration of chemotherapy with chest and elective brain irradiation appears to produce the best results, with cisplatin/etoposide as the core chemotherapy. Using such programs, 2-year survival in the 40% range and 5-year survivals in excess of 20% may be expected, based on the results of multiple studies. Attempts to improve on these results through the use of altered schemes of chest irradiation or the delivery of high-dose consolidation chemotherapy are ongoing but to date have not been shown to affect survival significantly. We remain at a plateau in the effectiveness of combined modality therapy for small cell lung cancer, with little evidence that it impacts survival at all in extensive-stage disease. The incorporation of new agents in combination chemotherapy regimens, more "specific" immunotherapy directed at tumor-associated antigens, and the potential adjunctive use of broad-spectrum neuropeptide antagonists offer promise for the future. In non-small cell lung cancer, the sequential use of platinum-based chemotherapy and chest irradiation appears superior in survival to standard, daily fractionated radiation therapy used alone, with long-term survival increased from 5-10% to 15-20%. Concurrent administration of chemotherapy with cisplatin/etoposide and chest irradiation produces 2-year survival in the range of 30%, about twice that would be expected for radiation therapy alone, but has not been compared to it in the setting of a randomized trial. Low-dose cisplatin on a daily basis has been combined as a "sensitizer" with chest irradiation, producing initial results that appeared encouraging. However, these have not been reproduced in subsequent, randomized trials. Another approach to combined modalities has been to give chemotherapy or chemotherapy/radiation therapy as induction, followed by surgical resection, with or without subsequent additional treatment. Most patients (80-85%) can be resected, with encouraging survival at 2 and 3 years in the Southwest Oncology Group experience (37 and 26%, respectively). However, toxicity is greater, and such an approach is associated with an overall mortality risk in the range of 10%. A current intergroup study attempts to define the role of surgery in this setting. The major recent development that is likely to influence the future of combined modality therapy for this disease is the advent of multiple new chemotherapeutic agents, such as the taxanes, gemcitabine, vinorelbine, and the topoisomerase-I inhibitors, which have activity in stage IV disease. The immediate challenge is how to combine these agents with platinum analogues, radiation, and surgery. Aiding this process may be the use of molecular biological "markers" that may predict the chance of success or failure with a given systemic agent. The next decade is likely to see substantial improvements in the outcome of treatment for patients with stages I-III non-small cell lung cancer, based on the systemic exploration of combined modalities.  (+info)

The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study. (8/7523)

AIMS: To investigate the expression of beta-catenin in non-small-cell lung cancer (NSCLC) and its clinical significance. METHODS: 101 patients were surgically treated for NSCLC by lobectomy or pneumectomy with systematic lymph node dissection. Follow up was available in all patients, ranging from 24 to 110 months. Immunostaining of tissue sections from primary tumours and (when present) their lymph node metastases was performed and evaluated using a monoclonal antibody against beta-catenin. Correlations were investigated between beta-catenin immunostaining in primary tumours and E-cadherin immunostaining (data available from a previous study), lymph node stage, and survival. RESULTS: There were significant correlations between scores for beta-catenin immunostaining and E-cadherin immunostaining in primary tumours (p = 0.007), and between the beta-catenin immunostaining score in primary tumours and in their lymph node metastases (p = 0.006). An inverse correlation was found between the beta-catenin immunostaining score in primary tumours and lymph node stage N0, N1, or N2 (p = 0.03). According to the Kaplan-Meier survival estimate, the level of beta-catenin expression in primary tumours was a statistically significant prognostic factor (p = 0.01). CONCLUSIONS: Reduced beta-catenin expression in surgically treated NSCLC is clearly associated with lymph node metastasis and an infavourable prognosis. The existence of a functional relation between E-cadherin and beta-catenin is supported by the results of this clinicopathological study.  (+info)

Lung neoplasms refer to abnormal growths or tumors in the lung tissue. These tumors can be benign (non-cancerous) or malignant (cancerous). Malignant lung neoplasms are further classified into two main types: small cell lung carcinoma and non-small cell lung carcinoma. Lung neoplasms can cause symptoms such as cough, chest pain, shortness of breath, and weight loss. They are often caused by smoking or exposure to secondhand smoke, but can also occur due to genetic factors, radiation exposure, and other environmental carcinogens. Early detection and treatment of lung neoplasms is crucial for improving outcomes and survival rates.

Carcinoma, non-small-cell lung (NSCLC) is a type of lung cancer that includes several subtypes of malignant tumors arising from the epithelial cells of the lung. These subtypes are classified based on the appearance of the cancer cells under a microscope and include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC accounts for about 85% of all lung cancers and tends to grow and spread more slowly than small-cell lung cancer (SCLC).

NSCLC is often asymptomatic in its early stages, but as the tumor grows, symptoms such as coughing, chest pain, shortness of breath, hoarseness, and weight loss may develop. Treatment options for NSCLC depend on the stage and location of the cancer, as well as the patient's overall health and lung function. Common treatments include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

Carcinoma, small cell is a type of lung cancer that typically starts in the bronchi (the airways that lead to the lungs). It is called "small cell" because the cancer cells are small and appear round or oval in shape. This type of lung cancer is also sometimes referred to as "oat cell carcinoma" due to the distinctive appearance of the cells, which can resemble oats when viewed under a microscope.

Small cell carcinoma is a particularly aggressive form of lung cancer that tends to spread quickly to other parts of the body. It is strongly associated with smoking and is less common than non-small cell lung cancer (NSCLC), which accounts for about 85% of all lung cancers.

Like other types of lung cancer, small cell carcinoma may not cause any symptoms in its early stages. However, as the tumor grows and spreads, it can cause a variety of symptoms, including coughing, chest pain, shortness of breath, hoarseness, and weight loss. Treatment for small cell carcinoma typically involves a combination of chemotherapy, radiation therapy, and sometimes surgery.

Small Cell Lung Carcinoma (SCLC) is a type of lung cancer that typically originates in the central part of the lungs. It is called "small cell" because the tumor cells appear small and round under a microscope. SCLC is an aggressive form of lung cancer that tends to spread rapidly to other parts of the body, such as the lymph nodes, liver, bones, and brain.

SCLC is strongly associated with smoking and is relatively uncommon in people who have never smoked. It accounts for about 10-15% of all lung cancer cases. SCLC is often diagnosed at a later stage because it can grow quickly and cause symptoms such as coughing, chest pain, shortness of breath, and weight loss.

Treatment for SCLC typically involves a combination of chemotherapy and radiation therapy. Surgery is not usually an option due to the advanced stage of the disease at diagnosis. The prognosis for SCLC is generally poor, with a five-year survival rate of less than 7%. However, early detection and treatment can improve outcomes in some cases.

Carcinoma, large cell is a type of lung cancer that is characterized by the presence of large, abnormal-looking cells when viewed under a microscope. These cells have a large nucleus and a significant amount of cytoplasm. This type of lung cancer can be further divided into subtypes based on the appearance of the cells and the presence or absence of specific genetic mutations.

Large cell carcinoma is often aggressive and tends to grow and spread quickly. It is typically treated with a combination of surgery, chemotherapy, and/or radiation therapy. The prognosis for large cell carcinoma varies depending on the stage at diagnosis and the individual's overall health.

Squamous cell carcinoma is a type of skin cancer that begins in the squamous cells, which are flat, thin cells that form the outer layer of the skin (epidermis). It commonly occurs on sun-exposed areas such as the face, ears, lips, and backs of the hands. Squamous cell carcinoma can also develop in other areas of the body including the mouth, lungs, and cervix.

This type of cancer usually develops slowly and may appear as a rough or scaly patch of skin, a red, firm nodule, or a sore or ulcer that doesn't heal. While squamous cell carcinoma is not as aggressive as some other types of cancer, it can metastasize (spread) to other parts of the body if left untreated, making early detection and treatment important.

Risk factors for developing squamous cell carcinoma include prolonged exposure to ultraviolet (UV) radiation from the sun or tanning beds, fair skin, a history of sunburns, a weakened immune system, and older age. Prevention measures include protecting your skin from the sun by wearing protective clothing, using a broad-spectrum sunscreen with an SPF of at least 30, avoiding tanning beds, and getting regular skin examinations.

Adenocarcinoma is a type of cancer that arises from glandular epithelial cells. These cells line the inside of many internal organs, including the breasts, prostate, colon, and lungs. Adenocarcinomas can occur in any of these organs, as well as in other locations where glands are present.

The term "adenocarcinoma" is used to describe a cancer that has features of glandular tissue, such as mucus-secreting cells or cells that produce hormones. These cancers often form glandular structures within the tumor mass and may produce mucus or other substances.

Adenocarcinomas are typically slow-growing and tend to spread (metastasize) to other parts of the body through the lymphatic system or bloodstream. They can be treated with surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these treatments. The prognosis for adenocarcinoma depends on several factors, including the location and stage of the cancer, as well as the patient's overall health and age.

Neoplasm staging is a systematic process used in medicine to describe the extent of spread of a cancer, including the size and location of the original (primary) tumor and whether it has metastasized (spread) to other parts of the body. The most widely accepted system for this purpose is the TNM classification system developed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC).

In this system, T stands for tumor, and it describes the size and extent of the primary tumor. N stands for nodes, and it indicates whether the cancer has spread to nearby lymph nodes. M stands for metastasis, and it shows whether the cancer has spread to distant parts of the body.

Each letter is followed by a number that provides more details about the extent of the disease. For example, a T1N0M0 cancer means that the primary tumor is small and has not spread to nearby lymph nodes or distant sites. The higher the numbers, the more advanced the cancer.

Staging helps doctors determine the most appropriate treatment for each patient and estimate the patient's prognosis. It is an essential tool for communication among members of the healthcare team and for comparing outcomes of treatments in clinical trials.

Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.

Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.

It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.

A cell line that is derived from tumor cells and has been adapted to grow in culture. These cell lines are often used in research to study the characteristics of cancer cells, including their growth patterns, genetic changes, and responses to various treatments. They can be established from many different types of tumors, such as carcinomas, sarcomas, and leukemias. Once established, these cell lines can be grown and maintained indefinitely in the laboratory, allowing researchers to conduct experiments and studies that would not be feasible using primary tumor cells. It is important to note that tumor cell lines may not always accurately represent the behavior of the original tumor, as they can undergo genetic changes during their time in culture.

The Epidermal Growth Factor Receptor (EGFR) is a type of receptor found on the surface of many cells in the body, including those of the epidermis or outer layer of the skin. It is a transmembrane protein that has an extracellular ligand-binding domain and an intracellular tyrosine kinase domain.

EGFR plays a crucial role in various cellular processes such as proliferation, differentiation, migration, and survival. When EGF (Epidermal Growth Factor) or other ligands bind to the extracellular domain of EGFR, it causes the receptor to dimerize and activate its intrinsic tyrosine kinase activity. This leads to the autophosphorylation of specific tyrosine residues on the receptor, which in turn recruits and activates various downstream signaling molecules, resulting in a cascade of intracellular signaling events that ultimately regulate gene expression and cell behavior.

Abnormal activation of EGFR has been implicated in several human diseases, including cancer. Overexpression or mutation of EGFR can lead to uncontrolled cell growth and division, angiogenesis, and metastasis, making it an important target for cancer therapy.

Quinazolines are not a medical term per se, but they are a class of organic compounds that have been widely used in the development of various pharmaceutical drugs. Therefore, I will provide you with a chemical definition of quinazolines:

Quinazolines are heterocyclic aromatic organic compounds consisting of a benzene ring fused to a pyrazine ring. The structure can be represented as follows:

Quinazoline

They are often used as building blocks in the synthesis of various drugs, including those used for treating cancer, cardiovascular diseases, and microbial infections. Some examples of FDA-approved drugs containing a quinazoline core include the tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva), which are used to treat non-small cell lung cancer, and the calcium channel blocker verapamil (Calan, Isoptin), which is used to treat hypertension and angina.

Prognosis is a medical term that refers to the prediction of the likely outcome or course of a disease, including the chances of recovery or recurrence, based on the patient's symptoms, medical history, physical examination, and diagnostic tests. It is an important aspect of clinical decision-making and patient communication, as it helps doctors and patients make informed decisions about treatment options, set realistic expectations, and plan for future care.

Prognosis can be expressed in various ways, such as percentages, categories (e.g., good, fair, poor), or survival rates, depending on the nature of the disease and the available evidence. However, it is important to note that prognosis is not an exact science and may vary depending on individual factors, such as age, overall health status, and response to treatment. Therefore, it should be used as a guide rather than a definitive forecast.

Carcinoma is a type of cancer that develops from epithelial cells, which are the cells that line the inner and outer surfaces of the body. These cells cover organs, glands, and other structures within the body. Carcinomas can occur in various parts of the body, including the skin, lungs, breasts, prostate, colon, and pancreas. They are often characterized by the uncontrolled growth and division of abnormal cells that can invade surrounding tissues and spread to other parts of the body through a process called metastasis. Carcinomas can be further classified based on their appearance under a microscope, such as adenocarcinoma, squamous cell carcinoma, and basal cell carcinoma.

Antineoplastic combined chemotherapy protocols refer to a treatment plan for cancer that involves the use of more than one antineoplastic (chemotherapy) drug given in a specific sequence and schedule. The combination of drugs is used because they may work better together to destroy cancer cells compared to using a single agent alone. This approach can also help to reduce the likelihood of cancer cells becoming resistant to the treatment.

The choice of drugs, dose, duration, and frequency are determined by various factors such as the type and stage of cancer, patient's overall health, and potential side effects. Combination chemotherapy protocols can be used in various settings, including as a primary treatment, adjuvant therapy (given after surgery or radiation to kill any remaining cancer cells), neoadjuvant therapy (given before surgery or radiation to shrink the tumor), or palliative care (to alleviate symptoms and prolong survival).

It is important to note that while combined chemotherapy protocols can be effective in treating certain types of cancer, they can also cause significant side effects, including nausea, vomiting, hair loss, fatigue, and an increased risk of infection. Therefore, patients undergoing such treatment should be closely monitored and managed by a healthcare team experienced in administering chemotherapy.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Medical survival rate is a statistical measure used to determine the percentage of patients who are still alive for a specific period of time after their diagnosis or treatment for a certain condition or disease. It is often expressed as a five-year survival rate, which refers to the proportion of people who are alive five years after their diagnosis. Survival rates can be affected by many factors, including the stage of the disease at diagnosis, the patient's age and overall health, the effectiveness of treatment, and other health conditions that the patient may have. It is important to note that survival rates are statistical estimates and do not necessarily predict an individual patient's prognosis.

A lung is a pair of spongy, elastic organs in the chest that work together to enable breathing. They are responsible for taking in oxygen and expelling carbon dioxide through the process of respiration. The left lung has two lobes, while the right lung has three lobes. The lungs are protected by the ribcage and are covered by a double-layered membrane called the pleura. The trachea divides into two bronchi, which further divide into smaller bronchioles, leading to millions of tiny air sacs called alveoli, where the exchange of gases occurs.

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults. It originates from the hepatocytes, which are the main functional cells of the liver. This type of cancer is often associated with chronic liver diseases such as cirrhosis caused by hepatitis B or C virus infection, alcohol abuse, non-alcoholic fatty liver disease (NAFLD), and aflatoxin exposure.

The symptoms of HCC can vary but may include unexplained weight loss, lack of appetite, abdominal pain or swelling, jaundice, and fatigue. The diagnosis of HCC typically involves imaging tests such as ultrasound, CT scan, or MRI, as well as blood tests to measure alpha-fetoprotein (AFP) levels. Treatment options for Hepatocellular carcinoma depend on the stage and extent of the cancer, as well as the patient's overall health and liver function. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or liver transplantation.

'Tumor cells, cultured' refers to the process of removing cancerous cells from a tumor and growing them in controlled laboratory conditions. This is typically done by isolating the tumor cells from a patient's tissue sample, then placing them in a nutrient-rich environment that promotes their growth and multiplication.

The resulting cultured tumor cells can be used for various research purposes, including the study of cancer biology, drug development, and toxicity testing. They provide a valuable tool for researchers to better understand the behavior and characteristics of cancer cells outside of the human body, which can lead to the development of more effective cancer treatments.

It is important to note that cultured tumor cells may not always behave exactly the same way as they do in the human body, so findings from cell culture studies must be validated through further research, such as animal models or clinical trials.

Gastrin-Releasing Peptide (GRP) is defined as a 27-amino acid peptide that shares structural and functional similarities with the C-terminal part of gastrin. It is widely distributed in the central and peripheral nervous systems, where it functions as a neurotransmitter or neuromodulator. GRP plays a crucial role in various physiological processes such as regulation of gastrointestinal motility, smooth muscle relaxation, and mucous secretion. Additionally, GRP has been implicated in several pathophysiological conditions, including cancer, where it can act as a growth factor for certain types of tumors, such as small cell lung carcinoma.

Tumor markers are substances that can be found in the body and their presence can indicate the presence of certain types of cancer or other conditions. Biological tumor markers refer to those substances that are produced by cancer cells or by other cells in response to cancer or certain benign (non-cancerous) conditions. These markers can be found in various bodily fluids such as blood, urine, or tissue samples.

Examples of biological tumor markers include:

1. Proteins: Some tumor markers are proteins that are produced by cancer cells or by other cells in response to the presence of cancer. For example, prostate-specific antigen (PSA) is a protein produced by normal prostate cells and in higher amounts by prostate cancer cells.
2. Genetic material: Tumor markers can also include genetic material such as DNA, RNA, or microRNA that are shed by cancer cells into bodily fluids. For example, circulating tumor DNA (ctDNA) is genetic material from cancer cells that can be found in the bloodstream.
3. Metabolites: Tumor markers can also include metabolic products produced by cancer cells or by other cells in response to cancer. For example, lactate dehydrogenase (LDH) is an enzyme that is released into the bloodstream when cancer cells break down glucose for energy.

It's important to note that tumor markers are not specific to cancer and can be elevated in non-cancerous conditions as well. Therefore, they should not be used alone to diagnose cancer but rather as a tool in conjunction with other diagnostic tests and clinical evaluations.

Etoposide is a chemotherapy medication used to treat various types of cancer, including lung cancer, testicular cancer, and certain types of leukemia. It works by inhibiting the activity of an enzyme called topoisomerase II, which is involved in DNA replication and transcription. By doing so, etoposide can interfere with the growth and multiplication of cancer cells.

Etoposide is often administered intravenously in a hospital or clinic setting, although it may also be given orally in some cases. The medication can cause a range of side effects, including nausea, vomiting, hair loss, and an increased risk of infection. It can also have more serious side effects, such as bone marrow suppression, which can lead to anemia, bleeding, and a weakened immune system.

Like all chemotherapy drugs, etoposide is not without risks and should only be used under the close supervision of a qualified healthcare provider. It is important for patients to discuss the potential benefits and risks of this medication with their doctor before starting treatment.

Carcinoma, neuroendocrine is a type of cancer that arises from the neuroendocrine cells, which are specialized cells that have both nerve and hormone-producing functions. These cells are found throughout the body, but neuroendocrine tumors (NETs) most commonly occur in the lungs, gastrointestinal tract, pancreas, and thyroid gland.

Neuroendocrine carcinomas can be classified as well-differentiated or poorly differentiated based on how closely they resemble normal neuroendocrine cells under a microscope. Well-differentiated tumors tend to grow more slowly and are less aggressive than poorly differentiated tumors.

Neuroendocrine carcinomas can produce and release hormones and other substances that can cause a variety of symptoms, such as flushing, diarrhea, wheezing, and heart palpitations. Treatment for neuroendocrine carcinoma depends on the location and extent of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

Lung diseases refer to a broad category of disorders that affect the lungs and other structures within the respiratory system. These diseases can impair lung function, leading to symptoms such as coughing, shortness of breath, chest pain, and wheezing. They can be categorized into several types based on the underlying cause and nature of the disease process. Some common examples include:

1. Obstructive lung diseases: These are characterized by narrowing or blockage of the airways, making it difficult to breathe out. Examples include chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, and cystic fibrosis.
2. Restrictive lung diseases: These involve stiffening or scarring of the lungs, which reduces their ability to expand and take in air. Examples include idiopathic pulmonary fibrosis, sarcoidosis, and asbestosis.
3. Infectious lung diseases: These are caused by bacteria, viruses, fungi, or parasites that infect the lungs. Examples include pneumonia, tuberculosis, and influenza.
4. Vascular lung diseases: These affect the blood vessels in the lungs, impairing oxygen exchange. Examples include pulmonary embolism, pulmonary hypertension, and chronic thromboembolic pulmonary hypertension (CTEPH).
5. Neoplastic lung diseases: These involve abnormal growth of cells within the lungs, leading to cancer. Examples include small cell lung cancer, non-small cell lung cancer, and mesothelioma.
6. Other lung diseases: These include interstitial lung diseases, pleural effusions, and rare disorders such as pulmonary alveolar proteinosis and lymphangioleiomyomatosis (LAM).

It is important to note that this list is not exhaustive, and there are many other conditions that can affect the lungs. Proper diagnosis and treatment of lung diseases require consultation with a healthcare professional, such as a pulmonologist or respiratory therapist.

Carcinoma in situ is a medical term used to describe the earliest stage of cancer, specifically a type of cancer that begins in the epithelial tissue, which is the tissue that lines the outer surfaces of organs and body structures. In this stage, the cancer cells are confined to the layer of cells where they first developed and have not spread beyond that layer into the surrounding tissues or organs.

Carcinoma in situ can occur in various parts of the body, including the skin, cervix, breast, lung, prostate, bladder, and other areas. It is often detected through routine screening tests, such as Pap smears for cervical cancer or mammograms for breast cancer.

While carcinoma in situ is not invasive, it can still be a serious condition because it has the potential to develop into an invasive cancer if left untreated. Treatment options for carcinoma in situ may include surgery, radiation therapy, or other forms of treatment, depending on the location and type of cancer. It is important to consult with a healthcare provider to determine the best course of action for each individual case.

Phosphopyruvate Hydratase is an enzyme also known as Enolase. It plays a crucial role in the glycolytic pathway, which is a series of reactions that occur in the cell to break down glucose into pyruvate, producing ATP and NADH as energy-rich intermediates.

Specifically, Phosphopyruvate Hydratase catalyzes the conversion of 2-phospho-D-glycerate (2-PG) to phosphoenolpyruvate (PEP), which is the second to last step in the glycolytic pathway. This reaction includes the removal of a water molecule from 2-PG, resulting in the formation of PEP and the release of a molecule of water.

The enzyme requires magnesium ions as a cofactor for its activity, and it is inhibited by fluoride ions. Deficiency or dysfunction of Phosphopyruvate Hydratase can lead to various metabolic disorders, including some forms of muscular dystrophy and neurodegenerative diseases.

Neoplastic gene expression regulation refers to the processes that control the production of proteins and other molecules from genes in neoplastic cells, or cells that are part of a tumor or cancer. In a normal cell, gene expression is tightly regulated to ensure that the right genes are turned on or off at the right time. However, in cancer cells, this regulation can be disrupted, leading to the overexpression or underexpression of certain genes.

Neoplastic gene expression regulation can be affected by a variety of factors, including genetic mutations, epigenetic changes, and signals from the tumor microenvironment. These changes can lead to the activation of oncogenes (genes that promote cancer growth and development) or the inactivation of tumor suppressor genes (genes that prevent cancer).

Understanding neoplastic gene expression regulation is important for developing new therapies for cancer, as targeting specific genes or pathways involved in this process can help to inhibit cancer growth and progression.

Bombesin is a type of peptide that occurs naturally in the body. It is a small protein-like molecule made up of amino acids, and it is involved in various physiological processes, including regulating appetite and digestion. Bombesin was first discovered in the skin of a frog species called Bombina bombina, hence its name. In the human body, bombesin-like peptides are produced by various tissues, including the stomach and brain. They bind to specific receptors in the body, triggering a range of responses, such as stimulating the release of hormones and increasing gut motility. Bombesin has been studied for its potential role in treating certain medical conditions, including cancer, although more research is needed to establish its safety and efficacy.

Cisplatin is a chemotherapeutic agent used to treat various types of cancers, including testicular, ovarian, bladder, head and neck, lung, and cervical cancers. It is an inorganic platinum compound that contains a central platinum atom surrounded by two chloride atoms and two ammonia molecules in a cis configuration.

Cisplatin works by forming crosslinks between DNA strands, which disrupts the structure of DNA and prevents cancer cells from replicating. This ultimately leads to cell death and slows down or stops the growth of tumors. However, cisplatin can also cause damage to normal cells, leading to side effects such as nausea, vomiting, hearing loss, and kidney damage. Therefore, it is essential to monitor patients closely during treatment and manage any adverse effects promptly.

Paraneoplastic syndromes refer to a group of rare disorders that are caused by an abnormal immune system response to a cancerous (malignant) tumor. These syndromes are characterized by symptoms or signs that do not result directly from the growth of the tumor itself, but rather from substances produced by the tumor or the body's immune system in response to the tumor.

Paraneoplastic syndromes can affect various organs and systems in the body, including the nervous system, endocrine system, skin, and joints. Examples of paraneoplastic syndromes include Lambert-Eaton myasthenic syndrome (LEMS), which affects nerve function and causes muscle weakness; cerebellar degeneration, which can cause difficulty with coordination and balance; and dermatomyositis, which is an inflammatory condition that affects the skin and muscles.

Paraneoplastic syndromes can occur in association with a variety of different types of cancer, including lung cancer, breast cancer, ovarian cancer, and lymphoma. Treatment typically involves addressing the underlying cancer, as well as managing the symptoms of the paraneoplastic syndrome.

Carcinoma, papillary is a type of cancer that begins in the cells that line the glandular structures or the lining of organs. In a papillary carcinoma, the cancerous cells grow and form small finger-like projections, called papillae, within the tumor. This type of cancer most commonly occurs in the thyroid gland, but can also be found in other organs such as the lung, breast, and kidney. Papillary carcinoma of the thyroid gland is usually slow-growing and has a good prognosis, especially when it is diagnosed at an early stage.

Carcinoma, bronchogenic is a medical term that refers to a type of lung cancer that originates in the bronchi, which are the branching tubes that carry air into the lungs. It is the most common form of lung cancer and can be further classified into different types based on the specific cell type involved, such as squamous cell carcinoma, adenocarcinoma, or large cell carcinoma.

Bronchogenic carcinomas are often associated with smoking and exposure to environmental pollutants, although they can also occur in non-smokers. Symptoms may include coughing, chest pain, shortness of breath, wheezing, hoarseness, or unexplained weight loss. Treatment options depend on the stage and location of the cancer, as well as the patient's overall health and may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

"Nude mice" is a term used in the field of laboratory research to describe a strain of mice that have been genetically engineered to lack a functional immune system. Specifically, nude mice lack a thymus gland and have a mutation in the FOXN1 gene, which results in a failure to develop a mature T-cell population. This means that they are unable to mount an effective immune response against foreign substances or organisms.

The name "nude" refers to the fact that these mice also have a lack of functional hair follicles, resulting in a hairless or partially hairless phenotype. This feature is actually a secondary consequence of the same genetic mutation that causes their immune deficiency.

Nude mice are commonly used in research because their weakened immune system makes them an ideal host for transplanted tumors, tissues, and cells from other species, including humans. This allows researchers to study the behavior of these foreign substances in a living organism without the complication of an immune response. However, it's important to note that because nude mice lack a functional immune system, they must be kept in sterile conditions and are more susceptible to infection than normal mice.

Liver neoplasms refer to abnormal growths in the liver that can be benign or malignant. Benign liver neoplasms are non-cancerous tumors that do not spread to other parts of the body, while malignant liver neoplasms are cancerous tumors that can invade and destroy surrounding tissue and spread to other organs.

Liver neoplasms can be primary, meaning they originate in the liver, or secondary, meaning they have metastasized (spread) to the liver from another part of the body. Primary liver neoplasms can be further classified into different types based on their cell of origin and behavior, including hepatocellular carcinoma, cholangiocarcinoma, and hepatic hemangioma.

The diagnosis of liver neoplasms typically involves a combination of imaging studies, such as ultrasound, CT scan, or MRI, and biopsy to confirm the type and stage of the tumor. Treatment options depend on the type and extent of the neoplasm and may include surgery, radiation therapy, chemotherapy, or liver transplantation.

Neoplasm antigens, also known as tumor antigens, are substances that are produced by cancer cells (neoplasms) and can stimulate an immune response. These antigens can be proteins, carbohydrates, or other molecules that are either unique to the cancer cells or are overexpressed or mutated versions of normal cellular proteins.

Neoplasm antigens can be classified into two main categories: tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells and are not expressed by normal cells, while TAAs are present at low levels in normal cells but are overexpressed or altered in cancer cells.

TSAs can be further divided into viral antigens and mutated antigens. Viral antigens are produced when cancer is caused by a virus, such as human papillomavirus (HPV) in cervical cancer. Mutated antigens are the result of genetic mutations that occur during cancer development and are unique to each patient's tumor.

Neoplasm antigens play an important role in the immune response against cancer. They can be recognized by the immune system, leading to the activation of immune cells such as T cells and natural killer (NK) cells, which can then attack and destroy cancer cells. However, cancer cells often develop mechanisms to evade the immune response, allowing them to continue growing and spreading.

Understanding neoplasm antigens is important for the development of cancer immunotherapies, which aim to enhance the body's natural immune response against cancer. These therapies include checkpoint inhibitors, which block proteins that inhibit T cell activation, and therapeutic vaccines, which stimulate an immune response against specific tumor antigens.

Bombesin receptors are a group of G protein-coupled receptors that bind to bombesin-like peptides. These receptors play important roles in various physiological processes, including regulation of appetite and energy balance, smooth muscle contraction, and neurotransmission. There are three subtypes of bombesin receptors: BB1, BB2, and BB3 (also known as GRP receptor). They are activated by different bombesin-like peptides, such as bombesin, gastrin-releasing peptide (GRP), and neuromedin B. These receptors have been found to be expressed in a variety of tissues, including the gastrointestinal tract, lung, pancreas, and brain. They are also implicated in several pathological conditions, such as cancer, where they can contribute to tumor growth and progression.

The term "DNA, neoplasm" is not a standard medical term or concept. DNA refers to deoxyribonucleic acid, which is the genetic material present in the cells of living organisms. A neoplasm, on the other hand, is a tumor or growth of abnormal tissue that can be benign (non-cancerous) or malignant (cancerous).

In some contexts, "DNA, neoplasm" may refer to genetic alterations found in cancer cells. These genetic changes can include mutations, amplifications, deletions, or rearrangements of DNA sequences that contribute to the development and progression of cancer. Identifying these genetic abnormalities can help doctors diagnose and treat certain types of cancer more effectively.

However, it's important to note that "DNA, neoplasm" is not a term that would typically be used in medical reports or research papers without further clarification. If you have any specific questions about DNA changes in cancer cells or neoplasms, I would recommend consulting with a healthcare professional or conducting further research on the topic.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Human chromosome pair 3 consists of two rod-shaped structures present in the nucleus of each cell in the human body. Each member of the pair is a single chromosome, and together they contain the genetic material that is inherited from both parents. Chromosomes are made up of DNA, which contains the instructions for the development and function of all living organisms.

Human chromosomes are numbered from 1 to 22, with an additional two sex chromosomes (X and Y) that determine biological sex. Chromosome pair 3 is one of the autosomal pairs, meaning it contains genes that are not related to sex determination. Each member of chromosome pair 3 is identical in size and shape and contains a single long DNA molecule that is coiled tightly around histone proteins to form a compact structure.

Chromosome pair 3 is associated with several genetic disorders, including Waardenburg syndrome, which affects pigmentation and hearing; Marfan syndrome, which affects the connective tissue; and some forms of retinoblastoma, a rare eye cancer that typically affects young children.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

Combined modality therapy (CMT) is a medical treatment approach that utilizes more than one method or type of therapy simultaneously or in close succession, with the goal of enhancing the overall effectiveness of the treatment. In the context of cancer care, CMT often refers to the combination of two or more primary treatment modalities, such as surgery, radiation therapy, and systemic therapies (chemotherapy, immunotherapy, targeted therapy, etc.).

The rationale behind using combined modality therapy is that each treatment method can target cancer cells in different ways, potentially increasing the likelihood of eliminating all cancer cells and reducing the risk of recurrence. The specific combination and sequence of treatments will depend on various factors, including the type and stage of cancer, patient's overall health, and individual preferences.

For example, a common CMT approach for locally advanced rectal cancer may involve preoperative (neoadjuvant) chemoradiation therapy, followed by surgery to remove the tumor, and then postoperative (adjuvant) chemotherapy. This combined approach allows for the reduction of the tumor size before surgery, increases the likelihood of complete tumor removal, and targets any remaining microscopic cancer cells with systemic chemotherapy.

It is essential to consult with a multidisciplinary team of healthcare professionals to determine the most appropriate CMT plan for each individual patient, considering both the potential benefits and risks associated with each treatment method.

Survival analysis is a branch of statistics that deals with the analysis of time to event data. It is used to estimate the time it takes for a certain event of interest to occur, such as death, disease recurrence, or treatment failure. The event of interest is called the "failure" event, and survival analysis estimates the probability of not experiencing the failure event until a certain point in time, also known as the "survival" probability.

Survival analysis can provide important information about the effectiveness of treatments, the prognosis of patients, and the identification of risk factors associated with the event of interest. It can handle censored data, which is common in medical research where some participants may drop out or be lost to follow-up before the event of interest occurs.

Survival analysis typically involves estimating the survival function, which describes the probability of surviving beyond a certain time point, as well as hazard functions, which describe the instantaneous rate of failure at a given time point. Other important concepts in survival analysis include median survival times, restricted mean survival times, and various statistical tests to compare survival curves between groups.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

A neoplasm is a tumor or growth that is formed by an abnormal and excessive proliferation of cells, which can be benign or malignant. Neoplasm proteins are therefore any proteins that are expressed or produced in these neoplastic cells. These proteins can play various roles in the development, progression, and maintenance of neoplasms.

Some neoplasm proteins may contribute to the uncontrolled cell growth and division seen in cancer, such as oncogenic proteins that promote cell cycle progression or inhibit apoptosis (programmed cell death). Others may help the neoplastic cells evade the immune system, allowing them to proliferate undetected. Still others may be involved in angiogenesis, the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Neoplasm proteins can also serve as biomarkers for cancer diagnosis, prognosis, or treatment response. For example, the presence or level of certain neoplasm proteins in biological samples such as blood or tissue may indicate the presence of a specific type of cancer, help predict the likelihood of cancer recurrence, or suggest whether a particular therapy will be effective.

Overall, understanding the roles and behaviors of neoplasm proteins can provide valuable insights into the biology of cancer and inform the development of new diagnostic and therapeutic strategies.

Cell division is the process by which a single eukaryotic cell (a cell with a true nucleus) divides into two identical daughter cells. This complex process involves several stages, including replication of DNA, separation of chromosomes, and division of the cytoplasm. There are two main types of cell division: mitosis and meiosis.

Mitosis is the type of cell division that results in two genetically identical daughter cells. It is a fundamental process for growth, development, and tissue repair in multicellular organisms. The stages of mitosis include prophase, prometaphase, metaphase, anaphase, and telophase, followed by cytokinesis, which divides the cytoplasm.

Meiosis, on the other hand, is a type of cell division that occurs in the gonads (ovaries and testes) during the production of gametes (sex cells). Meiosis results in four genetically unique daughter cells, each with half the number of chromosomes as the parent cell. This process is essential for sexual reproduction and genetic diversity. The stages of meiosis include meiosis I and meiosis II, which are further divided into prophase, prometaphase, metaphase, anaphase, and telophase.

In summary, cell division is the process by which a single cell divides into two daughter cells, either through mitosis or meiosis. This process is critical for growth, development, tissue repair, and sexual reproduction in multicellular organisms.

Topotecan is a chemotherapeutic agent, specifically a topoisomerase I inhibitor. It is a semi-synthetic derivative of camptothecin and works by interfering with the function of topoisomerase I, an enzyme that helps to relax supercoiled DNA during transcription and replication. By inhibiting this enzyme, topotecan causes DNA damage and apoptosis (programmed cell death) in rapidly dividing cells, such as cancer cells. It is used in the treatment of various types of cancer, including small cell lung cancer and ovarian cancer.

Carcinoma, ductal, breast is a type of breast cancer that begins in the milk ducts (the tubes that carry milk from the lobules of the breast to the nipple). It is called "ductal" because it starts in the cells that line the milk ducts. Ductal carcinoma can be further classified as either non-invasive or invasive, based on whether the cancer cells are confined to the ducts or have spread beyond them into the surrounding breast tissue.

Non-invasive ductal carcinoma (also known as intraductal carcinoma or ductal carcinoma in situ) is a condition where abnormal cells have been found in the lining of the milk ducts, but they have not spread outside of the ducts. These cells have the potential to become invasive and spread to other parts of the breast or body if left untreated.

Invasive ductal carcinoma (IDC) is a type of breast cancer that starts in a milk duct and then grows into the surrounding breast tissue. From there, it can spread to other parts of the body through the bloodstream and lymphatic system. IDC is the most common form of breast cancer, accounting for about 80% of all cases.

Symptoms of ductal carcinoma may include a lump or thickening in the breast, changes in the size or shape of the breast, dimpling or puckering of the skin on the breast, nipple discharge (especially if it is clear or bloody), and/or redness or scaling of the nipple or breast skin. However, many cases of ductal carcinoma are detected through mammography before any symptoms develop.

Treatment for ductal carcinoma depends on several factors, including the stage and grade of the cancer, as well as the patient's overall health and personal preferences. Treatment options may include surgery (such as a lumpectomy or mastectomy), radiation therapy, chemotherapy, hormone therapy, and/or targeted therapies.

Neoplasm metastasis is the spread of cancer cells from the primary site (where the original or primary tumor formed) to other places in the body. This happens when cancer cells break away from the original (primary) tumor and enter the bloodstream or lymphatic system. The cancer cells can then travel to other parts of the body and form new tumors, called secondary tumors or metastases.

Metastasis is a key feature of malignant neoplasms (cancers), and it is one of the main ways that cancer can cause harm in the body. The metastatic tumors may continue to grow and may cause damage to the organs and tissues where they are located. They can also release additional cancer cells into the bloodstream or lymphatic system, leading to further spread of the cancer.

The metastatic tumors are named based on the location where they are found, as well as the type of primary cancer. For example, if a patient has a primary lung cancer that has metastasized to the liver, the metastatic tumor would be called a liver metastasis from lung cancer.

It is important to note that the presence of metastases can significantly affect a person's prognosis and treatment options. In general, metastatic cancer is more difficult to treat than cancer that has not spread beyond its original site. However, there are many factors that can influence a person's prognosis and response to treatment, so it is important for each individual to discuss their specific situation with their healthcare team.

Carcinoma, basal cell is a type of skin cancer that arises from the basal cells, which are located in the lower part of the epidermis (the outermost layer of the skin). It is also known as basal cell carcinoma (BCC) and is the most common form of skin cancer.

BCC typically appears as a small, shiny, pearly bump or nodule on the skin, often in sun-exposed areas such as the face, ears, neck, hands, and arms. It may also appear as a scar-like area that is white, yellow, or waxy. BCCs are usually slow growing and rarely spread (metastasize) to other parts of the body. However, they can be locally invasive and destroy surrounding tissue if left untreated.

The exact cause of BCC is not known, but it is thought to be related to a combination of genetic and environmental factors, including exposure to ultraviolet (UV) radiation from the sun or tanning beds. People with fair skin, light hair, and blue or green eyes are at increased risk of developing BCC.

Treatment for BCC typically involves surgical removal of the tumor, along with a margin of healthy tissue. Other treatment options may include radiation therapy, topical chemotherapy, or photodynamic therapy. Prevention measures include protecting your skin from UV radiation by wearing protective clothing, using sunscreen, and avoiding tanning beds.

Lung injury, also known as pulmonary injury, refers to damage or harm caused to the lung tissue, blood vessels, or air sacs (alveoli) in the lungs. This can result from various causes such as infection, trauma, exposure to harmful substances, or systemic diseases. Common types of lung injuries include acute respiratory distress syndrome (ARDS), pneumonia, and chemical pneumonitis. Symptoms may include difficulty breathing, cough, chest pain, and decreased oxygen levels in the blood. Treatment depends on the underlying cause and may include medications, oxygen therapy, or mechanical ventilation.

Drug resistance in neoplasms (also known as cancer drug resistance) refers to the ability of cancer cells to withstand the effects of chemotherapeutic agents or medications designed to kill or inhibit the growth of cancer cells. This can occur due to various mechanisms, including changes in the cancer cell's genetic makeup, alterations in drug targets, increased activity of drug efflux pumps, and activation of survival pathways.

Drug resistance can be intrinsic (present at the beginning of treatment) or acquired (developed during the course of treatment). It is a significant challenge in cancer therapy as it often leads to reduced treatment effectiveness, disease progression, and poor patient outcomes. Strategies to overcome drug resistance include the use of combination therapies, development of new drugs that target different mechanisms, and personalized medicine approaches that consider individual patient and tumor characteristics.

Neoplasm invasiveness is a term used in pathology and oncology to describe the aggressive behavior of cancer cells as they invade surrounding tissues and organs. This process involves the loss of cell-to-cell adhesion, increased motility and migration, and the ability of cancer cells to degrade the extracellular matrix (ECM) through the production of enzymes such as matrix metalloproteinases (MMPs).

Invasive neoplasms are cancers that have spread beyond the original site where they first developed and have infiltrated adjacent tissues or structures. This is in contrast to non-invasive or in situ neoplasms, which are confined to the epithelial layer where they originated and have not yet invaded the underlying basement membrane.

The invasiveness of a neoplasm is an important prognostic factor in cancer diagnosis and treatment, as it can indicate the likelihood of metastasis and the potential effectiveness of various therapies. In general, more invasive cancers are associated with worse outcomes and require more aggressive treatment approaches.

Neoplasm transplantation is not a recognized or established medical procedure in the field of oncology. The term "neoplasm" refers to an abnormal growth of cells, which can be benign or malignant (cancerous). "Transplantation" typically refers to the surgical transfer of living cells, tissues, or organs from one part of the body to another or between individuals.

The concept of neoplasm transplantation may imply the transfer of cancerous cells or tissues from a donor to a recipient, which is not a standard practice due to ethical considerations and the potential harm it could cause to the recipient. In some rare instances, researchers might use laboratory animals to study the transmission and growth of human cancer cells, but this is done for scientific research purposes only and under strict regulatory guidelines.

In summary, there is no medical definition for 'Neoplasm Transplantation' as it does not represent a standard or ethical medical practice.

Immunoenzyme techniques are a group of laboratory methods used in immunology and clinical chemistry that combine the specificity of antibody-antigen reactions with the sensitivity and amplification capabilities of enzyme reactions. These techniques are primarily used for the detection, quantitation, or identification of various analytes (such as proteins, hormones, drugs, viruses, or bacteria) in biological samples.

In immunoenzyme techniques, an enzyme is linked to an antibody or antigen, creating a conjugate. This conjugate then interacts with the target analyte in the sample, forming an immune complex. The presence and amount of this immune complex can be visualized or measured by detecting the enzymatic activity associated with it.

There are several types of immunoenzyme techniques, including:

1. Enzyme-linked Immunosorbent Assay (ELISA): A widely used method for detecting and quantifying various analytes in a sample. In ELISA, an enzyme is attached to either the capture antibody or the detection antibody. After the immune complex formation, a substrate is added that reacts with the enzyme, producing a colored product that can be measured spectrophotometrically.
2. Immunoblotting (Western blot): A method used for detecting specific proteins in a complex mixture, such as a protein extract from cells or tissues. In this technique, proteins are separated by gel electrophoresis and transferred to a membrane, where they are probed with an enzyme-conjugated antibody directed against the target protein.
3. Immunohistochemistry (IHC): A method used for detecting specific antigens in tissue sections or cells. In IHC, an enzyme-conjugated primary or secondary antibody is applied to the sample, and the presence of the antigen is visualized using a chromogenic substrate that produces a colored product at the site of the antigen-antibody interaction.
4. Immunofluorescence (IF): A method used for detecting specific antigens in cells or tissues by employing fluorophore-conjugated antibodies. The presence of the antigen is visualized using a fluorescence microscope.
5. Enzyme-linked immunosorbent assay (ELISA): A method used for detecting and quantifying specific antigens or antibodies in liquid samples, such as serum or culture supernatants. In ELISA, an enzyme-conjugated detection antibody is added after the immune complex formation, and a substrate is added that reacts with the enzyme to produce a colored product that can be measured spectrophotometrically.

These techniques are widely used in research and diagnostic laboratories for various applications, including protein characterization, disease diagnosis, and monitoring treatment responses.

Heterologous transplantation is a type of transplantation where an organ or tissue is transferred from one species to another. This is in contrast to allogeneic transplantation, where the donor and recipient are of the same species, or autologous transplantation, where the donor and recipient are the same individual.

In heterologous transplantation, the immune systems of the donor and recipient are significantly different, which can lead to a strong immune response against the transplanted organ or tissue. This is known as a graft-versus-host disease (GVHD), where the immune cells in the transplanted tissue attack the recipient's body.

Heterologous transplantation is not commonly performed in clinical medicine due to the high risk of rejection and GVHD. However, it may be used in research settings to study the biology of transplantation and to develop new therapies for transplant rejection.

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a laboratory technique used in molecular biology to amplify and detect specific DNA sequences. This technique is particularly useful for the detection and quantification of RNA viruses, as well as for the analysis of gene expression.

The process involves two main steps: reverse transcription and polymerase chain reaction (PCR). In the first step, reverse transcriptase enzyme is used to convert RNA into complementary DNA (cDNA) by reading the template provided by the RNA molecule. This cDNA then serves as a template for the PCR amplification step.

In the second step, the PCR reaction uses two primers that flank the target DNA sequence and a thermostable polymerase enzyme to repeatedly copy the targeted cDNA sequence. The reaction mixture is heated and cooled in cycles, allowing the primers to anneal to the template, and the polymerase to extend the new strand. This results in exponential amplification of the target DNA sequence, making it possible to detect even small amounts of RNA or cDNA.

RT-PCR is a sensitive and specific technique that has many applications in medical research and diagnostics, including the detection of viruses such as HIV, hepatitis C virus, and SARS-CoV-2 (the virus that causes COVID-19). It can also be used to study gene expression, identify genetic mutations, and diagnose genetic disorders.

Apoptosis is a programmed and controlled cell death process that occurs in multicellular organisms. It is a natural process that helps maintain tissue homeostasis by eliminating damaged, infected, or unwanted cells. During apoptosis, the cell undergoes a series of morphological changes, including cell shrinkage, chromatin condensation, and fragmentation into membrane-bound vesicles called apoptotic bodies. These bodies are then recognized and engulfed by neighboring cells or phagocytic cells, preventing an inflammatory response. Apoptosis is regulated by a complex network of intracellular signaling pathways that involve proteins such as caspases, Bcl-2 family members, and inhibitors of apoptosis (IAPs).

A pneumonectomy is a surgical procedure in which an entire lung is removed. This type of surgery is typically performed as a treatment for certain types of lung cancer, although it may also be used to treat other conditions such as severe damage or infection in the lung that does not respond to other treatments. The surgery requires general anesthesia and can be quite complex, with potential risks including bleeding, infection, pneumonia, and air leaks. Recovery from a pneumonectomy can take several weeks, and patients may require ongoing rehabilitation to regain strength and mobility.

Lymphatic metastasis is the spread of cancer cells from a primary tumor to distant lymph nodes through the lymphatic system. It occurs when malignant cells break away from the original tumor, enter the lymphatic vessels, and travel to nearby or remote lymph nodes. Once there, these cancer cells can multiply and form new tumors, leading to further progression of the disease. Lymphatic metastasis is a common way for many types of cancer to spread and can have significant implications for prognosis and treatment strategies.

Cell proliferation is the process by which cells increase in number, typically through the process of cell division. In the context of biology and medicine, it refers to the reproduction of cells that makes up living tissue, allowing growth, maintenance, and repair. It involves several stages including the transition from a phase of quiescence (G0 phase) to an active phase (G1 phase), DNA replication in the S phase, and mitosis or M phase, where the cell divides into two daughter cells.

Abnormal or uncontrolled cell proliferation is a characteristic feature of many diseases, including cancer, where deregulated cell cycle control leads to excessive and unregulated growth of cells, forming tumors that can invade surrounding tissues and metastasize to distant sites in the body.

X-ray computed tomography (CT or CAT scan) is a medical imaging method that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional (tomographic) images (virtual "slices") of the body. These cross-sectional images can then be used to display detailed internal views of organs, bones, and soft tissues in the body.

The term "computed tomography" is used instead of "CT scan" or "CAT scan" because the machines take a series of X-ray measurements from different angles around the body and then use a computer to process these data to create detailed images of internal structures within the body.

CT scanning is a noninvasive, painless medical test that helps physicians diagnose and treat medical conditions. CT imaging provides detailed information about many types of tissue including lung, bone, soft tissue and blood vessels. CT examinations can be performed on every part of the body for a variety of reasons including diagnosis, surgical planning, and monitoring of therapeutic responses.

In computed tomography (CT), an X-ray source and detector rotate around the patient, measuring the X-ray attenuation at many different angles. A computer uses this data to construct a cross-sectional image by the process of reconstruction. This technique is called "tomography". The term "computed" refers to the use of a computer to reconstruct the images.

CT has become an important tool in medical imaging and diagnosis, allowing radiologists and other physicians to view detailed internal images of the body. It can help identify many different medical conditions including cancer, heart disease, lung nodules, liver tumors, and internal injuries from trauma. CT is also commonly used for guiding biopsies and other minimally invasive procedures.

In summary, X-ray computed tomography (CT or CAT scan) is a medical imaging technique that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional images of the body. It provides detailed internal views of organs, bones, and soft tissues in the body, allowing physicians to diagnose and treat medical conditions.

Carboplatin is a chemotherapeutic agent used to treat various types of cancers, including ovarian, lung, and head and neck cancer. It is a platinum-containing compound that works by forming crosslinks in DNA, which leads to the death of rapidly dividing cells, such as cancer cells. Carboplatin is often used in combination with other chemotherapy drugs and is administered intravenously.

The medical definition of Carboplatin is:

"A platinum-containing antineoplastic agent that forms crosslinks with DNA, inducing cell cycle arrest and apoptosis. It is used to treat a variety of cancers, including ovarian, lung, and head and neck cancer."

Local neoplasm recurrence is the return or regrowth of a tumor in the same location where it was originally removed or treated. This means that cancer cells have survived the initial treatment and started to grow again in the same area. It's essential to monitor and detect any local recurrence as early as possible, as it can affect the prognosis and may require additional treatment.

Lung transplantation is a surgical procedure where one or both diseased lungs are removed and replaced with healthy lungs from a deceased donor. It is typically considered as a treatment option for patients with end-stage lung diseases, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis, and alpha-1 antitrypsin deficiency, who have exhausted all other medical treatments and continue to suffer from severe respiratory failure.

The procedure involves several steps, including evaluating the patient's eligibility for transplantation, matching the donor's lung size and blood type with the recipient, and performing the surgery under general anesthesia. After the surgery, patients require close monitoring and lifelong immunosuppressive therapy to prevent rejection of the new lungs.

Lung transplantation can significantly improve the quality of life and survival rates for some patients with end-stage lung disease, but it is not without risks, including infection, bleeding, and rejection. Therefore, careful consideration and thorough evaluation are necessary before pursuing this treatment option.

A fatal outcome is a term used in medical context to describe a situation where a disease, injury, or illness results in the death of an individual. It is the most severe and unfortunate possible outcome of any medical condition, and is often used as a measure of the severity and prognosis of various diseases and injuries. In clinical trials and research, fatal outcome may be used as an endpoint to evaluate the effectiveness and safety of different treatments or interventions.

Bronchial neoplasms refer to abnormal growths or tumors in the bronchi, which are the large airways that lead into the lungs. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Malignant bronchial neoplasms are often referred to as lung cancer and can be further classified into small cell lung cancer and non-small cell lung cancer, depending on the type of cells involved.

Benign bronchial neoplasms are less common than malignant ones and may include growths such as papillomas, hamartomas, or chondromas. While benign neoplasms are not cancerous, they can still cause symptoms and complications if they grow large enough to obstruct the airways or if they become infected.

Treatment for bronchial neoplasms depends on several factors, including the type, size, location, and stage of the tumor, as well as the patient's overall health and medical history. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

A carcinoid tumor is a type of slow-growing neuroendocrine tumor that usually originates in the digestive tract, particularly in the small intestine. These tumors can also arise in other areas such as the lungs, appendix, and rarely in other organs. Carcinoid tumors develop from cells of the diffuse endocrine system (also known as the neuroendocrine system) that are capable of producing hormones or biologically active amines.

Carcinoid tumors can produce and release various hormones and bioactive substances, such as serotonin, histamine, bradykinins, prostaglandins, and tachykinins, which can lead to a variety of symptoms. The most common syndrome associated with carcinoid tumors is the carcinoid syndrome, characterized by flushing, diarrhea, abdominal cramping, and wheezing or difficulty breathing.

Carcinoid tumors are typically classified as functional or nonfunctional based on whether they produce and secrete hormones that cause symptoms. Functional carcinoid tumors account for approximately 30% of cases and can lead to the development of carcinoid syndrome, while nonfunctional tumors do not produce significant amounts of hormones and are often asymptomatic until they grow large enough to cause local or distant complications.

Treatment options for carcinoid tumors depend on the location, size, and extent of the tumor, as well as whether it is functional or nonfunctional. Treatment may include surgery, medications (such as somatostatin analogs, chemotherapy, or targeted therapies), and radiation therapy. Regular follow-up with imaging studies and biochemical tests is essential to monitor for recurrence and assess treatment response.

A cell line is a culture of cells that are grown in a laboratory for use in research. These cells are usually taken from a single cell or group of cells, and they are able to divide and grow continuously in the lab. Cell lines can come from many different sources, including animals, plants, and humans. They are often used in scientific research to study cellular processes, disease mechanisms, and to test new drugs or treatments. Some common types of human cell lines include HeLa cells (which come from a cancer patient named Henrietta Lacks), HEK293 cells (which come from embryonic kidney cells), and HUVEC cells (which come from umbilical vein endothelial cells). It is important to note that cell lines are not the same as primary cells, which are cells that are taken directly from a living organism and have not been grown in the lab.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

Dopa decarboxylase (DDC) is an enzyme that plays a crucial role in the synthesis of dopamine and serotonin, two important neurotransmitters in the human body. This enzyme is responsible for converting levodopa (L-DOPA), an amino acid precursor, into dopamine, a critical neurotransmitter involved in movement regulation, motivation, reward, and mood.

The gene that encodes dopa decarboxylase is DDC, located on chromosome 7p12.2-p12.1. The enzyme is widely expressed throughout the body, including the brain, kidneys, liver, and gut. In addition to its role in neurotransmitter synthesis, dopa decarboxylase also contributes to the metabolism of certain drugs, such as levodopa and carbidopa, which are used in the treatment of Parkinson's disease.

Deficiencies or mutations in the DDC gene can lead to various neurological disorders, including aromatic L-amino acid decarboxylase deficiency (AADCD), a rare autosomal recessive disorder characterized by decreased levels of dopamine and serotonin. Symptoms of AADCD may include developmental delay, movement disorders, seizures, autonomic dysfunction, and oculogyric crises.

Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder characterized by muscle weakness and fatigability. It is caused by the presence of antibodies against voltage-gated calcium channels (VGCC) in the neuromuscular junction, which disrupts the normal transmission of signals between nerves and muscles.

The symptoms of LEMS include proximal muscle weakness, which may affect the legs more than the arms, and autonomic dysfunction such as dry mouth and constipation. The weakness tends to improve with exercise but worsens after periods of rest. In some cases, LEMS can be associated with cancer, particularly small cell lung cancer.

Diagnosis of LEMS typically involves a combination of clinical evaluation, electromyography (EMG) studies, and blood tests to detect VGCC antibodies. Treatment may include medications such as pyridostigmine, which improves neuromuscular transmission, or intravenous immunoglobulin and plasma exchange, which help to reduce the immune response. In cases where LEMS is associated with cancer, treatment of the underlying malignancy can also improve muscle strength and function.

Transitional cell carcinoma (TCC) is a type of cancer that develops in the transitional epithelium, which is the tissue that lines the inner surface of the urinary tract. This includes the renal pelvis, ureters, bladder, and urethra. Transitional cell carcinoma is the most common type of bladder cancer and can also occur in other parts of the urinary system.

Transitional cells are specialized epithelial cells that can stretch and change shape as the organs they line expand or contract. These cells normally have a flat, squamous appearance when at rest but become more cuboidal and columnar when the organ is full. Transitional cell carcinomas typically start in the urothelium, which is the innermost lining of the urinary tract.

Transitional cell carcinoma can be classified as non-invasive (also called papillary or superficial), invasive, or both. Non-invasive TCCs are confined to the urothelium and have not grown into the underlying connective tissue. Invasive TCCs have grown through the urothelium and invaded the lamina propria (a layer of connective tissue beneath the urothelium) or the muscle wall of the bladder.

Transitional cell carcinoma can also be categorized as low-grade or high-grade, depending on how abnormal the cancer cells look under a microscope and how likely they are to grow and spread. Low-grade TCCs tend to have a better prognosis than high-grade TCCs.

Treatment for transitional cell carcinoma depends on the stage and grade of the cancer, as well as other factors such as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or immunotherapy.

Paclitaxel is a chemotherapeutic agent derived from the bark of the Pacific yew tree (Taxus brevifolia). It is an antimicrotubule agent that promotes the assembly and stabilization of microtubules, thereby interfering with the normal dynamic reorganization of the microtubule network that is essential for cell division.

Paclitaxel is used in the treatment of various types of cancer including ovarian, breast, lung, and pancreatic cancers. It works by inhibiting the disassembly of microtubules, which prevents the separation of chromosomes during mitosis, leading to cell cycle arrest and apoptosis (programmed cell death).

Common side effects of paclitaxel include neutropenia (low white blood cell count), anemia (low red blood cell count), alopecia (hair loss), peripheral neuropathy (nerve damage causing numbness or tingling in the hands and feet), myalgias (muscle pain), arthralgias (joint pain), and hypersensitivity reactions.

Breast neoplasms refer to abnormal growths in the breast tissue that can be benign or malignant. Benign breast neoplasms are non-cancerous tumors or growths, while malignant breast neoplasms are cancerous tumors that can invade surrounding tissues and spread to other parts of the body.

Breast neoplasms can arise from different types of cells in the breast, including milk ducts, milk sacs (lobules), or connective tissue. The most common type of breast cancer is ductal carcinoma, which starts in the milk ducts and can spread to other parts of the breast and nearby structures.

Breast neoplasms are usually detected through screening methods such as mammography, ultrasound, or MRI, or through self-examination or clinical examination. Treatment options for breast neoplasms depend on several factors, including the type and stage of the tumor, the patient's age and overall health, and personal preferences. Treatment may include surgery, radiation therapy, chemotherapy, hormone therapy, or targeted therapy.

RNA (Ribonucleic acid) is a single-stranded molecule similar in structure to DNA, involved in the process of protein synthesis in the cell. It acts as a messenger carrying genetic information from DNA to the ribosomes, where proteins are produced.

A neoplasm, on the other hand, is an abnormal growth of cells, which can be benign or malignant. Benign neoplasms are not cancerous and do not invade nearby tissues or spread to other parts of the body. Malignant neoplasms, however, are cancerous and have the potential to invade surrounding tissues and spread to distant sites in the body through a process called metastasis.

Therefore, an 'RNA neoplasm' is not a recognized medical term as RNA is not a type of growth or tumor. However, there are certain types of cancer-causing viruses known as oncoviruses that contain RNA as their genetic material and can cause neoplasms. For example, human T-cell leukemia virus (HTLV-1) and hepatitis C virus (HCV) are RNA viruses that can cause certain types of cancer in humans.

Drug screening assays for antitumor agents are laboratory tests used to identify and evaluate the effectiveness of potential drugs or compounds that can inhibit the growth of tumor cells or induce their death. These assays are typically performed in vitro (in a test tube or petri dish) using cell cultures of various types of cancer cells.

The assays measure different parameters such as cell viability, proliferation, apoptosis (programmed cell death), and cytotoxicity to determine the ability of the drug to kill or inhibit the growth of tumor cells. The results of these assays can help researchers identify promising antitumor agents that can be further developed for clinical use in cancer treatment.

There are different types of drug screening assays for antitumor agents, including high-throughput screening (HTS) assays, which allow for the rapid and automated testing of a large number of compounds against various cancer cell lines. Other types of assays include phenotypic screening assays, target-based screening assays, and functional screening assays, each with its own advantages and limitations.

Overall, drug screening assays for antitumor agents play a critical role in the development of new cancer therapies by providing valuable information on the activity and safety of potential drugs, helping to identify effective treatments and reduce the time and cost associated with bringing new drugs to market.

Adenosquamous carcinoma is a rare type of cancer that contains two types of cells: glandular (adeno) and squamous. This mixed composition leads to a unique microscopic appearance and more aggressive behavior compared to other types of carcinomas. Adenosquamous carcinoma can occur in various organs, such as the lung, pancreas, cervix, and skin.

The glandular (adeno) component is made up of columnar epithelial cells that form glands or tubular structures. These cells produce mucus or other secretions. The squamous component consists of flat, scale-like cells that resemble the cells found in the outer layer of the skin.

The presence of both adeno and squamous components in a single tumor can lead to more rapid growth, increased likelihood of metastasis (spreading to other parts of the body), and poorer prognosis compared to carcinomas with only one cell type. Treatment typically involves surgical resection, radiation therapy, chemotherapy, or a combination of these approaches, depending on the location and stage of the cancer.

Chromogranins are a group of proteins that are stored in the secretory vesicles of neuroendocrine cells, including neurons and endocrine cells. These proteins are co-released with neurotransmitters and hormones upon stimulation of the cells. Chromogranin A is the most abundant and best studied member of this protein family.

Chromogranins have several functions in the body. They play a role in the biogenesis, processing, and storage of neuropeptides and neurotransmitters within secretory vesicles. Additionally, chromogranins can be cleaved into smaller peptides, some of which have hormonal or regulatory activities. For example, vasostatin-1, a peptide derived from chromogranin A, has been shown to have vasodilatory and cardioprotective effects.

Measurement of chromogranin levels in blood can be used as a biomarker for the diagnosis and monitoring of neuroendocrine tumors, which are characterized by excessive secretion of chromogranins and other neuroendocrine markers.

Antineoplastic agents, phytogenic, also known as plant-derived anticancer drugs, are medications that are derived from plants and used to treat cancer. These agents have natural origins and work by interfering with the growth and multiplication of cancer cells, helping to slow or stop the spread of the disease. Some examples of antineoplastic agents, phytogenic include paclitaxel (Taxol), vincristine, vinblastine, and etoposide. These drugs are often used in combination with other treatments such as surgery, radiation therapy, and other medications to provide a comprehensive approach to cancer care.

Western blotting is a laboratory technique used in molecular biology to detect and quantify specific proteins in a mixture of many different proteins. This technique is commonly used to confirm the expression of a protein of interest, determine its size, and investigate its post-translational modifications. The name "Western" blotting distinguishes this technique from Southern blotting (for DNA) and Northern blotting (for RNA).

The Western blotting procedure involves several steps:

1. Protein extraction: The sample containing the proteins of interest is first extracted, often by breaking open cells or tissues and using a buffer to extract the proteins.
2. Separation of proteins by electrophoresis: The extracted proteins are then separated based on their size by loading them onto a polyacrylamide gel and running an electric current through the gel (a process called sodium dodecyl sulfate-polyacrylamide gel electrophoresis or SDS-PAGE). This separates the proteins according to their molecular weight, with smaller proteins migrating faster than larger ones.
3. Transfer of proteins to a membrane: After separation, the proteins are transferred from the gel onto a nitrocellulose or polyvinylidene fluoride (PVDF) membrane using an electric current in a process called blotting. This creates a replica of the protein pattern on the gel but now immobilized on the membrane for further analysis.
4. Blocking: The membrane is then blocked with a blocking agent, such as non-fat dry milk or bovine serum albumin (BSA), to prevent non-specific binding of antibodies in subsequent steps.
5. Primary antibody incubation: A primary antibody that specifically recognizes the protein of interest is added and allowed to bind to its target protein on the membrane. This step may be performed at room temperature or 4°C overnight, depending on the antibody's properties.
6. Washing: The membrane is washed with a buffer to remove unbound primary antibodies.
7. Secondary antibody incubation: A secondary antibody that recognizes the primary antibody (often coupled to an enzyme or fluorophore) is added and allowed to bind to the primary antibody. This step may involve using a horseradish peroxidase (HRP)-conjugated or alkaline phosphatase (AP)-conjugated secondary antibody, depending on the detection method used later.
8. Washing: The membrane is washed again to remove unbound secondary antibodies.
9. Detection: A detection reagent is added to visualize the protein of interest by detecting the signal generated from the enzyme-conjugated or fluorophore-conjugated secondary antibody. This can be done using chemiluminescent, colorimetric, or fluorescent methods.
10. Analysis: The resulting image is analyzed to determine the presence and quantity of the protein of interest in the sample.

Western blotting is a powerful technique for identifying and quantifying specific proteins within complex mixtures. It can be used to study protein expression, post-translational modifications, protein-protein interactions, and more. However, it requires careful optimization and validation to ensure accurate and reproducible results.

Keratins are a type of fibrous structural proteins that constitute the main component of the integumentary system, which includes the hair, nails, and skin of vertebrates. They are also found in other tissues such as horns, hooves, feathers, and reptilian scales. Keratins are insoluble proteins that provide strength, rigidity, and protection to these structures.

Keratins are classified into two types: soft keratins (Type I) and hard keratins (Type II). Soft keratins are found in the skin and simple epithelial tissues, while hard keratins are present in structures like hair, nails, horns, and hooves.

Keratin proteins have a complex structure consisting of several domains, including an alpha-helical domain, beta-pleated sheet domain, and a non-repetitive domain. These domains provide keratin with its unique properties, such as resistance to heat, chemicals, and mechanical stress.

In summary, keratins are fibrous structural proteins that play a crucial role in providing strength, rigidity, and protection to various tissues in the body.

A Tumor Stem Cell Assay is not a widely accepted or standardized medical definition. However, in the context of cancer research, a tumor stem cell assay generally refers to an experimental procedure used to identify and isolate cancer stem cells (also known as tumor-initiating cells) from a tumor sample.

Cancer stem cells are a subpopulation of cells within a tumor that are believed to be responsible for driving tumor growth, metastasis, and resistance to therapy. They have the ability to self-renew and differentiate into various cell types within the tumor, making them a promising target for cancer therapies.

A tumor stem cell assay typically involves isolating cells from a tumor sample and subjecting them to various tests to identify those with stem cell-like properties. These tests may include assessing their ability to form tumors in animal models or their expression of specific surface markers associated with cancer stem cells. The goal of the assay is to provide researchers with a better understanding of the biology of cancer stem cells and to develop new therapies that target them specifically.

Cranial irradiation is a medical treatment that involves the use of radiation therapy to target the brain. It is often used to treat various conditions affecting the brain, such as brain tumors, leukemia, and certain neurological disorders. The radiation is directed at the skull and can be focused on specific areas of the brain or delivered more broadly, depending on the nature and location of the condition being treated.

The goal of cranial irradiation may be to destroy cancer cells, reduce the size of tumors, prevent the spread of cancer, or provide symptomatic relief for patients with advanced disease. However, it is important to note that cranial irradiation can have side effects, including hair loss, fatigue, memory problems, and cognitive changes, among others. These side effects can vary in severity and duration depending on the individual patient and the specific treatment regimen.

Disease-free survival (DFS) is a term used in medical research and clinical practice, particularly in the field of oncology. It refers to the length of time after primary treatment for a cancer during which no evidence of the disease can be found. This means that the patient shows no signs or symptoms of the cancer, and any imaging studies or other tests do not reveal any tumors or other indications of the disease.

DFS is often used as an important endpoint in clinical trials to evaluate the effectiveness of different treatments for cancer. By measuring the length of time until the cancer recurs or a new cancer develops, researchers can get a better sense of how well a particular treatment is working and whether it is improving patient outcomes.

It's important to note that DFS is not the same as overall survival (OS), which refers to the length of time from primary treatment until death from any cause. While DFS can provide valuable information about the effectiveness of cancer treatments, it does not necessarily reflect the impact of those treatments on patients' overall survival.

Disease progression is the worsening or advancement of a medical condition over time. It refers to the natural course of a disease, including its development, the severity of symptoms and complications, and the impact on the patient's overall health and quality of life. Understanding disease progression is important for developing appropriate treatment plans, monitoring response to therapy, and predicting outcomes.

The rate of disease progression can vary widely depending on the type of medical condition, individual patient factors, and the effectiveness of treatment. Some diseases may progress rapidly over a short period of time, while others may progress more slowly over many years. In some cases, disease progression may be slowed or even halted with appropriate medical interventions, while in other cases, the progression may be inevitable and irreversible.

In clinical practice, healthcare providers closely monitor disease progression through regular assessments, imaging studies, and laboratory tests. This information is used to guide treatment decisions and adjust care plans as needed to optimize patient outcomes and improve quality of life.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that originates from the uncontrolled growth of Merkel cells, which are specialized nerve cells found in the top layer of the skin (epidermis). These cells are responsible for touch sensation. MCC typically presents as a painless, firm, rapidly growing nodule or mass, often on sun-exposed areas such as the head, neck, and arms of older adults.

The primary risk factors for Merkel cell carcinoma include:

1. Exposure to ultraviolet (UV) radiation from sunlight or tanning beds
2. Advanced age (most commonly occurs in people over 50)
3. A weakened immune system due to conditions like HIV/AIDS, organ transplantation, or long-term use of immunosuppressive medications
4. History of other types of skin cancer, such as melanoma or basal cell carcinoma
5. Fair skin and light eye color

MCC is considered an aggressive cancer because it can spread quickly to nearby lymph nodes and other parts of the body (metastasize). The major prognostic factor for MCC is the presence or absence of lymph node involvement at the time of diagnosis. Early detection and treatment are crucial for improving outcomes.

Standard treatments for Merkel cell carcinoma include surgical excision, radiation therapy, and chemotherapy. Immunotherapy with drugs like avelumab has also shown promising results in treating advanced stages of MCC. Regular follow-up care is essential to monitor for recurrence or metastasis.

Keratin-19 is a type I acidic keratin that is primarily expressed in simple epithelia, such as the gastrointestinal tract, respiratory tract, and epidermal appendages (e.g., hair follicles, sweat glands). It plays an essential role in maintaining the structure and integrity of these tissues by forming intermediate filaments that provide mechanical support to cells.

Keratin-19 is often used as a marker for simple epithelial differentiation and has been implicated in various pathological conditions, including cancer progression and metastasis. Mutations in the KRT19 gene, which encodes keratin-19, have been associated with certain genetic disorders, such as epidermolysis bullosa simplex, a blistering skin disorder.

In summary, Keratin-19 is an important structural protein expressed in simple epithelia that plays a crucial role in maintaining tissue integrity and has implications in various pathological conditions.

Tumor suppressor protein p53, also known as p53 or tumor protein p53, is a nuclear phosphoprotein that plays a crucial role in preventing cancer development and maintaining genomic stability. It does so by regulating the cell cycle and acting as a transcription factor for various genes involved in apoptosis (programmed cell death), DNA repair, and cell senescence (permanent cell growth arrest).

In response to cellular stress, such as DNA damage or oncogene activation, p53 becomes activated and accumulates in the nucleus. Activated p53 can then bind to specific DNA sequences and promote the transcription of target genes that help prevent the proliferation of potentially cancerous cells. These targets include genes involved in cell cycle arrest (e.g., CDKN1A/p21), apoptosis (e.g., BAX, PUMA), and DNA repair (e.g., GADD45).

Mutations in the TP53 gene, which encodes p53, are among the most common genetic alterations found in human cancers. These mutations often lead to a loss or reduction of p53's tumor suppressive functions, allowing cancer cells to proliferate uncontrollably and evade apoptosis. As a result, p53 has been referred to as "the guardian of the genome" due to its essential role in preventing tumorigenesis.

Intraductal carcinoma, noninfiltrating is a medical term used to describe a type of breast cancer that is confined to the milk ducts of the breast. It is also sometimes referred to as ductal carcinoma in situ (DCIS). Noninfiltrating means that the cancer cells have not spread beyond the ducts into the surrounding breast tissue or elsewhere in the body.

In this type of cancer, abnormal cells line the milk ducts and fill the inside of the ducts. These abnormal cells may look like cancer cells under a microscope, but they have not grown through the walls of the ducts into the surrounding breast tissue. However, if left untreated, noninfiltrating intraductal carcinoma can progress to an invasive form of breast cancer where the cancer cells spread beyond the milk ducts and invade the surrounding breast tissue.

It is important to note that while noninfiltrating intraductal carcinoma is considered a precancerous condition, it still requires medical treatment to prevent the development of invasive breast cancer. Treatment options may include surgery, radiation therapy, or hormone therapy, depending on the size and location of the tumor and other individual factors.

Gene expression is the process by which the information encoded in a gene is used to synthesize a functional gene product, such as a protein or RNA molecule. This process involves several steps: transcription, RNA processing, and translation. During transcription, the genetic information in DNA is copied into a complementary RNA molecule, known as messenger RNA (mRNA). The mRNA then undergoes RNA processing, which includes adding a cap and tail to the mRNA and splicing out non-coding regions called introns. The resulting mature mRNA is then translated into a protein on ribosomes in the cytoplasm through the process of translation.

The regulation of gene expression is a complex and highly controlled process that allows cells to respond to changes in their environment, such as growth factors, hormones, and stress signals. This regulation can occur at various stages of gene expression, including transcriptional activation or repression, RNA processing, mRNA stability, and translation. Dysregulation of gene expression has been implicated in many diseases, including cancer, genetic disorders, and neurological conditions.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

Adenoid cystic carcinoma (AdCC) is a rare type of cancer that can occur in various glands and tissues of the body, most commonly in the salivary glands. AdCC is characterized by its slow growth and tendency to spread along nerves. It typically forms solid, cystic, or mixed tumors with distinct histological features, including epithelial cells arranged in tubular, cribriform, or solid patterns.

The term "carcinoma" refers to a malignant tumor originating from the epithelial cells lining various organs and glands. In this case, adenoid cystic carcinoma is a specific type of carcinoma that arises in the salivary glands or other glandular tissues.

The primary treatment options for AdCC include surgical resection, radiation therapy, and sometimes chemotherapy. Despite its slow growth, adenoid cystic carcinoma has a propensity to recur locally and metastasize to distant sites such as the lungs, bones, and liver. Long-term follow-up is essential due to the risk of late recurrences.

A "Drug Administration Schedule" refers to the plan for when and how a medication should be given to a patient. It includes details such as the dose, frequency (how often it should be taken), route (how it should be administered, such as orally, intravenously, etc.), and duration (how long it should be taken) of the medication. This schedule is often created and prescribed by healthcare professionals, such as doctors or pharmacists, to ensure that the medication is taken safely and effectively. It may also include instructions for missed doses or changes in the dosage.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Signal transduction is the process by which a cell converts an extracellular signal, such as a hormone or neurotransmitter, into an intracellular response. This involves a series of molecular events that transmit the signal from the cell surface to the interior of the cell, ultimately resulting in changes in gene expression, protein activity, or metabolism.

The process typically begins with the binding of the extracellular signal to a receptor located on the cell membrane. This binding event activates the receptor, which then triggers a cascade of intracellular signaling molecules, such as second messengers, protein kinases, and ion channels. These molecules amplify and propagate the signal, ultimately leading to the activation or inhibition of specific cellular responses.

Signal transduction pathways are highly regulated and can be modulated by various factors, including other signaling molecules, post-translational modifications, and feedback mechanisms. Dysregulation of these pathways has been implicated in a variety of diseases, including cancer, diabetes, and neurological disorders.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Proto-oncogene proteins c-kit, also known as CD117 or stem cell factor receptor, are transmembrane receptor tyrosine kinases that play crucial roles in various biological processes, including cell survival, proliferation, differentiation, and migration. They are encoded by the c-KIT gene located on human chromosome 4q12.

These proteins consist of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain. The binding of their ligand, stem cell factor (SCF), leads to receptor dimerization, autophosphorylation, and activation of several downstream signaling pathways such as PI3K/AKT, MAPK/ERK, and JAK/STAT.

Abnormal activation or mutation of c-kit proto-oncogene proteins has been implicated in the development and progression of various malignancies, including gastrointestinal stromal tumors (GISTs), acute myeloid leukemia (AML), mast cell diseases, and melanoma. Targeted therapies against c-kit, such as imatinib mesylate (Gleevec), have shown promising results in the treatment of these malignancies.

Cell survival refers to the ability of a cell to continue living and functioning normally, despite being exposed to potentially harmful conditions or treatments. This can include exposure to toxins, radiation, chemotherapeutic drugs, or other stressors that can damage cells or interfere with their normal processes.

In scientific research, measures of cell survival are often used to evaluate the effectiveness of various therapies or treatments. For example, researchers may expose cells to a particular drug or treatment and then measure the percentage of cells that survive to assess its potential therapeutic value. Similarly, in toxicology studies, measures of cell survival can help to determine the safety of various chemicals or substances.

It's important to note that cell survival is not the same as cell proliferation, which refers to the ability of cells to divide and multiply. While some treatments may promote cell survival, they may also inhibit cell proliferation, making them useful for treating diseases such as cancer. Conversely, other treatments may be designed to specifically target and kill cancer cells, even if it means sacrificing some healthy cells in the process.

Tumor suppressor genes are a type of gene that helps to regulate and prevent cells from growing and dividing too rapidly or in an uncontrolled manner. They play a critical role in preventing the formation of tumors and cancer. When functioning properly, tumor suppressor genes help to repair damaged DNA, control the cell cycle, and trigger programmed cell death (apoptosis) when necessary. However, when these genes are mutated or altered, they can lose their ability to function correctly, leading to uncontrolled cell growth and the development of tumors. Examples of tumor suppressor genes include TP53, BRCA1, and BRCA2.

A xenograft model antitumor assay is a type of preclinical cancer research study that involves transplanting human tumor cells or tissues into an immunodeficient mouse. This model allows researchers to study the effects of various treatments, such as drugs or immune therapies, on human tumors in a living organism.

In this assay, human tumor cells or tissues are implanted into the mouse, typically under the skin or in another organ, where they grow and form a tumor. Once the tumor has established, the mouse is treated with the experimental therapy, and the tumor's growth is monitored over time. The response of the tumor to the treatment is then assessed by measuring changes in tumor size or weight, as well as other parameters such as survival rate and metastasis.

Xenograft model antitumor assays are useful for evaluating the efficacy and safety of new cancer therapies before they are tested in human clinical trials. They provide valuable information on how the tumors respond to treatment, drug pharmacokinetics, and toxicity, which can help researchers optimize dosing regimens and identify potential side effects. However, it is important to note that xenograft models have limitations, such as differences in tumor biology between mice and humans, and may not always predict how well a therapy will work in human patients.

Medullary carcinoma is a type of cancer that develops in the neuroendocrine cells of the thyroid gland. These cells produce hormones that help regulate various bodily functions. Medullary carcinoma is a relatively rare form of thyroid cancer, accounting for about 5-10% of all cases.

Medullary carcinoma is characterized by the presence of certain genetic mutations that cause the overproduction of calcitonin, a hormone produced by the neuroendocrine cells. This overproduction can lead to the formation of tumors in the thyroid gland.

Medullary carcinoma can be hereditary or sporadic. Hereditary forms of the disease are caused by mutations in the RET gene and are often associated with multiple endocrine neoplasia type 2 (MEN 2), a genetic disorder that affects the thyroid gland, adrenal glands, and parathyroid glands. Sporadic forms of medullary carcinoma, on the other hand, are not inherited and occur randomly in people with no family history of the disease.

Medullary carcinoma is typically more aggressive than other types of thyroid cancer and tends to spread (metastasize) to other parts of the body, such as the lymph nodes, lungs, and liver. Symptoms may include a lump or nodule in the neck, difficulty swallowing, hoarseness, and coughing. Treatment options may include surgery, radiation therapy, and chemotherapy. Regular monitoring of calcitonin levels is also recommended to monitor the effectiveness of treatment and detect any recurrence of the disease.

The Kaplan-Meier estimate is a statistical method used to calculate the survival probability over time in a population. It is commonly used in medical research to analyze time-to-event data, such as the time until a patient experiences a specific event like disease progression or death. The Kaplan-Meier estimate takes into account censored data, which occurs when some individuals are lost to follow-up before experiencing the event of interest.

The method involves constructing a survival curve that shows the proportion of subjects still surviving at different time points. At each time point, the survival probability is calculated as the product of the conditional probabilities of surviving from one time point to the next. The Kaplan-Meier estimate provides an unbiased and consistent estimator of the survival function, even when censoring is present.

In summary, the Kaplan-Meier estimate is a crucial tool in medical research for analyzing time-to-event data and estimating survival probabilities over time while accounting for censored observations.

Acute Lung Injury (ALI) is a medical condition characterized by inflammation and damage to the lung tissue, which can lead to difficulty breathing and respiratory failure. It is often caused by direct or indirect injury to the lungs, such as pneumonia, sepsis, trauma, or inhalation of harmful substances.

The symptoms of ALI include shortness of breath, rapid breathing, cough, and low oxygen levels in the blood. The condition can progress rapidly and may require mechanical ventilation to support breathing. Treatment typically involves addressing the underlying cause of the injury, providing supportive care, and managing symptoms.

In severe cases, ALI can lead to Acute Respiratory Distress Syndrome (ARDS), a more serious and life-threatening condition that requires intensive care unit (ICU) treatment.

Carcinoma, lobular is a type of breast cancer that begins in the milk-producing glands (lobules) of the breast. It can be either invasive or non-invasive (in situ). Invasive lobular carcinoma (ILC) occurs when the cancer cells break through the wall of the lobule and invade the surrounding breast tissue, and can potentially spread to other parts of the body. Non-invasive lobular carcinoma (LCIS), on the other hand, refers to the presence of abnormal cells within the lobule that have not invaded nearby breast tissue.

ILC is usually detected as a mass or thickening in the breast, and it may not cause any symptoms or show up on mammograms until it has grown quite large. It tends to grow more slowly than some other types of breast cancer, but it can still be serious and require extensive treatment. LCIS does not typically cause any symptoms and is usually found during a biopsy performed for another reason.

Treatment options for carcinoma, lobular depend on several factors, including the stage of the cancer, the patient's overall health, and their personal preferences. Treatment may include surgery, radiation therapy, chemotherapy, hormone therapy, or targeted therapy. Regular follow-up care is essential to monitor for recurrence or the development of new cancers.

Thyroid neoplasms refer to abnormal growths or tumors in the thyroid gland, which can be benign (non-cancerous) or malignant (cancerous). These growths can vary in size and may cause a noticeable lump or nodule in the neck. Thyroid neoplasms can also affect the function of the thyroid gland, leading to hormonal imbalances and related symptoms. The exact causes of thyroid neoplasms are not fully understood, but risk factors include radiation exposure, family history, and certain genetic conditions. It is important to note that most thyroid nodules are benign, but a proper medical evaluation is necessary to determine the nature of the growth and develop an appropriate treatment plan.

Small cell sarcoma is a very rare and aggressive type of cancer that affects the connective tissues in the body, such as muscles, tendons, bones, cartilage, and fat. It is called "small cell" because the cancer cells are small and appear round or oval in shape, with scant cytoplasm and finely granular chromatin.

Small cell sarcoma typically occurs in adults between the ages of 40 and 70, and it can develop in any part of the body. However, it is most commonly found in the extremities, trunk, and retroperitoneum. The exact cause of small cell sarcoma is not known, but it is thought to be associated with genetic mutations that occur during a person's lifetime.

Small cell sarcoma can be difficult to diagnose because it often does not cause any symptoms until it has advanced to an aggressive stage. When symptoms do occur, they may include pain, swelling, or a lump in the affected area. Diagnosis typically involves a biopsy of the tumor tissue, followed by imaging tests such as CT scans, MRI scans, or PET scans to determine the extent of the cancer.

Treatment for small cell sarcoma usually involves surgery to remove the tumor, followed by radiation therapy and/or chemotherapy to kill any remaining cancer cells. However, because small cell sarcoma is so rare and aggressive, treatment options may be limited, and the prognosis is often poor. Clinical trials of new treatments are also an option for some patients.

Brain neoplasms, also known as brain tumors, are abnormal growths of cells within the brain. These growths can be benign (non-cancerous) or malignant (cancerous). Benign brain tumors typically grow slowly and do not spread to other parts of the body. However, they can still cause serious problems if they press on sensitive areas of the brain. Malignant brain tumors, on the other hand, are cancerous and can grow quickly, invading surrounding brain tissue and spreading to other parts of the brain or spinal cord.

Brain neoplasms can arise from various types of cells within the brain, including glial cells (which provide support and insulation for nerve cells), neurons (nerve cells that transmit signals in the brain), and meninges (the membranes that cover the brain and spinal cord). They can also result from the spread of cancer cells from other parts of the body, known as metastatic brain tumors.

Symptoms of brain neoplasms may vary depending on their size, location, and growth rate. Common symptoms include headaches, seizures, weakness or paralysis in the limbs, difficulty with balance and coordination, changes in speech or vision, confusion, memory loss, and changes in behavior or personality.

Treatment for brain neoplasms depends on several factors, including the type, size, location, and grade of the tumor, as well as the patient's age and overall health. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches. Regular follow-up care is essential to monitor for recurrence and manage any long-term effects of treatment.

Carcinoembryonic antigen (CEA) is a protein that is normally produced in small amounts during fetal development. In adults, low levels of CEA can be found in the blood, but elevated levels are typically associated with various types of cancer, particularly colon, rectal, and breast cancer.

Measurement of CEA levels in the blood is sometimes used as a tumor marker to monitor response to treatment, detect recurrence, or screen for secondary cancers in patients with a history of certain types of cancer. However, it's important to note that CEA is not a specific or sensitive indicator of cancer and can be elevated in various benign conditions such as inflammation, smoking, and some gastrointestinal diseases. Therefore, the test should be interpreted in conjunction with other clinical and diagnostic findings.

Gene amplification is a process in molecular biology where a specific gene or set of genes are copied multiple times, leading to an increased number of copies of that gene within the genome. This can occur naturally in cells as a response to various stimuli, such as stress or exposure to certain chemicals, but it can also be induced artificially through laboratory techniques for research purposes.

In cancer biology, gene amplification is often associated with tumor development and progression, where the amplified genes can contribute to increased cell growth, survival, and drug resistance. For example, the overamplification of the HER2/neu gene in breast cancer has been linked to more aggressive tumors and poorer patient outcomes.

In diagnostic and research settings, gene amplification techniques like polymerase chain reaction (PCR) are commonly used to detect and analyze specific genes or genetic sequences of interest. These methods allow researchers to quickly and efficiently generate many copies of a particular DNA sequence, facilitating downstream analysis and detection of low-abundance targets.

Esophageal neoplasms refer to abnormal growths in the tissue of the esophagus, which is the muscular tube that connects the throat to the stomach. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant esophageal neoplasms are typically classified as either squamous cell carcinomas or adenocarcinomas, depending on the type of cell from which they originate.

Esophageal cancer is a serious and often life-threatening condition that can cause symptoms such as difficulty swallowing, chest pain, weight loss, and coughing. Risk factors for esophageal neoplasms include smoking, heavy alcohol consumption, gastroesophageal reflux disease (GERD), and Barrett's esophagus. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

BALB/c is an inbred strain of laboratory mouse that is widely used in biomedical research. The strain was developed at the Institute of Cancer Research in London by Henry Baldwin and his colleagues in the 1920s, and it has since become one of the most commonly used inbred strains in the world.

BALB/c mice are characterized by their black coat color, which is determined by a recessive allele at the tyrosinase locus. They are also known for their docile and friendly temperament, making them easy to handle and work with in the laboratory.

One of the key features of BALB/c mice that makes them useful for research is their susceptibility to certain types of tumors and immune responses. For example, they are highly susceptible to developing mammary tumors, which can be induced by chemical carcinogens or viral infection. They also have a strong Th2-biased immune response, which makes them useful models for studying allergic diseases and asthma.

BALB/c mice are also commonly used in studies of genetics, neuroscience, behavior, and infectious diseases. Because they are an inbred strain, they have a uniform genetic background, which makes it easier to control for genetic factors in experiments. Additionally, because they have been bred in the laboratory for many generations, they are highly standardized and reproducible, making them ideal subjects for scientific research.

Gene expression profiling is a laboratory technique used to measure the activity (expression) of thousands of genes at once. This technique allows researchers and clinicians to identify which genes are turned on or off in a particular cell, tissue, or organism under specific conditions, such as during health, disease, development, or in response to various treatments.

The process typically involves isolating RNA from the cells or tissues of interest, converting it into complementary DNA (cDNA), and then using microarray or high-throughput sequencing technologies to determine which genes are expressed and at what levels. The resulting data can be used to identify patterns of gene expression that are associated with specific biological states or processes, providing valuable insights into the underlying molecular mechanisms of diseases and potential targets for therapeutic intervention.

In recent years, gene expression profiling has become an essential tool in various fields, including cancer research, drug discovery, and personalized medicine, where it is used to identify biomarkers of disease, predict patient outcomes, and guide treatment decisions.

Nasopharyngeal neoplasms refer to abnormal growths or tumors in the nasopharynx, which is the upper part of the pharynx (throat) behind the nose. These growths can be benign (non-cancerous) or malignant (cancerous).

Malignant nasopharyngeal neoplasms are often referred to as nasopharyngeal carcinoma or cancer. There are different types of nasopharyngeal carcinomas, including keratinizing squamous cell carcinoma, non-keratinizing carcinoma, and basaloid squamous cell carcinoma.

The risk factors for developing nasopharyngeal neoplasms include exposure to the Epstein-Barr virus (EBV), consumption of certain foods, smoking, and genetic factors. Symptoms may include a lump in the neck, nosebleeds, hearing loss, ringing in the ears, and difficulty swallowing or speaking. Treatment options depend on the type, size, and stage of the neoplasm and may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

Sensitivity and specificity are statistical measures used to describe the performance of a diagnostic test or screening tool in identifying true positive and true negative results.

* Sensitivity refers to the proportion of people who have a particular condition (true positives) who are correctly identified by the test. It is also known as the "true positive rate" or "recall." A highly sensitive test will identify most or all of the people with the condition, but may also produce more false positives.
* Specificity refers to the proportion of people who do not have a particular condition (true negatives) who are correctly identified by the test. It is also known as the "true negative rate." A highly specific test will identify most or all of the people without the condition, but may also produce more false negatives.

In medical testing, both sensitivity and specificity are important considerations when evaluating a diagnostic test. High sensitivity is desirable for screening tests that aim to identify as many cases of a condition as possible, while high specificity is desirable for confirmatory tests that aim to rule out the condition in people who do not have it.

It's worth noting that sensitivity and specificity are often influenced by factors such as the prevalence of the condition in the population being tested, the threshold used to define a positive result, and the reliability and validity of the test itself. Therefore, it's important to consider these factors when interpreting the results of a diagnostic test.

Flow cytometry is a medical and research technique used to measure physical and chemical characteristics of cells or particles, one cell at a time, as they flow in a fluid stream through a beam of light. The properties measured include:

* Cell size (light scatter)
* Cell internal complexity (granularity, also light scatter)
* Presence or absence of specific proteins or other molecules on the cell surface or inside the cell (using fluorescent antibodies or other fluorescent probes)

The technique is widely used in cell counting, cell sorting, protein engineering, biomarker discovery and monitoring disease progression, particularly in hematology, immunology, and cancer research.

A biopsy is a medical procedure in which a small sample of tissue is taken from the body to be examined under a microscope for the presence of disease. This can help doctors diagnose and monitor various medical conditions, such as cancer, infections, or autoimmune disorders. The type of biopsy performed will depend on the location and nature of the suspected condition. Some common types of biopsies include:

1. Incisional biopsy: In this procedure, a surgeon removes a piece of tissue from an abnormal area using a scalpel or other surgical instrument. This type of biopsy is often used when the lesion is too large to be removed entirely during the initial biopsy.

2. Excisional biopsy: An excisional biopsy involves removing the entire abnormal area, along with a margin of healthy tissue surrounding it. This technique is typically employed for smaller lesions or when cancer is suspected.

3. Needle biopsy: A needle biopsy uses a thin, hollow needle to extract cells or fluid from the body. There are two main types of needle biopsies: fine-needle aspiration (FNA) and core needle biopsy. FNA extracts loose cells, while a core needle biopsy removes a small piece of tissue.

4. Punch biopsy: In a punch biopsy, a round, sharp tool is used to remove a small cylindrical sample of skin tissue. This type of biopsy is often used for evaluating rashes or other skin abnormalities.

5. Shave biopsy: During a shave biopsy, a thin slice of tissue is removed from the surface of the skin using a sharp razor-like instrument. This technique is typically used for superficial lesions or growths on the skin.

After the biopsy sample has been collected, it is sent to a laboratory where a pathologist will examine the tissue under a microscope and provide a diagnosis based on their findings. The results of the biopsy can help guide further treatment decisions and determine the best course of action for managing the patient's condition.

Chromogranin A is a protein that is widely used as a marker for neuroendocrine tumors. These are tumors that arise from cells of the neuroendocrine system, which is a network of cells throughout the body that produce hormones and help to regulate various bodily functions. Chromogranin A is stored in secretory granules within these cells and is released into the bloodstream when the cells are stimulated to release their hormones.

Chromogranin A is measured in the blood as a way to help diagnose neuroendocrine tumors, monitor the effectiveness of treatment, and track the progression of the disease. Elevated levels of chromogranin A in the blood may indicate the presence of a neuroendocrine tumor, although other factors can also cause an increase in this protein.

It's important to note that while chromogranin A is a useful marker for neuroendocrine tumors, it is not specific to any one type of tumor and should be used in conjunction with other diagnostic tests and clinical evaluation.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

'Antibodies, Neoplasm' is a medical term that refers to abnormal antibodies produced by neoplastic cells, which are cells that have undergone uncontrolled division and form a tumor or malignancy. These antibodies can be produced in large quantities and may have altered structures or functions compared to normal antibodies.

Neoplastic antibodies can arise from various types of malignancies, including leukemias, lymphomas, and multiple myeloma. In some cases, these abnormal antibodies can interfere with the normal functioning of the immune system and contribute to the progression of the disease.

In addition, neoplastic antibodies can also be used as tumor markers for diagnostic purposes. For example, certain types of monoclonal gammopathy, such as multiple myeloma, are characterized by the overproduction of a single type of immunoglobulin, which can be detected in the blood or urine and used to monitor the disease.

Overall, 'Antibodies, Neoplasm' is a term that encompasses a wide range of abnormal antibodies produced by neoplastic cells, which can have significant implications for both the diagnosis and treatment of malignancies.

Protein kinase inhibitors (PKIs) are a class of drugs that work by interfering with the function of protein kinases. Protein kinases are enzymes that play a crucial role in many cellular processes by adding a phosphate group to specific proteins, thereby modifying their activity, localization, or interaction with other molecules. This process of adding a phosphate group is known as phosphorylation and is a key mechanism for regulating various cellular functions, including signal transduction, metabolism, and cell division.

In some diseases, such as cancer, protein kinases can become overactive or mutated, leading to uncontrolled cell growth and division. Protein kinase inhibitors are designed to block the activity of these dysregulated kinases, thereby preventing or slowing down the progression of the disease. These drugs can be highly specific, targeting individual protein kinases or families of kinases, making them valuable tools for targeted therapy in cancer and other diseases.

Protein kinase inhibitors can work in various ways to block the activity of protein kinases. Some bind directly to the active site of the enzyme, preventing it from interacting with its substrates. Others bind to allosteric sites, changing the conformation of the enzyme and making it inactive. Still, others target upstream regulators of protein kinases or interfere with their ability to form functional complexes.

Examples of protein kinase inhibitors include imatinib (Gleevec), which targets the BCR-ABL kinase in chronic myeloid leukemia, and gefitinib (Iressa), which inhibits the EGFR kinase in non-small cell lung cancer. These drugs have shown significant clinical benefits in treating these diseases and have become important components of modern cancer therapy.

Paraneoplastic cerebellar degeneration (PCD) is a rare disorder characterized by progressive damage to the cerebellum, the part of the brain responsible for coordinating muscle movements. It is considered a paraneoplastic syndrome, which means it is caused by an abnormal immune system response to a cancerous tumor (neoplasm) located elsewhere in the body.

In PCD, antibodies produced by the immune system to fight the tumor mistakenly attack proteins in the cerebellum that are similar to those found in the tumor. This leads to inflammation and degeneration of the Purkinje cells, a type of neuron critical for maintaining balance and coordinating movements.

PCD can present with symptoms such as unsteady gait, loss of coordination, slurred speech, nystagmus (involuntary eye movement), and tremors. These symptoms often develop rapidly, over the course of days to weeks, and may progress even after the tumor has been removed or treated.

PCD is associated with several types of cancers, including small cell lung cancer, breast cancer, ovarian cancer, Hodgkin's lymphoma, and others. Early diagnosis and treatment of the underlying cancer are essential to slowing down the progression of PCD and improving outcomes.

Tissue Microarray (TMA) analysis is a surgical pathology technique that allows for the simultaneous analysis of multiple tissue samples (known as "cores") from different patients or even different regions of the same tumor, on a single microscope slide. This technique involves the extraction of small cylindrical samples of tissue, which are then arrayed in a grid-like pattern on a recipient paraffin block. Once the TMA is created, sections can be cut and stained with various histochemical or immunohistochemical stains to evaluate the expression of specific proteins or other molecules of interest.

Tissue Array Analysis has become an important tool in biomedical research, enabling high-throughput analysis of tissue samples for molecular markers, gene expression patterns, and other features that can help inform clinical decision making, drug development, and our understanding of disease processes. It's widely used in cancer research to study the heterogeneity of tumors, identify new therapeutic targets, and evaluate patient prognosis.

Doxorubicin is a type of chemotherapy medication known as an anthracycline. It works by interfering with the DNA in cancer cells, which prevents them from growing and multiplying. Doxorubicin is used to treat a wide variety of cancers, including leukemia, lymphoma, breast cancer, lung cancer, ovarian cancer, and many others. It may be given alone or in combination with other chemotherapy drugs.

Doxorubicin is usually administered through a vein (intravenously) and can cause side effects such as nausea, vomiting, hair loss, mouth sores, and increased risk of infection. It can also cause damage to the heart muscle, which can lead to heart failure in some cases. For this reason, doctors may monitor patients' heart function closely while they are receiving doxorubicin treatment.

It is important for patients to discuss the potential risks and benefits of doxorubicin therapy with their healthcare provider before starting treatment.

Drug resistance, also known as antimicrobial resistance, is the ability of a microorganism (such as bacteria, viruses, fungi, or parasites) to withstand the effects of a drug that was originally designed to inhibit or kill it. This occurs when the microorganism undergoes genetic changes that allow it to survive in the presence of the drug. As a result, the drug becomes less effective or even completely ineffective at treating infections caused by these resistant organisms.

Drug resistance can develop through various mechanisms, including mutations in the genes responsible for producing the target protein of the drug, alteration of the drug's target site, modification or destruction of the drug by enzymes produced by the microorganism, and active efflux of the drug from the cell.

The emergence and spread of drug-resistant microorganisms pose significant challenges in medical treatment, as they can lead to increased morbidity, mortality, and healthcare costs. The overuse and misuse of antimicrobial agents, as well as poor infection control practices, contribute to the development and dissemination of drug-resistant strains. To address this issue, it is crucial to promote prudent use of antimicrobials, enhance surveillance and monitoring of resistance patterns, invest in research and development of new antimicrobial agents, and strengthen infection prevention and control measures.

Multiple primary neoplasms refer to the occurrence of more than one primary malignant tumor in an individual, where each tumor is unrelated to the other and originates from separate cells or organs. This differs from metastatic cancer, where a single malignancy spreads to multiple sites in the body. Multiple primary neoplasms can be synchronous (occurring at the same time) or metachronous (occurring at different times). The risk of developing multiple primary neoplasms increases with age and is associated with certain genetic predispositions, environmental factors, and lifestyle choices such as smoking and alcohol consumption.

Ovarian neoplasms refer to abnormal growths or tumors in the ovary, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various cell types within the ovary, including epithelial cells, germ cells, and stromal cells. Ovarian neoplasms are often classified based on their cell type of origin, histological features, and potential for invasive or metastatic behavior.

Epithelial ovarian neoplasms are the most common type and can be further categorized into several subtypes, such as serous, mucinous, endometrioid, clear cell, and Brenner tumors. Some of these epithelial tumors have a higher risk of becoming malignant and spreading to other parts of the body.

Germ cell ovarian neoplasms arise from the cells that give rise to eggs (oocytes) and can include teratomas, dysgerminomas, yolk sac tumors, and embryonal carcinomas. Stromal ovarian neoplasms develop from the connective tissue cells supporting the ovary and can include granulosa cell tumors, thecomas, and fibromas.

It is essential to diagnose and treat ovarian neoplasms promptly, as some malignant forms can be aggressive and potentially life-threatening if not managed appropriately. Regular gynecological exams, imaging studies, and tumor marker tests are often used for early detection and monitoring of ovarian neoplasms. Treatment options may include surgery, chemotherapy, or radiation therapy, depending on the type, stage, and patient's overall health condition.

Urinary Bladder Neoplasms are abnormal growths or tumors in the urinary bladder, which can be benign (non-cancerous) or malignant (cancerous). Malignant neoplasms can be further classified into various types of bladder cancer, such as urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. These malignant tumors often invade surrounding tissues and organs, potentially spreading to other parts of the body (metastasis), which can lead to serious health consequences if not detected and treated promptly and effectively.

Camptothecin is a topoisomerase I inhibitor, which is a type of chemotherapeutic agent used in cancer treatment. It works by interfering with the function of an enzyme called topoisomerase I, which helps to uncoil DNA during cell division. By inhibiting this enzyme, camptothecin prevents the cancer cells from dividing and growing, ultimately leading to their death.

Camptothecin is found naturally in the bark and stem of the Camptotheca acuminata tree, also known as the "happy tree," which is native to China. It was first isolated in 1966 and has since been developed into several synthetic derivatives, including irinotecan and topotecan, which are used clinically to treat various types of cancer, such as colon, lung, and ovarian cancers.

Like other chemotherapeutic agents, camptothecin can have significant side effects, including nausea, vomiting, diarrhea, and myelosuppression (suppression of bone marrow function). It is important for patients receiving camptothecin-based therapies to be closely monitored by their healthcare team to manage these side effects effectively.

p53 is a tumor suppressor gene that encodes a protein responsible for controlling cell growth and division. The p53 protein plays a crucial role in preventing the development of cancer by regulating the cell cycle and activating DNA repair processes when genetic damage is detected. If the damage is too severe to be repaired, p53 can trigger apoptosis, or programmed cell death, to prevent the propagation of potentially cancerous cells. Mutations in the TP53 gene, which encodes the p53 protein, are among the most common genetic alterations found in human cancers and are often associated with a poor prognosis.

Loss of Heterozygosity (LOH) is a term used in genetics to describe the loss of one copy of a gene or a segment of a chromosome, where there was previously a pair of different genes or chromosomal segments (heterozygous). This can occur due to various genetic events such as mutation, deletion, or mitotic recombination.

LOH is often associated with the development of cancer, as it can lead to the loss of tumor suppressor genes, which normally help to regulate cell growth and division. When both copies of a tumor suppressor gene are lost or inactivated, it can result in uncontrolled cell growth and the formation of a tumor.

In medical terms, LOH is used as a biomarker for cancer susceptibility, progression, and prognosis. It can also be used to identify individuals who may be at increased risk for certain types of cancer, or to monitor patients for signs of cancer recurrence.

Inappropriate Antidiuretic Hormone (ADH) Syndrome, also known as the Syndrome of Inappropriate Antidiuresis (SIAD), is a condition characterized by the excessive release or action of antidiuretic hormone (ADH) leading to an imbalance of water and electrolytes in the body.

ADH is a hormone produced by the pituitary gland that helps regulate water balance in the body by controlling the amount of urine produced by the kidneys. In normal conditions, ADH levels increase in response to dehydration or decreased blood volume, causing the kidneys to retain water and decrease urine output.

However, in Inappropriate ADH Syndrome, there is an overproduction or inappropriate release of ADH, even when the body does not need it. This can lead to a condition called hyponatremia, which is low sodium levels in the blood. Hyponatremia can cause symptoms such as headache, confusion, seizures, and in severe cases, coma or death.

Inappropriate ADH Syndrome can be caused by various factors, including certain medications, brain tumors, lung diseases, and other medical conditions that affect the production or release of ADH. It is important to diagnose and treat Inappropriate ADH Syndrome promptly to prevent serious complications from hyponatremia. Treatment typically involves addressing the underlying cause and adjusting fluid intake and electrolyte levels as needed.

Neurosecretory systems are specialized components of the nervous system that produce and release chemical messengers called neurohormones. These neurohormones are released into the bloodstream and can have endocrine effects on various target organs in the body. The cells that make up neurosecretory systems, known as neurosecretory cells, are found in specific regions of the brain, such as the hypothalamus, and in peripheral nerves.

Neurosecretory systems play a critical role in regulating many physiological processes, including fluid and electrolyte balance, stress responses, growth and development, reproductive functions, and behavior. The neurohormones released by these systems can act synergistically or antagonistically to maintain homeostasis and coordinate the body's response to internal and external stimuli.

Neurosecretory cells are characterized by their ability to synthesize and store neurohormones in secretory granules, which are released upon stimulation. The release of neurohormones can be triggered by a variety of signals, including neural impulses, hormonal changes, and other physiological cues. Once released into the bloodstream, neurohormones can travel to distant target organs, where they bind to specific receptors and elicit a range of responses.

Overall, neurosecretory systems are an essential component of the neuroendocrine system, which plays a critical role in regulating many aspects of human physiology and behavior.

Vincristine is an antineoplastic agent, specifically a vinca alkaloid. It is derived from the Madagascar periwinkle plant (Catharanthus roseus). Vincristine binds to tubulin, a protein found in microtubules, and inhibits their polymerization, which results in disruption of mitotic spindles leading to cell cycle arrest and apoptosis (programmed cell death). It is used in the treatment of various types of cancer including leukemias, lymphomas, and solid tumors. Common side effects include peripheral neuropathy, constipation, and alopecia.

Smoking is not a medical condition, but it's a significant health risk behavior. Here is the definition from a public health perspective:

Smoking is the act of inhaling and exhaling the smoke of burning tobacco that is commonly consumed through cigarettes, pipes, and cigars. The smoke contains over 7,000 chemicals, including nicotine, tar, carbon monoxide, and numerous toxic and carcinogenic substances. These toxins contribute to a wide range of diseases and health conditions, such as lung cancer, heart disease, stroke, chronic obstructive pulmonary disease (COPD), and various other cancers, as well as adverse reproductive outcomes and negative impacts on the developing fetus during pregnancy. Smoking is highly addictive due to the nicotine content, which makes quitting smoking a significant challenge for many individuals.

Tumor suppressor proteins are a type of regulatory protein that helps control the cell cycle and prevent cells from dividing and growing in an uncontrolled manner. They work to inhibit tumor growth by preventing the formation of tumors or slowing down their progression. These proteins can repair damaged DNA, regulate gene expression, and initiate programmed cell death (apoptosis) if the damage is too severe for repair.

Mutations in tumor suppressor genes, which provide the code for these proteins, can lead to a decrease or loss of function in the resulting protein. This can result in uncontrolled cell growth and division, leading to the formation of tumors and cancer. Examples of tumor suppressor proteins include p53, Rb (retinoblastoma), and BRCA1/2.

Head and neck neoplasms refer to abnormal growths or tumors in the head and neck region, which can be benign (non-cancerous) or malignant (cancerous). These tumors can develop in various sites, including the oral cavity, nasopharynx, oropharynx, larynx, hypopharynx, paranasal sinuses, salivary glands, and thyroid gland.

Benign neoplasms are slow-growing and generally do not spread to other parts of the body. However, they can still cause problems if they grow large enough to press on surrounding tissues or structures. Malignant neoplasms, on the other hand, can invade nearby tissues and organs and may also metastasize (spread) to other parts of the body.

Head and neck neoplasms can have various symptoms depending on their location and size. Common symptoms include difficulty swallowing, speaking, or breathing; pain in the mouth, throat, or ears; persistent coughing or hoarseness; and swelling or lumps in the neck or face. Early detection and treatment of head and neck neoplasms are crucial for improving outcomes and reducing the risk of complications.

Synaptophysin is a protein found in the presynaptic vesicles of neurons, which are involved in the release of neurotransmitters during synaptic transmission. It is often used as a marker for neuronal differentiation and is widely expressed in neuroendocrine cells and tumors. Synaptophysin plays a role in the regulation of neurotransmitter release and has been implicated in various neurological disorders, including Alzheimer's disease and synaptic dysfunction-related conditions.

Neuroendocrine cells are specialized cells that are found throughout the body, but primarily in the respiratory and digestive tracts. These cells have characteristics of both neurons and endocrine cells. Like neurons, neuroendocrine cells can receive and transmit signals to other cells using chemical messengers called neurotransmitters. Like endocrine cells, they can produce and secrete hormones into the bloodstream, where they can travel to other parts of the body and affect the function of distant organs.

Neuroendocrine cells are responsible for a variety of physiological functions, including regulating air and blood flow in the lungs, controlling the motility and secretion of the gastrointestinal tract, and modulating immune responses. They can also play a role in the development and progression of certain diseases, such as neuroendocrine tumors, which are rare but aggressive cancers that can arise from these cells.

Anatomically, neuroendocrine cells can be found as scattered individual cells or as clusters of cells called neuroepithelial bodies. They are characterized by the presence of dense-core granules containing hormones and neurotransmitters, which can be released in response to various stimuli. Neuroendocrine cells can also express a variety of receptors, including those for neurotransmitters, hormones, and growth factors, which allow them to respond to signals from other cells and modulate their own activity.

Mucoepidermoid carcinoma is a type of cancer that develops in the salivary glands or, less commonly, in other areas such as the lungs or skin. It is called "mucoepidermoid" because it contains two types of cells: mucus-secreting cells and squamous (or epidermoid) cells.

Mucoepidermoid carcinomas can vary in their behavior, ranging from low-grade tumors that grow slowly and rarely spread to other parts of the body, to high-grade tumors that are aggressive and can metastasize. The treatment and prognosis for mucoepidermoid carcinoma depend on several factors, including the grade and stage of the tumor, as well as the patient's overall health.

It is important to note that while I strive to provide accurate and up-to-date information, this definition may not capture all the nuances of this medical condition. Therefore, it is always best to consult with a healthcare professional for medical advice.

Drug synergism is a pharmacological concept that refers to the interaction between two or more drugs, where the combined effect of the drugs is greater than the sum of their individual effects. This means that when these drugs are administered together, they produce an enhanced therapeutic response compared to when they are given separately.

Drug synergism can occur through various mechanisms, such as:

1. Pharmacodynamic synergism - When two or more drugs interact with the same target site in the body and enhance each other's effects.
2. Pharmacokinetic synergism - When one drug affects the metabolism, absorption, distribution, or excretion of another drug, leading to an increased concentration of the second drug in the body and enhanced therapeutic effect.
3. Physiochemical synergism - When two drugs interact physically, such as when one drug enhances the solubility or permeability of another drug, leading to improved absorption and bioavailability.

It is important to note that while drug synergism can result in enhanced therapeutic effects, it can also increase the risk of adverse reactions and toxicity. Therefore, healthcare providers must carefully consider the potential benefits and risks when prescribing combinations of drugs with known or potential synergistic effects.

Bronchoscopy is a medical procedure that involves the examination of the inside of the airways and lungs with a flexible or rigid tube called a bronchoscope. This procedure allows healthcare professionals to directly visualize the airways, take tissue samples for biopsy, and remove foreign objects or secretions. Bronchoscopy can be used to diagnose and manage various respiratory conditions such as lung infections, inflammation, cancer, and bleeding. It is usually performed under local or general anesthesia to minimize discomfort and risks associated with the procedure.

Proto-oncogene proteins are normal cellular proteins that play crucial roles in various cellular processes, such as signal transduction, cell cycle regulation, and apoptosis (programmed cell death). They are involved in the regulation of cell growth, differentiation, and survival under physiological conditions.

When proto-oncogene proteins undergo mutations or aberrations in their expression levels, they can transform into oncogenic forms, leading to uncontrolled cell growth and division. These altered proteins are then referred to as oncogene products or oncoproteins. Oncogenic mutations can occur due to various factors, including genetic predisposition, environmental exposures, and aging.

Examples of proto-oncogene proteins include:

1. Ras proteins: Involved in signal transduction pathways that regulate cell growth and differentiation. Activating mutations in Ras genes are found in various human cancers.
2. Myc proteins: Regulate gene expression related to cell cycle progression, apoptosis, and metabolism. Overexpression of Myc proteins is associated with several types of cancer.
3. EGFR (Epidermal Growth Factor Receptor): A transmembrane receptor tyrosine kinase that regulates cell proliferation, survival, and differentiation. Mutations or overexpression of EGFR are linked to various malignancies, such as lung cancer and glioblastoma.
4. Src family kinases: Intracellular tyrosine kinases that regulate signal transduction pathways involved in cell proliferation, survival, and migration. Dysregulation of Src family kinases is implicated in several types of cancer.
5. Abl kinases: Cytoplasmic tyrosine kinases that regulate various cellular processes, including cell growth, differentiation, and stress responses. Aberrant activation of Abl kinases, as seen in chronic myelogenous leukemia (CML), leads to uncontrolled cell proliferation.

Understanding the roles of proto-oncogene proteins and their dysregulation in cancer development is essential for developing targeted cancer therapies that aim to inhibit or modulate these aberrant signaling pathways.

I'm sorry for any confusion, but "Genes, myc" is not a recognized medical term or abbreviation. It seems like there might be a misunderstanding or a missing word in the request. "Myc" could refer to the Myc family of transcription factors that are involved in cell growth and division, and are often deregulated in cancer. However, without more context, it's difficult to provide an accurate definition. If you could provide more information or clarify your question, I would be happy to help further!

Bronchioloalveolar carcinoma (BAC) is a subtype of adenocarcinoma, which is a type of lung cancer that originates in the cells that line the alveoli (tiny air sacs) in the lungs. BAC is characterized by the spread of cancerous cells along the alveolar walls, without invading the surrounding tissues. It often appears as multiple nodules or a large mass in the lung and can be difficult to diagnose due to its growth pattern.

BAC is typically associated with a better prognosis compared to other types of lung cancer, but it can still be aggressive and spread to other parts of the body. Treatment options for BAC may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches. It's important to note that medical definitions and classifications of diseases and conditions are constantly evolving as new research emerges, so it's always a good idea to consult with a healthcare professional for the most up-to-date information.

A case-control study is an observational research design used to identify risk factors or causes of a disease or health outcome. In this type of study, individuals with the disease or condition (cases) are compared with similar individuals who do not have the disease or condition (controls). The exposure history or other characteristics of interest are then compared between the two groups to determine if there is an association between the exposure and the disease.

Case-control studies are often used when it is not feasible or ethical to conduct a randomized controlled trial, as they can provide valuable insights into potential causes of diseases or health outcomes in a relatively short period of time and at a lower cost than other study designs. However, because case-control studies rely on retrospective data collection, they are subject to biases such as recall bias and selection bias, which can affect the validity of the results. Therefore, it is important to carefully design and conduct case-control studies to minimize these potential sources of bias.

Positron-Emission Tomography (PET) is a type of nuclear medicine imaging that uses small amounts of radioactive material, called a radiotracer, to produce detailed, three-dimensional images. This technique measures metabolic activity within the body, such as sugar metabolism, to help distinguish between healthy and diseased tissue, identify cancerous cells, or examine the function of organs.

During a PET scan, the patient is injected with a radiotracer, typically a sugar-based compound labeled with a positron-emitting radioisotope, such as fluorine-18 (^18^F). The radiotracer accumulates in cells that are metabolically active, like cancer cells. As the radiotracer decays, it emits positrons, which then collide with electrons in nearby tissue, producing gamma rays. A special camera, called a PET scanner, detects these gamma rays and uses this information to create detailed images of the body's internal structures and processes.

PET is often used in conjunction with computed tomography (CT) or magnetic resonance imaging (MRI) to provide both functional and anatomical information, allowing for more accurate diagnosis and treatment planning. Common applications include detecting cancer recurrence, staging and monitoring cancer, evaluating heart function, and assessing brain function in conditions like dementia and epilepsy.

Neuroendocrine tumors (NETs) are a diverse group of neoplasms that arise from cells of the neuroendocrine system, which is composed of dispersed neuroendocrine cells throughout the body, often in close association with nerves and blood vessels. These cells have the ability to produce and secrete hormones or hormone-like substances in response to various stimuli. NETs can occur in a variety of organs, including the lungs, pancreas, small intestine, colon, rectum, stomach, and thyroid gland, as well as in some less common sites such as the thymus, adrenal glands, and nervous system.

NETs can be functional or nonfunctional, depending on whether they produce and secrete hormones or hormone-like substances that cause specific symptoms related to hormonal excess. Functional NETs may give rise to a variety of clinical syndromes, such as carcinoid syndrome, Zollinger-Ellison syndrome, pancreatic neuroendocrine tumor syndrome (also known as Verner-Morrison or WDHA syndrome), and others. Nonfunctional NETs are more likely to present with symptoms related to the size and location of the tumor, such as abdominal pain, intestinal obstruction, or bleeding.

The diagnosis of NETs typically involves a combination of imaging studies, biochemical tests (e.g., measurement of serum hormone levels), and histopathological examination of tissue samples obtained through biopsy or surgical resection. Treatment options depend on the type, location, stage, and grade of the tumor, as well as the presence or absence of functional symptoms. They may include surgery, radiation therapy, chemotherapy, targeted therapy, and/or peptide receptor radionuclide therapy (PRRT).

Ifosfamide is an alkylating agent, which is a type of chemotherapy medication. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. Ifosfamide is used to treat various types of cancers, such as testicular cancer, small cell lung cancer, ovarian cancer, cervical cancer, and certain types of sarcomas.

The medical definition of Ifosfamide is:

Ifosfamide is a synthetic antineoplastic agent, an oxazaphosphorine derivative, with the chemical formula C6H15Cl2N2O2P. It is used in the treatment of various malignancies, including germ cell tumors, sarcomas, lymphomas, and testicular cancer. The drug is administered intravenously and exerts its cytotoxic effects through the alkylation and cross-linking of DNA, leading to the inhibition of DNA replication and transcription. Ifosfamide can cause significant myelosuppression and has been associated with urotoxicity, neurotoxicity, and secondary malignancies. Therefore, it is essential to monitor patients closely during treatment and manage any adverse effects promptly.

DNA Mutational Analysis is a laboratory test used to identify genetic variations or changes (mutations) in the DNA sequence of a gene. This type of analysis can be used to diagnose genetic disorders, predict the risk of developing certain diseases, determine the most effective treatment for cancer, or assess the likelihood of passing on an inherited condition to offspring.

The test involves extracting DNA from a patient's sample (such as blood, saliva, or tissue), amplifying specific regions of interest using polymerase chain reaction (PCR), and then sequencing those regions to determine the precise order of nucleotide bases in the DNA molecule. The resulting sequence is then compared to reference sequences to identify any variations or mutations that may be present.

DNA Mutational Analysis can detect a wide range of genetic changes, including single-nucleotide polymorphisms (SNPs), insertions, deletions, duplications, and rearrangements. The test is often used in conjunction with other diagnostic tests and clinical evaluations to provide a comprehensive assessment of a patient's genetic profile.

It is important to note that not all mutations are pathogenic or associated with disease, and the interpretation of DNA Mutational Analysis results requires careful consideration of the patient's medical history, family history, and other relevant factors.

In situ hybridization, fluorescence (FISH) is a type of molecular cytogenetic technique used to detect and localize the presence or absence of specific DNA sequences on chromosomes through the use of fluorescent probes. This technique allows for the direct visualization of genetic material at a cellular level, making it possible to identify chromosomal abnormalities such as deletions, duplications, translocations, and other rearrangements.

The process involves denaturing the DNA in the sample to separate the double-stranded molecules into single strands, then adding fluorescently labeled probes that are complementary to the target DNA sequence. The probe hybridizes to the complementary sequence in the sample, and the location of the probe is detected by fluorescence microscopy.

FISH has a wide range of applications in both clinical and research settings, including prenatal diagnosis, cancer diagnosis and monitoring, and the study of gene expression and regulation. It is a powerful tool for identifying genetic abnormalities and understanding their role in human disease.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

The Predictive Value of Tests, specifically the Positive Predictive Value (PPV) and Negative Predictive Value (NPV), are measures used in diagnostic tests to determine the probability that a positive or negative test result is correct.

Positive Predictive Value (PPV) is the proportion of patients with a positive test result who actually have the disease. It is calculated as the number of true positives divided by the total number of positive results (true positives + false positives). A higher PPV indicates that a positive test result is more likely to be a true positive, and therefore the disease is more likely to be present.

Negative Predictive Value (NPV) is the proportion of patients with a negative test result who do not have the disease. It is calculated as the number of true negatives divided by the total number of negative results (true negatives + false negatives). A higher NPV indicates that a negative test result is more likely to be a true negative, and therefore the disease is less likely to be present.

The predictive value of tests depends on the prevalence of the disease in the population being tested, as well as the sensitivity and specificity of the test. A test with high sensitivity and specificity will generally have higher predictive values than a test with low sensitivity and specificity. However, even a highly sensitive and specific test can have low predictive values if the prevalence of the disease is low in the population being tested.

The cell cycle is a series of events that take place in a cell leading to its division and duplication. It consists of four main phases: G1 phase, S phase, G2 phase, and M phase.

During the G1 phase, the cell grows in size and synthesizes mRNA and proteins in preparation for DNA replication. In the S phase, the cell's DNA is copied, resulting in two complete sets of chromosomes. During the G2 phase, the cell continues to grow and produces more proteins and organelles necessary for cell division.

The M phase is the final stage of the cell cycle and consists of mitosis (nuclear division) and cytokinesis (cytoplasmic division). Mitosis results in two genetically identical daughter nuclei, while cytokinesis divides the cytoplasm and creates two separate daughter cells.

The cell cycle is regulated by various checkpoints that ensure the proper completion of each phase before progressing to the next. These checkpoints help prevent errors in DNA replication and division, which can lead to mutations and cancer.

Deoxycytidine is a chemical compound that is a component of DNA, one of the nucleic acids in living organisms. It is a nucleoside, consisting of the sugar deoxyribose and the base cytosine. Deoxycytidine pairs with guanine via hydrogen bonds to form base pairs in the double helix structure of DNA.

In biochemistry, deoxycytidine can also exist as a free nucleoside, not bound to other molecules. It is involved in various cellular processes related to DNA metabolism and replication. Deoxycytidine can be phosphorylated to form deoxycytidine monophosphate (dCMP), which is an important intermediate in the synthesis of DNA.

It's worth noting that while deoxycytidine is a component of DNA, its counterpart in RNA is cytidine, which contains ribose instead of deoxyribose as the sugar component.

Chemoradiotherapy is a medical treatment that combines chemotherapy and radiotherapy. Chemotherapy involves the use of drugs to kill or damage cancer cells, while radiotherapy uses ionizing radiation to achieve the same goal. In chemoradiotherapy, these two modalities are used simultaneously or sequentially to treat a malignancy.

The aim of chemoradiotherapy is to increase the effectiveness of treatment by targeting cancer cells with both chemotherapy and radiation therapy. This approach can be particularly effective in treating certain types of cancer, such as head and neck cancer, lung cancer, esophageal cancer, cervical cancer, anal cancer, and rectal cancer.

The specific drugs used in chemoradiotherapy and the doses and schedules of both chemotherapy and radiotherapy vary depending on the type and stage of cancer being treated. The side effects of chemoradiotherapy can be significant and may include fatigue, skin reactions, mucositis, nausea, vomiting, diarrhea, and myelosuppression. However, these side effects are usually manageable with appropriate supportive care.

"Carcinoma, Lewis lung" is a term used to describe a specific type of lung cancer that was first discovered in strain C57BL/6J mice by Dr. Margaret R. Lewis in 1951. It is a spontaneously occurring undifferentiated carcinoma that originates from the lung epithelium and is highly invasive and metastatic, making it a popular model for studying cancer biology and testing potential therapies.

The Lewis lung carcinoma (LLC) cells are typically characterized by their rapid growth rate, ability to form tumors when implanted into syngeneic mice, and high levels of vascular endothelial growth factor (VEGF), which promotes angiogenesis and tumor growth.

It is important to note that while the LLC model has been useful for studying certain aspects of lung cancer, it may not fully recapitulate the complexity and heterogeneity of human lung cancers. Therefore, findings from LLC studies should be validated in more clinically relevant models before being translated into human therapies.

Transfection is a term used in molecular biology that refers to the process of deliberately introducing foreign genetic material (DNA, RNA or artificial gene constructs) into cells. This is typically done using chemical or physical methods, such as lipofection or electroporation. Transfection is widely used in research and medical settings for various purposes, including studying gene function, producing proteins, developing gene therapies, and creating genetically modified organisms. It's important to note that transfection is different from transduction, which is the process of introducing genetic material into cells using viruses as vectors.

Paraneoplastic syndromes of the nervous system are a group of rare disorders that occur in some individuals with cancer. These syndromes are caused by an immune system response to the cancer tumor, which can lead to the damage or destruction of nerve cells. The immune system produces antibodies and/or activated immune cells that attack the neural tissue, leading to neurological symptoms.

Paraneoplastic syndromes can affect any part of the nervous system, including the brain, spinal cord, peripheral nerves, and muscles. Symptoms vary depending on the specific syndrome and the location of the affected nerve tissue. Some common neurological symptoms include muscle weakness, numbness or tingling, seizures, memory loss, confusion, difficulty speaking or swallowing, visual disturbances, and coordination problems.

Paraneoplastic syndromes are often associated with specific types of cancer, such as small cell lung cancer, breast cancer, ovarian cancer, and lymphoma. Diagnosis can be challenging because the symptoms may precede the discovery of the underlying cancer. A combination of clinical evaluation, imaging studies, laboratory tests, and sometimes a brain biopsy may be necessary to confirm the diagnosis.

Treatment typically involves addressing the underlying cancer with surgery, chemotherapy, or radiation therapy. Immunosuppressive therapies may also be used to manage the immune response that is causing the neurological symptoms. While treatment can help alleviate symptoms and improve quality of life, paraneoplastic syndromes are often difficult to cure completely.

Carcinoma, endometrioid is a type of cancer that arises from the glandular cells of the endometrium, which is the lining of the uterus. This type of cancer is named for its similarity in appearance to the normal endometrial cells, and it is the second most common type of endometrial cancer after serous carcinoma.

Endometrioid carcinomas are typically divided into different grades based on how abnormal the cells look under a microscope. Low-grade tumors tend to grow more slowly and are less likely to spread beyond the uterus than high-grade tumors.

Risk factors for endometrioid carcinoma include obesity, older age, early menstruation, late menopause, never having been pregnant, and a history of taking estrogen hormone replacement therapy without progesterone. Treatment typically involves surgery to remove the uterus, fallopian tubes, ovaries, and nearby lymph nodes, followed by radiation therapy, chemotherapy, or hormonal therapy in some cases.

Paraneoplastic polyneuropathy is a rare neurological disorder that can occur in some individuals with cancer. It's caused by the immune system producing antibodies or cells that attack the nervous system (neurons, nerve axons, or myelin sheath) as a response to the presence of a tumor or cancer in the body.

The term "polyneuropathy" refers to damage or dysfunction affecting multiple peripheral nerves simultaneously. This can lead to various symptoms such as numbness, tingling, muscle weakness, and pain, typically starting in the hands and feet and progressing upwards.

In paraneoplastic polyneuropathy, these symptoms are related to the immune system's response to the cancer rather than direct invasion of the nerves by the tumor itself. The specific type of polyneuropathy can vary between individuals, and it may present as sensorimotor polyneuropathy, autonomic neuropathy, or a combination of both.

Early diagnosis and treatment of the underlying cancer are crucial for managing paraneoplastic polyneuropathy. Immunotherapy, plasma exchange, and intravenous immunoglobulin may be used to help control the immune response and alleviate symptoms.

Radiopharmaceuticals are defined as pharmaceutical preparations that contain radioactive isotopes and are used for diagnosis or therapy in nuclear medicine. These compounds are designed to interact specifically with certain biological targets, such as cells, tissues, or organs, and emit radiation that can be detected and measured to provide diagnostic information or used to destroy abnormal cells or tissue in therapeutic applications.

The radioactive isotopes used in radiopharmaceuticals have carefully controlled half-lives, which determine how long they remain radioactive and how long the pharmaceutical preparation remains effective. The choice of radioisotope depends on the intended use of the radiopharmaceutical, as well as factors such as its energy, range of emission, and chemical properties.

Radiopharmaceuticals are used in a wide range of medical applications, including imaging, cancer therapy, and treatment of other diseases and conditions. Examples of radiopharmaceuticals include technetium-99m for imaging the heart, lungs, and bones; iodine-131 for treating thyroid cancer; and samarium-153 for palliative treatment of bone metastases.

The use of radiopharmaceuticals requires specialized training and expertise in nuclear medicine, as well as strict adherence to safety protocols to minimize radiation exposure to patients and healthcare workers.

Colonic neoplasms refer to abnormal growths in the large intestine, also known as the colon. These growths can be benign (non-cancerous) or malignant (cancerous). The two most common types of colonic neoplasms are adenomas and carcinomas.

Adenomas are benign tumors that can develop into cancer over time if left untreated. They are often found during routine colonoscopies and can be removed during the procedure.

Carcinomas, on the other hand, are malignant tumors that invade surrounding tissues and can spread to other parts of the body. Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and colonic neoplasms are a significant risk factor for developing this type of cancer.

Regular screenings for colonic neoplasms are recommended for individuals over the age of 50 or those with a family history of colorectal cancer or other risk factors. Early detection and removal of colonic neoplasms can significantly reduce the risk of developing colorectal cancer.

Small interfering RNA (siRNA) is a type of short, double-stranded RNA molecule that plays a role in the RNA interference (RNAi) pathway. The RNAi pathway is a natural cellular process that regulates gene expression by targeting and destroying specific messenger RNA (mRNA) molecules, thereby preventing the translation of those mRNAs into proteins.

SiRNAs are typically 20-25 base pairs in length and are generated from longer double-stranded RNA precursors called hairpin RNAs or dsRNAs by an enzyme called Dicer. Once generated, siRNAs associate with a protein complex called the RNA-induced silencing complex (RISC), which uses one strand of the siRNA (the guide strand) to recognize and bind to complementary sequences in the target mRNA. The RISC then cleaves the target mRNA, leading to its degradation and the inhibition of protein synthesis.

SiRNAs have emerged as a powerful tool for studying gene function and have shown promise as therapeutic agents for a variety of diseases, including viral infections, cancer, and genetic disorders. However, their use as therapeutics is still in the early stages of development, and there are challenges associated with delivering siRNAs to specific cells and tissues in the body.

APUD cells are a type of neuroendocrine cell that originated from the neural crest and are widely distributed throughout the body. The term "APUD" is an acronym for "Amine Precursor Uptake and Decarboxylation," which describes the ability of these cells to take up and decarboxylate amino acid precursors to produce biologically active amines, such as serotonin, histamine, and catecholamines.

APUD cells are capable of synthesizing, storing, and releasing hormones or neurotransmitters in response to various stimuli. They can be found in several endocrine and neural tissues, including the thyroid gland, adrenal medulla, pituitary gland, pancreas, lungs, and gastrointestinal tract.

In the gastrointestinal tract, APUD cells are often referred to as enterochromaffin cells or Kulchitsky cells. They play a crucial role in regulating gut motility, secretion, and blood flow through the release of hormones such as serotonin, gastrin, and somatostatin.

It's worth noting that the APUD cell concept has been largely replaced by the more comprehensive neuroendocrine system concept, which encompasses a broader range of cells with neurosecretory functions.

"Bronchi" are a pair of airways in the respiratory system that branch off from the trachea (windpipe) and lead to the lungs. They are responsible for delivering oxygen-rich air to the lungs and removing carbon dioxide during exhalation. The right bronchus is slightly larger and more vertical than the left, and they further divide into smaller branches called bronchioles within the lungs. Any abnormalities or diseases affecting the bronchi can impact lung function and overall respiratory health.

I'm sorry for any confusion, but I'm unable to provide a medical definition for "peptichemio" because it doesn't appear to be a recognized term in medicine or biochemistry. It might be a typographical error or a neologism without established meaning. If you have more context or information about where this term came from, I'd be happy to help you try to decipher it further.

Stomach neoplasms refer to abnormal growths in the stomach that can be benign or malignant. They include a wide range of conditions such as:

1. Gastric adenomas: These are benign tumors that develop from glandular cells in the stomach lining.
2. Gastrointestinal stromal tumors (GISTs): These are rare tumors that can be found in the stomach and other parts of the digestive tract. They originate from the stem cells in the wall of the digestive tract.
3. Leiomyomas: These are benign tumors that develop from smooth muscle cells in the stomach wall.
4. Lipomas: These are benign tumors that develop from fat cells in the stomach wall.
5. Neuroendocrine tumors (NETs): These are tumors that develop from the neuroendocrine cells in the stomach lining. They can be benign or malignant.
6. Gastric carcinomas: These are malignant tumors that develop from the glandular cells in the stomach lining. They are the most common type of stomach neoplasm and include adenocarcinomas, signet ring cell carcinomas, and others.
7. Lymphomas: These are malignant tumors that develop from the immune cells in the stomach wall.

Stomach neoplasms can cause various symptoms such as abdominal pain, nausea, vomiting, weight loss, and difficulty swallowing. The diagnosis of stomach neoplasms usually involves a combination of imaging tests, endoscopy, and biopsy. Treatment options depend on the type and stage of the neoplasm and may include surgery, chemotherapy, radiation therapy, or targeted therapy.

Neoplastic cell transformation is a process in which a normal cell undergoes genetic alterations that cause it to become cancerous or malignant. This process involves changes in the cell's DNA that result in uncontrolled cell growth and division, loss of contact inhibition, and the ability to invade surrounding tissues and metastasize (spread) to other parts of the body.

Neoplastic transformation can occur as a result of various factors, including genetic mutations, exposure to carcinogens, viral infections, chronic inflammation, and aging. These changes can lead to the activation of oncogenes or the inactivation of tumor suppressor genes, which regulate cell growth and division.

The transformation of normal cells into cancerous cells is a complex and multi-step process that involves multiple genetic and epigenetic alterations. It is characterized by several hallmarks, including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, enabling replicative immortality, induction of angiogenesis, activation of invasion and metastasis, reprogramming of energy metabolism, and evading immune destruction.

Neoplastic cell transformation is a fundamental concept in cancer biology and is critical for understanding the molecular mechanisms underlying cancer development and progression. It also has important implications for cancer diagnosis, prognosis, and treatment, as identifying the specific genetic alterations that underlie neoplastic transformation can help guide targeted therapies and personalized medicine approaches.

Clinical trials are research studies that involve human participants and are designed to evaluate the safety and efficacy of new medical treatments, drugs, devices, or behavioral interventions. The purpose of clinical trials is to determine whether a new intervention is safe, effective, and beneficial for patients, as well as to compare it with currently available treatments. Clinical trials follow a series of phases, each with specific goals and criteria, before a new intervention can be approved by regulatory authorities for widespread use.

Clinical trials are conducted according to a protocol, which is a detailed plan that outlines the study's objectives, design, methodology, statistical analysis, and ethical considerations. The protocol is developed and reviewed by a team of medical experts, statisticians, and ethicists, and it must be approved by an institutional review board (IRB) before the trial can begin.

Participation in clinical trials is voluntary, and participants must provide informed consent before enrolling in the study. Informed consent involves providing potential participants with detailed information about the study's purpose, procedures, risks, benefits, and alternatives, as well as their rights as research subjects. Participants can withdraw from the study at any time without penalty or loss of benefits to which they are entitled.

Clinical trials are essential for advancing medical knowledge and improving patient care. They help researchers identify new treatments, diagnostic tools, and prevention strategies that can benefit patients and improve public health. However, clinical trials also pose potential risks to participants, including adverse effects from experimental interventions, time commitment, and inconvenience. Therefore, it is important for researchers to carefully design and conduct clinical trials to minimize risks and ensure that the benefits outweigh the risks.

Peptides are short chains of amino acid residues linked by covalent bonds, known as peptide bonds. They are formed when two or more amino acids are joined together through a condensation reaction, which results in the elimination of a water molecule and the formation of an amide bond between the carboxyl group of one amino acid and the amino group of another.

Peptides can vary in length from two to about fifty amino acids, and they are often classified based on their size. For example, dipeptides contain two amino acids, tripeptides contain three, and so on. Oligopeptides typically contain up to ten amino acids, while polypeptides can contain dozens or even hundreds of amino acids.

Peptides play many important roles in the body, including serving as hormones, neurotransmitters, enzymes, and antibiotics. They are also used in medical research and therapeutic applications, such as drug delivery and tissue engineering.

Leukopenia is a medical term used to describe an abnormally low white blood cell (WBC) count in the blood. White blood cells are crucial components of the body's immune system, helping to fight infections and diseases. A normal WBC count ranges from 4,500 to 11,000 cells per microliter (μL) of blood in most laboratories. Leukopenia is typically diagnosed when the WBC count falls below 4,500 cells/μL.

There are several types of white blood cells, including neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Neutropenia, a specific type of leukopenia, refers to an abnormally low neutrophil count (less than 1,500 cells/μL). Neutropenia increases the risk of bacterial and fungal infections since neutrophils play a significant role in combating these types of pathogens.

Leukopenia can result from various factors, such as viral infections, certain medications (like chemotherapy or radiation therapy), bone marrow disorders, autoimmune diseases, or congenital conditions affecting white blood cell production. It is essential to identify the underlying cause of leukopenia to provide appropriate treatment and prevent complications.

A mouth neoplasm refers to an abnormal growth or tumor in the oral cavity, which can be benign (non-cancerous) or malignant (cancerous). Malignant mouth neoplasms are also known as oral cancer. They can develop on the lips, gums, tongue, roof and floor of the mouth, inside the cheeks, and in the oropharynx (the middle part of the throat at the back of the mouth).

Mouth neoplasms can have various causes, including genetic factors, tobacco use, alcohol consumption, and infection with human papillomavirus (HPV). Symptoms may include a lump or thickening in the oral soft tissues, white or red patches, persistent mouth sores, difficulty swallowing or speaking, and numbness in the mouth. Early detection and treatment of mouth neoplasms are crucial for improving outcomes and preventing complications.

Embryonal carcinoma is a rare and aggressive type of cancer that arises from primitive germ cells. It typically occurs in the gonads (ovaries or testicles), but can also occur in other areas of the body such as the mediastinum, retroperitoneum, or sacrococcygeal region.

Embryonal carcinoma is called "embryonal" because the cancerous cells resemble those found in an embryo during early stages of development. These cells are capable of differentiating into various cell types, which can lead to a mix of cell types within the tumor.

Embryonal carcinoma is a highly malignant tumor that tends to grow and spread quickly. It can metastasize to other parts of the body, including the lungs, liver, brain, and bones. Treatment typically involves surgical removal of the tumor, followed by chemotherapy and/or radiation therapy to kill any remaining cancer cells.

Prognosis for embryonal carcinoma depends on several factors, including the stage of the disease at diagnosis, the location of the tumor, and the patient's overall health. In general, this type of cancer has a poor prognosis, with a high risk of recurrence even after treatment.

A chromosome deletion is a type of genetic abnormality that occurs when a portion of a chromosome is missing or deleted. Chromosomes are thread-like structures located in the nucleus of cells that contain our genetic material, which is organized into genes.

Chromosome deletions can occur spontaneously during the formation of reproductive cells (eggs or sperm) or can be inherited from a parent. They can affect any chromosome and can vary in size, from a small segment to a large portion of the chromosome.

The severity of the symptoms associated with a chromosome deletion depends on the size and location of the deleted segment. In some cases, the deletion may be so small that it does not cause any noticeable symptoms. However, larger deletions can lead to developmental delays, intellectual disabilities, physical abnormalities, and various medical conditions.

Chromosome deletions are typically detected through a genetic test called karyotyping, which involves analyzing the number and structure of an individual's chromosomes. Other more precise tests, such as fluorescence in situ hybridization (FISH) or chromosomal microarray analysis (CMA), may also be used to confirm the diagnosis and identify the specific location and size of the deletion.

A phenotype is the physical or biochemical expression of an organism's genes, or the observable traits and characteristics resulting from the interaction of its genetic constitution (genotype) with environmental factors. These characteristics can include appearance, development, behavior, and resistance to disease, among others. Phenotypes can vary widely, even among individuals with identical genotypes, due to differences in environmental influences, gene expression, and genetic interactions.

Radiotherapy dosage refers to the total amount of radiation energy that is absorbed by tissues or organs, typically measured in units of Gray (Gy), during a course of radiotherapy treatment. It is the product of the dose rate (the amount of radiation delivered per unit time) and the duration of treatment. The prescribed dosage for cancer treatments can range from a few Gray to more than 70 Gy, depending on the type and location of the tumor, the patient's overall health, and other factors. The goal of radiotherapy is to deliver a sufficient dosage to destroy the cancer cells while minimizing damage to surrounding healthy tissues.

Lung volume measurements are clinical tests that determine the amount of air inhaled, exhaled, and present in the lungs at different times during the breathing cycle. These measurements include:

1. Tidal Volume (TV): The amount of air inhaled or exhaled during normal breathing, usually around 500 mL in resting adults.
2. Inspiratory Reserve Volume (IRV): The additional air that can be inhaled after a normal inspiration, approximately 3,000 mL in adults.
3. Expiratory Reserve Volume (ERV): The extra air that can be exhaled after a normal expiration, about 1,000-1,200 mL in adults.
4. Residual Volume (RV): The air remaining in the lungs after a maximal exhalation, approximately 1,100-1,500 mL in adults.
5. Total Lung Capacity (TLC): The total amount of air the lungs can hold at full inflation, calculated as TV + IRV + ERV + RV, around 6,000 mL in adults.
6. Functional Residual Capacity (FRC): The volume of air remaining in the lungs after a normal expiration, equal to ERV + RV, about 2,100-2,700 mL in adults.
7. Inspiratory Capacity (IC): The maximum amount of air that can be inhaled after a normal expiration, equal to TV + IRV, around 3,500 mL in adults.
8. Vital Capacity (VC): The total volume of air that can be exhaled after a maximal inspiration, calculated as IC + ERV, approximately 4,200-5,600 mL in adults.

These measurements help assess lung function and identify various respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and restrictive lung diseases.

Pathologic neovascularization is the abnormal growth of new blood vessels in previously avascular tissue or excessive growth within existing vasculature, which occurs as a result of hypoxia, inflammation, or angiogenic stimuli. These newly formed vessels are often disorganized, fragile, and lack proper vessel hierarchy, leading to impaired blood flow and increased vascular permeability. Pathologic neovascularization can be observed in various diseases such as cancer, diabetic retinopathy, age-related macular degeneration, and chronic inflammation. This process contributes to disease progression by promoting tumor growth, metastasis, and edema formation, ultimately leading to tissue damage and organ dysfunction.

Down-regulation is a process that occurs in response to various stimuli, where the number or sensitivity of cell surface receptors or the expression of specific genes is decreased. This process helps maintain homeostasis within cells and tissues by reducing the ability of cells to respond to certain signals or molecules.

In the context of cell surface receptors, down-regulation can occur through several mechanisms:

1. Receptor internalization: After binding to their ligands, receptors can be internalized into the cell through endocytosis. Once inside the cell, these receptors may be degraded or recycled back to the cell surface in smaller numbers.
2. Reduced receptor synthesis: Down-regulation can also occur at the transcriptional level, where the expression of genes encoding for specific receptors is decreased, leading to fewer receptors being produced.
3. Receptor desensitization: Prolonged exposure to a ligand can lead to a decrease in receptor sensitivity or affinity, making it more difficult for the cell to respond to the signal.

In the context of gene expression, down-regulation refers to the decreased transcription and/or stability of specific mRNAs, leading to reduced protein levels. This process can be induced by various factors, including microRNA (miRNA)-mediated regulation, histone modification, or DNA methylation.

Down-regulation is an essential mechanism in many physiological processes and can also contribute to the development of several diseases, such as cancer and neurodegenerative disorders.

Transcription factors are proteins that play a crucial role in regulating gene expression by controlling the transcription of DNA to messenger RNA (mRNA). They function by binding to specific DNA sequences, known as response elements, located in the promoter region or enhancer regions of target genes. This binding can either activate or repress the initiation of transcription, depending on the properties and interactions of the particular transcription factor. Transcription factors often act as part of a complex network of regulatory proteins that determine the precise spatiotemporal patterns of gene expression during development, differentiation, and homeostasis in an organism.

DNA-binding proteins are a type of protein that have the ability to bind to DNA (deoxyribonucleic acid), the genetic material of organisms. These proteins play crucial roles in various biological processes, such as regulation of gene expression, DNA replication, repair and recombination.

The binding of DNA-binding proteins to specific DNA sequences is mediated by non-covalent interactions, including electrostatic, hydrogen bonding, and van der Waals forces. The specificity of binding is determined by the recognition of particular nucleotide sequences or structural features of the DNA molecule.

DNA-binding proteins can be classified into several categories based on their structure and function, such as transcription factors, histones, and restriction enzymes. Transcription factors are a major class of DNA-binding proteins that regulate gene expression by binding to specific DNA sequences in the promoter region of genes and recruiting other proteins to modulate transcription. Histones are DNA-binding proteins that package DNA into nucleosomes, the basic unit of chromatin structure. Restriction enzymes are DNA-binding proteins that recognize and cleave specific DNA sequences, and are widely used in molecular biology research and biotechnology applications.

Phosphorylation is the process of adding a phosphate group (a molecule consisting of one phosphorus atom and four oxygen atoms) to a protein or other organic molecule, which is usually done by enzymes called kinases. This post-translational modification can change the function, localization, or activity of the target molecule, playing a crucial role in various cellular processes such as signal transduction, metabolism, and regulation of gene expression. Phosphorylation is reversible, and the removal of the phosphate group is facilitated by enzymes called phosphatases.

Radiotherapy, also known as radiation therapy, is a medical treatment that uses ionizing radiation to kill cancer cells, shrink tumors, and prevent the growth and spread of cancer. The radiation can be delivered externally using machines or internally via radioactive substances placed in or near the tumor. Radiotherapy works by damaging the DNA of cancer cells, which prevents them from dividing and growing. Normal cells are also affected by radiation, but they have a greater ability to repair themselves compared to cancer cells. The goal of radiotherapy is to destroy as many cancer cells as possible while minimizing damage to healthy tissue.

Carcinoma, ductal refers to a type of cancer that begins in the milk ducts (tubes that carry milk from the breast to the nipple). It is most commonly found in the breast and is often referred to as "invasive ductal carcinoma" when it has spread beyond the ducts into the surrounding breast tissue. Ductal carcinoma can also occur in other organs, such as the pancreas, where it is called "pancreatic ductal adenocarcinoma." This type of cancer is usually aggressive and can metastasize (spread) to other parts of the body.

Cyclophosphamide is an alkylating agent, which is a type of chemotherapy medication. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. This helps to stop the spread of cancer in the body. Cyclophosphamide is used to treat various types of cancer, including lymphoma, leukemia, multiple myeloma, and breast cancer. It can be given orally as a tablet or intravenously as an injection.

Cyclophosphamide can also have immunosuppressive effects, which means it can suppress the activity of the immune system. This makes it useful in treating certain autoimmune diseases, such as rheumatoid arthritis and lupus. However, this immunosuppression can also increase the risk of infections and other side effects.

Like all chemotherapy medications, cyclophosphamide can cause a range of side effects, including nausea, vomiting, hair loss, fatigue, and increased susceptibility to infections. It is important for patients receiving cyclophosphamide to be closely monitored by their healthcare team to manage these side effects and ensure the medication is working effectively.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

Taxoids are a class of naturally occurring compounds that are derived from the bark of the Pacific yew tree (Taxus brevifolia) and other species of the genus Taxus. They are known for their antineoplastic (cancer-fighting) properties and have been used in chemotherapy to treat various types of cancer, including ovarian, breast, and lung cancer.

The most well-known taxoid is paclitaxel (also known by the brand name Taxol), which was first discovered in the 1960s and has since become a widely used cancer drug. Paclitaxel works by stabilizing microtubules, which are important components of the cell's skeleton, and preventing them from disassembling. This disrupts the normal function of the cell's mitotic spindle, leading to cell cycle arrest and ultimately apoptosis (programmed cell death).

Other taxoids that have been developed for clinical use include docetaxel (Taxotere), which is a semi-synthetic analogue of paclitaxel, and cabazitaxel (Jevtana), which is a second-generation taxoid. These drugs have similar mechanisms of action to paclitaxel but may have different pharmacokinetic properties or be effective against cancer cells that have developed resistance to other taxoids.

While taxoids have been successful in treating certain types of cancer, they can also cause significant side effects, including neutropenia (low white blood cell count), anemia (low red blood cell count), and peripheral neuropathy (nerve damage). As with all chemotherapy drugs, the use of taxoids must be carefully balanced against their potential benefits and risks.

Oncogenes are genes that have the potential to cause cancer. They can do this by promoting cell growth and division (cellular proliferation), preventing cell death (apoptosis), or enabling cells to invade surrounding tissue and spread to other parts of the body (metastasis). Oncogenes can be formed when normal genes, called proto-oncogenes, are mutated or altered in some way. This can happen as a result of exposure to certain chemicals or radiation, or through inherited genetic mutations. When activated, oncogenes can contribute to the development of cancer by causing cells to divide and grow in an uncontrolled manner.

Promoter regions in genetics refer to specific DNA sequences located near the transcription start site of a gene. They serve as binding sites for RNA polymerase and various transcription factors that regulate the initiation of gene transcription. These regulatory elements help control the rate of transcription and, therefore, the level of gene expression. Promoter regions can be composed of different types of sequences, such as the TATA box and CAAT box, and their organization and composition can vary between different genes and species.

SCID mice is an acronym for Severe Combined Immunodeficiency mice. These are genetically modified mice that lack a functional immune system due to the mutation or knockout of several key genes required for immunity. This makes them ideal for studying the human immune system, infectious diseases, and cancer, as well as testing new therapies and treatments in a controlled environment without the risk of interference from the mouse's own immune system. SCID mice are often used in xenotransplantation studies, where human cells or tissues are transplanted into the mouse to study their behavior and interactions with the human immune system.

Limbic encephalitis is a rare type of inflammatory autoimmune disorder that affects the limbic system, which is a part of the brain involved in emotions, behavior, memory, and sense of smell. It is characterized by inflammation of the limbic system, leading to symptoms such as memory loss, confusion, seizures, changes in behavior and mood, and problems with autonomic functions.

Limbic encephalitis can be caused by a variety of factors, including viral infections, cancer, or autoimmune disorders. In some cases, the cause may remain unknown. Diagnosis typically involves a combination of clinical evaluation, imaging studies (such as MRI), and analysis of cerebrospinal fluid. Treatment usually involves immunosuppressive therapy to reduce inflammation, as well as addressing any underlying causes if they can be identified.

It is important to note that limbic encephalitis is a serious condition that requires prompt medical attention and treatment. If you or someone else experiences symptoms such as sudden confusion, memory loss, or seizures, it is essential to seek medical care immediately.

The Fluorescent Antibody Technique (FAT) is a type of immunofluorescence assay used in laboratory medicine and pathology for the detection and localization of specific antigens or antibodies in tissues, cells, or microorganisms. In this technique, a fluorescein-labeled antibody is used to selectively bind to the target antigen or antibody, forming an immune complex. When excited by light of a specific wavelength, the fluorescein label emits light at a longer wavelength, typically visualized as green fluorescence under a fluorescence microscope.

The FAT is widely used in diagnostic microbiology for the identification and characterization of various bacteria, viruses, fungi, and parasites. It has also been applied in the diagnosis of autoimmune diseases and certain cancers by detecting specific antibodies or antigens in patient samples. The main advantage of FAT is its high sensitivity and specificity, allowing for accurate detection and differentiation of various pathogens and disease markers. However, it requires specialized equipment and trained personnel to perform and interpret the results.

Adrenocortical carcinoma (ACC) is a rare cancer that develops in the outer layer of the adrenal gland, known as the adrenal cortex. The adrenal glands are small hormone-producing glands located on top of each kidney. They produce important hormones such as cortisol, aldosterone, and sex steroids.

ACC is a malignant tumor that can invade surrounding tissues and organs and may metastasize (spread) to distant parts of the body. Symptoms of ACC depend on the size and location of the tumor and whether it produces excess hormones. Common symptoms include abdominal pain, a mass in the abdomen, weight loss, and weakness. Excessive production of hormones can lead to additional symptoms such as high blood pressure, Cushing's syndrome, virilization (excessive masculinization), or feminization.

The exact cause of ACC is not known, but genetic factors, exposure to certain chemicals, and radiation therapy may increase the risk of developing this cancer. Treatment options for ACC include surgery, chemotherapy, radiation therapy, and targeted therapy. The prognosis for ACC varies depending on the stage and extent of the disease at diagnosis, as well as the patient's overall health.

Fluorodeoxyglucose F18 (FDG-18) is not a medical condition, but a radiopharmaceutical used in medical imaging. It is a type of glucose (a simple sugar) that has been chemically combined with a small amount of a radioactive isotope called fluorine-18.

FDG-18 is used in positron emission tomography (PET) scans to help identify areas of the body where cells are using more energy than normal, such as cancerous tumors. The FDG-18 is injected into the patient's vein and travels throughout the body. Because cancer cells often use more glucose than normal cells, they tend to absorb more FDG-18.

Once inside the body, the FDG-18 emits positrons, which interact with electrons in nearby tissue, producing gamma rays that can be detected by a PET scanner. The resulting images can help doctors locate and assess the size and activity of cancerous tumors, as well as monitor the effectiveness of treatment.

Tumor burden is a term used to describe the total amount of cancer in the body. It can refer to the number of tumors, the size of the tumors, or the amount of cancer cells in the body. In research and clinical trials, tumor burden is often measured to assess the effectiveness of treatments or to monitor disease progression. High tumor burden can cause various symptoms and complications, depending on the type and location of the cancer. It can also affect a person's prognosis and treatment options.

Enzyme inhibitors are substances that bind to an enzyme and decrease its activity, preventing it from catalyzing a chemical reaction in the body. They can work by several mechanisms, including blocking the active site where the substrate binds, or binding to another site on the enzyme to change its shape and prevent substrate binding. Enzyme inhibitors are often used as drugs to treat various medical conditions, such as high blood pressure, abnormal heart rhythms, and bacterial infections. They can also be found naturally in some foods and plants, and can be used in research to understand enzyme function and regulation.

Multivariate analysis is a statistical method used to examine the relationship between multiple independent variables and a dependent variable. It allows for the simultaneous examination of the effects of two or more independent variables on an outcome, while controlling for the effects of other variables in the model. This technique can be used to identify patterns, associations, and interactions among multiple variables, and is commonly used in medical research to understand complex health outcomes and disease processes. Examples of multivariate analysis methods include multiple regression, factor analysis, cluster analysis, and discriminant analysis.

Carcinoma, verrucous is a type of slow-growing, well-differentiated squamous cell carcinoma that has a exophytic, papillary, and warty appearance. It typically occurs in the oral cavity, larynx, and genital regions. The tumor often has a long clinical course and is locally invasive but has low potential for metastasis.

It's also known as Ackerman's tumor or Buschke-Lowenstein tumor when it occurs in the genital region. It can be caused by long-standing irritation, chronic inflammation, or infection with certain types of human papillomavirus (HPV). The diagnosis is usually made through a biopsy and imaging studies may be used to determine the extent of the tumor. Treatment typically involves surgical excision, but radiation therapy and chemotherapy may also be used in some cases.

Immunotoxins are biomolecules that combine the specificity of an antibody with the toxicity of a toxin. They are created by chemically linking a monoclonal antibody (that recognizes and binds to a specific cell surface antigen) to a protein toxin (that inhibits protein synthesis in cells). The immunotoxin selectively binds to the target cell, gets internalized, and releases the toxin into the cytosol, leading to cell death. Immunotoxins have been explored as potential therapeutic agents for targeted cancer therapy and treatment of other diseases.

Carcinoma, signet ring cell is a type of adenocarcinoma, which is a cancer that begins in glandular cells. In signet ring cell carcinoma, the cancer cells have a characteristic appearance when viewed under a microscope. They contain large amounts of mucin, a substance that causes the nucleus of the cell to be pushed to one side, giving the cell a crescent or "signet ring" shape.

Signet ring cell carcinoma can occur in various organs, including the stomach, colon, rectum, and breast. It is often aggressive and has a poor prognosis, as it tends to grow and spread quickly. Treatment options may include surgery, chemotherapy, and radiation therapy, depending on the location and extent of the cancer.

P-glycoprotein (P-gp) is a type of membrane transport protein that plays a crucial role in the efflux (extrusion) of various substrates, including drugs and toxins, out of cells. It is also known as multidrug resistance protein 1 (MDR1).

P-gp is encoded by the ABCB1 gene and is primarily located on the apical membrane of epithelial cells in several tissues, such as the intestine, liver, kidney, and blood-brain barrier. Its main function is to protect these organs from harmful substances by actively pumping them out of the cells and back into the lumen or bloodstream.

In the context of pharmacology, P-gp can contribute to multidrug resistance (MDR) in cancer cells. When overexpressed, P-gp can reduce the intracellular concentration of various anticancer drugs, making them less effective. This has led to extensive research on inhibitors of P-gp as potential adjuvants for cancer therapy.

In summary, P-glycoprotein is a vital efflux transporter that helps maintain homeostasis by removing potentially harmful substances from cells and can impact drug disposition and response in various tissues, including the intestine, liver, kidney, and blood-brain barrier.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Uterine cervical neoplasms, also known as cervical cancer or cervical dysplasia, refer to abnormal growths or lesions on the lining of the cervix that have the potential to become cancerous. These growths are usually caused by human papillomavirus (HPV) infection and can be detected through routine Pap smears.

Cervical neoplasms are classified into different grades based on their level of severity, ranging from mild dysplasia (CIN I) to severe dysplasia or carcinoma in situ (CIN III). In some cases, cervical neoplasms may progress to invasive cancer if left untreated.

Risk factors for developing cervical neoplasms include early sexual activity, multiple sexual partners, smoking, and a weakened immune system. Regular Pap smears and HPV testing are recommended for early detection and prevention of cervical cancer.

"Multiple drug resistance" (MDR) is a term used in medicine to describe the condition where a patient's infection becomes resistant to multiple antimicrobial drugs. This means that the bacteria, virus, fungus or parasite that is causing the infection has developed the ability to survive and multiply despite being exposed to medications that were originally designed to kill or inhibit its growth.

In particular, MDR occurs when an organism becomes resistant to at least one drug in three or more antimicrobial categories. This can happen due to genetic changes in the microorganism that allow it to survive in the presence of these drugs. The development of MDR is a significant concern for public health because it limits treatment options and can make infections harder, if not impossible, to treat.

MDR can develop through several mechanisms, including mutations in the genes that encode drug targets or enzymes involved in drug metabolism, as well as the acquisition of genetic elements such as plasmids and transposons that carry resistance genes. The overuse and misuse of antimicrobial drugs are major drivers of MDR, as they create selective pressure for the emergence and spread of resistant strains.

MDR infections can occur in various settings, including hospitals, long-term care facilities, and communities. They can affect people of all ages and backgrounds, although certain populations may be at higher risk, such as those with weakened immune systems or chronic medical conditions. Preventing the spread of MDR requires a multifaceted approach that includes surveillance, infection control, antimicrobial stewardship, and research into new therapies and diagnostics.

Cell movement, also known as cell motility, refers to the ability of cells to move independently and change their location within tissue or inside the body. This process is essential for various biological functions, including embryonic development, wound healing, immune responses, and cancer metastasis.

There are several types of cell movement, including:

1. **Crawling or mesenchymal migration:** Cells move by extending and retracting protrusions called pseudopodia or filopodia, which contain actin filaments. This type of movement is common in fibroblasts, immune cells, and cancer cells during tissue invasion and metastasis.
2. **Amoeboid migration:** Cells move by changing their shape and squeezing through tight spaces without forming protrusions. This type of movement is often observed in white blood cells (leukocytes) as they migrate through the body to fight infections.
3. **Pseudopodial extension:** Cells extend pseudopodia, which are temporary cytoplasmic projections containing actin filaments. These protrusions help the cell explore its environment and move forward.
4. **Bacterial flagellar motion:** Bacteria use a whip-like structure called a flagellum to propel themselves through their environment. The rotation of the flagellum is driven by a molecular motor in the bacterial cell membrane.
5. **Ciliary and ependymal movement:** Ciliated cells, such as those lining the respiratory tract and fallopian tubes, have hair-like structures called cilia that beat in coordinated waves to move fluids or mucus across the cell surface.

Cell movement is regulated by a complex interplay of signaling pathways, cytoskeletal rearrangements, and adhesion molecules, which enable cells to respond to environmental cues and navigate through tissues.

Vascular Endothelial Growth Factor A (VEGFA) is a specific isoform of the vascular endothelial growth factor (VEGF) family. It is a well-characterized signaling protein that plays a crucial role in angiogenesis, the process of new blood vessel formation from pre-existing vessels. VEGFA stimulates the proliferation and migration of endothelial cells, which line the interior surface of blood vessels, thereby contributing to the growth and development of new vasculature. This protein is essential for physiological processes such as embryonic development and wound healing, but it has also been implicated in various pathological conditions, including cancer, age-related macular degeneration, and diabetic retinopathy. The regulation of VEGFA expression and activity is critical to maintaining proper vascular function and homeostasis.

I'm sorry for any confusion, but "Menogaril" does not appear to have a widely recognized or established medical definition. It is possible that you may be referring to a specific chemical compound or experimental drug. However, without more context or information, it is difficult for me to provide a precise definition.

Menogaril is a synthetic compound that has been studied in preclinical trials for its potential anticancer properties. It is an analog of the natural product dictyostatin and has been shown to inhibit the activity of several enzymes involved in DNA replication and repair, including topoisomerase II and poly(ADP-ribose) polymerase (PARP). However, it is important to note that Menogaril is not currently approved for use in clinical medicine, and its safety and efficacy have not been established in human trials.

Interstitial lung diseases (ILDs) are a group of disorders characterized by inflammation and scarring (fibrosis) in the interstitium, the tissue and space around the air sacs (alveoli) of the lungs. The interstitium is where the blood vessels that deliver oxygen to the lungs are located. ILDs can be caused by a variety of factors, including environmental exposures, medications, connective tissue diseases, and autoimmune disorders.

The scarring and inflammation in ILDs can make it difficult for the lungs to expand and contract normally, leading to symptoms such as shortness of breath, cough, and fatigue. The scarring can also make it harder for oxygen to move from the air sacs into the bloodstream.

There are many different types of ILDs, including:

* Idiopathic pulmonary fibrosis (IPF): a type of ILD that is caused by unknown factors and tends to progress rapidly
* Hypersensitivity pneumonitis: an ILD that is caused by an allergic reaction to inhaled substances, such as mold or bird droppings
* Connective tissue diseases: ILDs can be a complication of conditions such as rheumatoid arthritis and scleroderma
* Sarcoidosis: an inflammatory disorder that can affect multiple organs, including the lungs
* Asbestosis: an ILD caused by exposure to asbestos fibers

Treatment for ILDs depends on the specific type of disease and its underlying cause. Some treatments may include corticosteroids, immunosuppressive medications, and oxygen therapy. In some cases, a lung transplant may be necessary.

Proportional hazards models are a type of statistical analysis used in medical research to investigate the relationship between covariates (predictor variables) and survival times. The most common application of proportional hazards models is in the Cox regression model, which is named after its developer, Sir David Cox.

In a proportional hazards model, the hazard rate or risk of an event occurring at a given time is assumed to be proportional to the hazard rate of a reference group, after adjusting for the covariates. This means that the ratio of the hazard rates between any two individuals remains constant over time, regardless of their survival times.

Mathematically, the hazard function h(t) at time t for an individual with a set of covariates X can be expressed as:

h(t|X) = h0(t) \* exp(β1X1 + β2X2 + ... + βpXp)

where h0(t) is the baseline hazard function, X1, X2, ..., Xp are the covariates, and β1, β2, ..., βp are the regression coefficients that represent the effect of each covariate on the hazard rate.

The assumption of proportionality is crucial in the interpretation of the results from a Cox regression model. If the assumption is violated, then the estimated regression coefficients may be biased and misleading. Therefore, it is important to test for the proportional hazards assumption before interpreting the results of a Cox regression analysis.

Aromatic-L-amino-acid decarboxylases (ALADs) are a group of enzymes that play a crucial role in the synthesis of neurotransmitters and biogenic amines in the body. These enzymes catalyze the decarboxylation of aromatic L-amino acids, such as L-dopa, L-tryptophan, and L-phenylalanine, to produce corresponding neurotransmitters or biogenic amines, including dopamine, serotonin, and histamine, respectively.

There are two main types of ALADs in humans: dopa decarboxylase (DDC) and tryptophan hydroxylase (TPH). DDC is responsible for the conversion of L-dopa to dopamine, which is a crucial neurotransmitter involved in movement regulation. TPH, on the other hand, catalyzes the rate-limiting step in serotonin synthesis by converting L-tryptophan to 5-hydroxytryptophan (5-HTP), which is then converted to serotonin by another enzyme called aromatic amino acid decarboxylase.

Deficiencies or mutations in ALADs can lead to various neurological and psychiatric disorders, such as Parkinson's disease, dopa-responsive dystonia, and depression. Therefore, understanding the function and regulation of ALADs is essential for developing effective therapies for these conditions.

Vinblastine is an alkaloid derived from the Madagascar periwinkle plant (Catharanthus roseus) and is primarily used in cancer chemotherapy. It is classified as a vinca alkaloid, along with vincristine, vinorelbine, and others.

Medically, vinblastine is an antimicrotubule agent that binds to tubulin, a protein involved in the formation of microtubules during cell division. By binding to tubulin, vinblastine prevents the assembly of microtubules, which are essential for mitosis (cell division). This leads to the inhibition of cell division and ultimately results in the death of rapidly dividing cells, such as cancer cells.

Vinblastine is used to treat various types of cancers, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, breast cancer, and others. It is often administered intravenously in a healthcare setting and may be given as part of a combination chemotherapy regimen with other anticancer drugs.

As with any medication, vinblastine can have side effects, including bone marrow suppression (leading to an increased risk of infection, anemia, and bleeding), neurotoxicity (resulting in peripheral neuropathy, constipation, and jaw pain), nausea, vomiting, hair loss, and mouth sores. Regular monitoring by a healthcare professional is necessary during vinblastine treatment to manage side effects and ensure the safe and effective use of this medication.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Up-regulation is a term used in molecular biology and medicine to describe an increase in the expression or activity of a gene, protein, or receptor in response to a stimulus. This can occur through various mechanisms such as increased transcription, translation, or reduced degradation of the molecule. Up-regulation can have important functional consequences, for example, enhancing the sensitivity or response of a cell to a hormone, neurotransmitter, or drug. It is a normal physiological process that can also be induced by disease or pharmacological interventions.

Northern blotting is a laboratory technique used in molecular biology to detect and analyze specific RNA molecules (such as mRNA) in a mixture of total RNA extracted from cells or tissues. This technique is called "Northern" blotting because it is analogous to the Southern blotting method, which is used for DNA detection.

The Northern blotting procedure involves several steps:

1. Electrophoresis: The total RNA mixture is first separated based on size by running it through an agarose gel using electrical current. This separates the RNA molecules according to their length, with smaller RNA fragments migrating faster than larger ones.

2. Transfer: After electrophoresis, the RNA bands are denatured (made single-stranded) and transferred from the gel onto a nitrocellulose or nylon membrane using a technique called capillary transfer or vacuum blotting. This step ensures that the order and relative positions of the RNA fragments are preserved on the membrane, similar to how they appear in the gel.

3. Cross-linking: The RNA is then chemically cross-linked to the membrane using UV light or heat treatment, which helps to immobilize the RNA onto the membrane and prevent it from washing off during subsequent steps.

4. Prehybridization: Before adding the labeled probe, the membrane is prehybridized in a solution containing blocking agents (such as salmon sperm DNA or yeast tRNA) to minimize non-specific binding of the probe to the membrane.

5. Hybridization: A labeled nucleic acid probe, specific to the RNA of interest, is added to the prehybridization solution and allowed to hybridize (form base pairs) with its complementary RNA sequence on the membrane. The probe can be either a DNA or an RNA molecule, and it is typically labeled with a radioactive isotope (such as ³²P) or a non-radioactive label (such as digoxigenin).

6. Washing: After hybridization, the membrane is washed to remove unbound probe and reduce background noise. The washing conditions (temperature, salt concentration, and detergent concentration) are optimized based on the stringency required for specific hybridization.

7. Detection: The presence of the labeled probe is then detected using an appropriate method, depending on the type of label used. For radioactive probes, this typically involves exposing the membrane to X-ray film or a phosphorimager screen and analyzing the resulting image. For non-radioactive probes, detection can be performed using colorimetric, chemiluminescent, or fluorescent methods.

8. Data analysis: The intensity of the signal is quantified and compared to controls (such as housekeeping genes) to determine the relative expression level of the RNA of interest. This information can be used for various purposes, such as identifying differentially expressed genes in response to a specific treatment or comparing gene expression levels across different samples or conditions.

Bone neoplasms are abnormal growths or tumors that develop in the bone. They can be benign (non-cancerous) or malignant (cancerous). Benign bone neoplasms do not spread to other parts of the body and are rarely a threat to life, although they may cause problems if they grow large enough to press on surrounding tissues or cause fractures. Malignant bone neoplasms, on the other hand, can invade and destroy nearby tissue and may spread (metastasize) to other parts of the body.

There are many different types of bone neoplasms, including:

1. Osteochondroma - a benign tumor that develops from cartilage and bone
2. Enchondroma - a benign tumor that forms in the cartilage that lines the inside of the bones
3. Chondrosarcoma - a malignant tumor that develops from cartilage
4. Osteosarcoma - a malignant tumor that develops from bone cells
5. Ewing sarcoma - a malignant tumor that develops in the bones or soft tissues around the bones
6. Giant cell tumor of bone - a benign or occasionally malignant tumor that develops from bone tissue
7. Fibrosarcoma - a malignant tumor that develops from fibrous tissue in the bone

The symptoms of bone neoplasms vary depending on the type, size, and location of the tumor. They may include pain, swelling, stiffness, fractures, or limited mobility. Treatment options depend on the type and stage of the tumor but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

DNA primers are short single-stranded DNA molecules that serve as a starting point for DNA synthesis. They are typically used in laboratory techniques such as the polymerase chain reaction (PCR) and DNA sequencing. The primer binds to a complementary sequence on the DNA template through base pairing, providing a free 3'-hydroxyl group for the DNA polymerase enzyme to add nucleotides and synthesize a new strand of DNA. This allows for specific and targeted amplification or analysis of a particular region of interest within a larger DNA molecule.

A precancerous condition, also known as a premalignant condition, is a state of abnormal cellular growth and development that has a higher-than-normal potential to progress into cancer. These conditions are characterized by the presence of certain anomalies in the cells, such as dysplasia (abnormal changes in cell shape or size), which can indicate an increased risk for malignant transformation.

It is important to note that not all precancerous conditions will eventually develop into cancer, and some may even regress on their own. However, individuals with precancerous conditions are often at a higher risk of developing cancer compared to the general population. Regular monitoring and appropriate medical interventions, if necessary, can help manage this risk and potentially prevent or detect cancer at an early stage when it is more treatable.

Examples of precancerous conditions include:

1. Dysplasia in the cervix (cervical intraepithelial neoplasia or CIN)
2. Atypical ductal hyperplasia or lobular hyperplasia in the breast
3. Actinic keratosis on the skin
4. Leukoplakia in the mouth
5. Barrett's esophagus in the digestive tract

Regular medical check-ups, screenings, and lifestyle modifications are crucial for individuals with precancerous conditions to monitor their health and reduce the risk of cancer development.

Immunoblotting, also known as western blotting, is a laboratory technique used in molecular biology and immunogenetics to detect and quantify specific proteins in a complex mixture. This technique combines the electrophoretic separation of proteins by gel electrophoresis with their detection using antibodies that recognize specific epitopes (protein fragments) on the target protein.

The process involves several steps: first, the protein sample is separated based on size through sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Next, the separated proteins are transferred onto a nitrocellulose or polyvinylidene fluoride (PVDF) membrane using an electric field. The membrane is then blocked with a blocking agent to prevent non-specific binding of antibodies.

After blocking, the membrane is incubated with a primary antibody that specifically recognizes the target protein. Following this, the membrane is washed to remove unbound primary antibodies and then incubated with a secondary antibody conjugated to an enzyme such as horseradish peroxidase (HRP) or alkaline phosphatase (AP). The enzyme catalyzes a colorimetric or chemiluminescent reaction that allows for the detection of the target protein.

Immunoblotting is widely used in research and clinical settings to study protein expression, post-translational modifications, protein-protein interactions, and disease biomarkers. It provides high specificity and sensitivity, making it a valuable tool for identifying and quantifying proteins in various biological samples.

Acid anhydride hydrolases are a class of enzymes that catalyze the hydrolysis (breakdown) of acid anhydrides, which are chemical compounds formed by the reaction between two carboxylic acids. This reaction results in the formation of a molecule of water and the release of a new carboxylic acid.

Acid anhydride hydrolases play important roles in various biological processes, including the metabolism of lipids, carbohydrates, and amino acids. They are also involved in the regulation of intracellular pH and the detoxification of xenobiotics (foreign substances).

Examples of acid anhydride hydrolases include esterases, lipases, and phosphatases. These enzymes have different substrate specificities and catalytic mechanisms, but they all share the ability to hydrolyze acid anhydrides.

The term "acid anhydride hydrolase" is often used interchangeably with "esterase," although not all esterases are capable of hydrolyzing acid anhydrides.

Antibiotics are a type of medication used to treat infections caused by bacteria. They work by either killing the bacteria or inhibiting their growth.

Antineoplastics, also known as chemotherapeutic agents, are a class of drugs used to treat cancer. These medications target and destroy rapidly dividing cells, such as cancer cells, although they can also affect other quickly dividing cells in the body, such as those in the hair follicles or digestive tract, which can lead to side effects.

Antibiotics and antineoplastics are two different classes of drugs with distinct mechanisms of action and uses. It is important to use them appropriately and under the guidance of a healthcare professional.

DNA topoisomerases are enzymes that regulate the topological state of DNA during various cellular processes such as replication, transcription, and repair. They do this by introducing temporary breaks in the DNA strands and allowing the strands to rotate around each other, thereby relieving torsional stress and supercoiling. Topoisomerases are classified into two types: type I and type II.

Type II topoisomerases are further divided into two subtypes: type IIA and type IIB. These enzymes function by forming a covalent bond with the DNA strands, cleaving them, and then passing another segment of DNA through the break before resealing the original strands. This process allows for the removal of both positive and negative supercoils from DNA as well as the separation of interlinked circular DNA molecules (catenanes) or knotted DNA structures.

Type II topoisomerases are essential for cell viability, and their dysfunction has been linked to various human diseases, including cancer and neurodegenerative disorders. They have also emerged as important targets for the development of anticancer drugs that inhibit their activity and induce DNA damage leading to cell death. Examples of type II topoisomerase inhibitors include etoposide, doxorubicin, and mitoxantrone.

Hu paraneoplastic encephalomyelitis antigens are a group of neuronal intracellular antigens associated with paraneoplastic neurological disorders (PNDs). PNDs are a group of rare, degenerative conditions that affect the nervous system and can occur in patients with cancer. The Hu antigens are part of a family of proteins known as onconeural antigens, which are expressed in both cancer cells and normal neurons.

The Hu antigens include three main proteins: HuD, HuC, and Rb/p75. These proteins are involved in the regulation of gene expression and are found in the nucleus and cytoplasm of neuronal cells. In patients with PNDs associated with Hu antigens, the immune system mistakenly recognizes these antigens as foreign and mounts an immune response against them. This leads to inflammation and damage to the nervous system, resulting in various neurological symptoms such as muscle weakness, sensory loss, and autonomic dysfunction.

Paraneoplastic encephalomyelitis is a specific type of PND that affects both the brain (encephalitis) and spinal cord (myelitis). It is often associated with small cell lung cancer but can also occur in other types of cancer. The presence of Hu antibodies in the blood or cerebrospinal fluid is a useful diagnostic marker for this condition, although not all patients with Hu-associated PNDs will have detectable Hu antibodies.

Oligonucleotide Array Sequence Analysis is a type of microarray analysis that allows for the simultaneous measurement of the expression levels of thousands of genes in a single sample. In this technique, oligonucleotides (short DNA sequences) are attached to a solid support, such as a glass slide, in a specific pattern. These oligonucleotides are designed to be complementary to specific target mRNA sequences from the sample being analyzed.

During the analysis, labeled RNA or cDNA from the sample is hybridized to the oligonucleotide array. The level of hybridization is then measured and used to determine the relative abundance of each target sequence in the sample. This information can be used to identify differences in gene expression between samples, which can help researchers understand the underlying biological processes involved in various diseases or developmental stages.

It's important to note that this technique requires specialized equipment and bioinformatics tools for data analysis, as well as careful experimental design and validation to ensure accurate and reproducible results.

An Enzyme-Linked Immunosorbent Assay (ELISA) is a type of analytical biochemistry assay used to detect and quantify the presence of a substance, typically a protein or peptide, in a liquid sample. It takes its name from the enzyme-linked antibodies used in the assay.

In an ELISA, the sample is added to a well containing a surface that has been treated to capture the target substance. If the target substance is present in the sample, it will bind to the surface. Next, an enzyme-linked antibody specific to the target substance is added. This antibody will bind to the captured target substance if it is present. After washing away any unbound material, a substrate for the enzyme is added. If the enzyme is present due to its linkage to the antibody, it will catalyze a reaction that produces a detectable signal, such as a color change or fluorescence. The intensity of this signal is proportional to the amount of target substance present in the sample, allowing for quantification.

ELISAs are widely used in research and clinical settings to detect and measure various substances, including hormones, viruses, and bacteria. They offer high sensitivity, specificity, and reproducibility, making them a reliable choice for many applications.

Nuclear proteins are a category of proteins that are primarily found in the nucleus of a eukaryotic cell. They play crucial roles in various nuclear functions, such as DNA replication, transcription, repair, and RNA processing. This group includes structural proteins like lamins, which form the nuclear lamina, and regulatory proteins, such as histones and transcription factors, that are involved in gene expression. Nuclear localization signals (NLS) often help target these proteins to the nucleus by interacting with importin proteins during active transport across the nuclear membrane.

Tissue Polypeptide Antigen (TPS) is not a medical definition itself, but rather an immunological marker that is often measured in laboratory tests. TPS is a complex of several intracellular proteins, including cytokeratins 8, 18, and 19, which are released into the bloodstream upon cell damage or death.

TPS is commonly used as a tumor marker to monitor treatment response and disease progression in patients with various types of cancer, such as breast, lung, colon, and ovarian cancers. Elevated levels of TPS in the blood may indicate active cancer growth or tissue damage due to other causes, such as inflammation or injury.

It is important to note that TPS is not specific to cancer and can be elevated in various benign conditions as well. Therefore, its interpretation should always be done in conjunction with clinical findings, imaging studies, and other laboratory tests.

Surface antigens are molecules found on the surface of cells that can be recognized by the immune system as being foreign or different from the host's own cells. Antigens are typically proteins or polysaccharides that are capable of stimulating an immune response, leading to the production of antibodies and activation of immune cells such as T-cells.

Surface antigens are important in the context of infectious diseases because they allow the immune system to identify and target infected cells for destruction. For example, viruses and bacteria often display surface antigens that are distinct from those found on host cells, allowing the immune system to recognize and attack them. In some cases, these surface antigens can also be used as targets for vaccines or other immunotherapies.

In addition to their role in infectious diseases, surface antigens are also important in the context of cancer. Tumor cells often display abnormal surface antigens that differ from those found on normal cells, allowing the immune system to potentially recognize and attack them. However, tumors can also develop mechanisms to evade the immune system, making it difficult to mount an effective response.

Overall, understanding the properties and behavior of surface antigens is crucial for developing effective immunotherapies and vaccines against infectious diseases and cancer.

Single-Stranded Conformational Polymorphism (SSCP) is not a medical condition but rather a laboratory technique used in molecular biology and genetics. It refers to the phenomenon where a single-stranded DNA or RNA molecule can adopt different conformations or shapes based on its nucleotide sequence, even if the difference in the sequence is as small as a single base pair change. This property is used in SSCP analysis to detect mutations or variations in DNA or RNA sequences.

In SSCP analysis, the denatured single-stranded DNA or RNA sample is subjected to electrophoresis on a non-denaturing polyacrylamide gel. The different conformations of the single-stranded molecules migrate at different rates in the gel, creating multiple bands that can be visualized by staining or other detection methods. The presence of additional bands or shifts in band patterns can indicate the presence of a sequence variant or mutation.

SSCP analysis is often used as a screening tool for genetic diseases, cancer, and infectious diseases to identify genetic variations associated with these conditions. However, it has largely been replaced by more sensitive and accurate methods such as next-generation sequencing.

Phase III clinical trials are a type of medical research study that involves testing the safety and efficacy of a new drug, device, or treatment in a large group of people. These studies typically enroll hundreds to thousands of participants, who are randomly assigned to receive either the experimental treatment or a standard of care comparison group.

The primary goal of Phase III clinical trials is to determine whether the new treatment works better than existing treatments and to assess its safety and side effects in a larger population. The data collected from these studies can help regulatory agencies like the U.S. Food and Drug Administration (FDA) decide whether to approve the new treatment for use in the general population.

Phase III clinical trials are usually conducted at multiple centers, often across different countries, to ensure that the results are generalizable to a wide range of patients. Participants may be followed for several years to assess long-term safety and efficacy outcomes.

Overall, Phase III clinical trials play a critical role in ensuring that new treatments are safe and effective before they become widely available to patients.

Tissue distribution, in the context of pharmacology and toxicology, refers to the way that a drug or xenobiotic (a chemical substance found within an organism that is not naturally produced by or expected to be present within that organism) is distributed throughout the body's tissues after administration. It describes how much of the drug or xenobiotic can be found in various tissues and organs, and is influenced by factors such as blood flow, lipid solubility, protein binding, and the permeability of cell membranes. Understanding tissue distribution is important for predicting the potential effects of a drug or toxin on different parts of the body, and for designing drugs with improved safety and efficacy profiles.

DNA methylation is a process by which methyl groups (-CH3) are added to the cytosine ring of DNA molecules, often at the 5' position of cytospine phosphate-deoxyguanosine (CpG) dinucleotides. This modification is catalyzed by DNA methyltransferase enzymes and results in the formation of 5-methylcytosine.

DNA methylation plays a crucial role in the regulation of gene expression, genomic imprinting, X chromosome inactivation, and suppression of transposable elements. Abnormal DNA methylation patterns have been associated with various diseases, including cancer, where tumor suppressor genes are often silenced by promoter methylation.

In summary, DNA methylation is a fundamental epigenetic modification that influences gene expression and genome stability, and its dysregulation has important implications for human health and disease.

Neurotensin is a neuropeptide that is widely distributed in the central nervous system and the gastrointestinal tract. It is composed of 13 amino acids and plays a role as a neurotransmitter or neuromodulator in various physiological functions, including pain regulation, temperature regulation, and feeding behavior. Neurotensin also has been shown to have potential roles in the development of certain diseases such as cancer and neurological disorders. It exerts its effects by binding to specific receptors, known as neurotensin receptors (NTSR1, NTSR2, and NTSR3), which are widely distributed throughout the body.

Mustard compounds refer to a group of chemical agents that are derivatives of mustard gas (sulfur mustard), a powerful blistering agent used in World War I and II. The term "mustard compounds" often includes sulfur mustard and nitrogen mustards. These compounds have alkylating properties, meaning they can interact with DNA and proteins to prevent cell division and cause damage to tissues. Nitrogen mustards are particularly potent alkylating agents and are used in chemotherapy for the treatment of various types of cancer. Sulfur mustard is not used medically but remains a significant concern as a chemical warfare agent.

Piperazines are a class of heterocyclic organic compounds that contain a seven-membered ring with two nitrogen atoms at positions 1 and 4. They have the molecular formula N-NRR' where R and R' can be alkyl or aryl groups. Piperazines have a wide range of uses in pharmaceuticals, agrochemicals, and as building blocks in organic synthesis.

In a medical context, piperazines are used in the manufacture of various drugs, including some antipsychotics, antidepressants, antihistamines, and anti-worm medications. For example, the antipsychotic drug trifluoperazine and the antidepressant drug nefazodone both contain a piperazine ring in their chemical structure.

However, it's important to note that some piperazines are also used as recreational drugs due to their stimulant and euphoric effects. These include compounds such as BZP (benzylpiperazine) and TFMPP (trifluoromethylphenylpiperazine), which have been linked to serious health risks, including addiction, seizures, and death. Therefore, the use of these substances should be avoided.

Iodine radioisotopes are radioactive isotopes of the element iodine, which decays and emits radiation in the form of gamma rays. Some commonly used iodine radioisotopes include I-123, I-125, I-131. These radioisotopes have various medical applications such as in diagnostic imaging, therapy for thyroid disorders, and cancer treatment.

For example, I-131 is commonly used to treat hyperthyroidism and differentiated thyroid cancer due to its ability to destroy thyroid tissue. On the other hand, I-123 is often used in nuclear medicine scans of the thyroid gland because it emits gamma rays that can be detected by a gamma camera, allowing for detailed images of the gland's structure and function.

It is important to note that handling and administering radioisotopes require specialized training and safety precautions due to their radiation-emitting properties.

Proto-oncogene proteins c-bcl-2 are a group of proteins that play a role in regulating cell death (apoptosis). The c-bcl-2 gene produces one of these proteins, which helps to prevent cells from undergoing apoptosis. This protein is located on the membrane of mitochondria and endoplasmic reticulum and it can inhibit the release of cytochrome c, a key player in the activation of caspases, which are enzymes that trigger apoptosis.

In normal cells, the regulation of c-bcl-2 protein helps to maintain a balance between cell proliferation and cell death, ensuring proper tissue homeostasis. However, when the c-bcl-2 gene is mutated or its expression is dysregulated, it can contribute to cancer development by allowing cancer cells to survive and proliferate. High levels of c-bcl-2 protein have been found in many types of cancer, including leukemia, lymphoma, and carcinomas, and are often associated with a poor prognosis.

Pyrimidines are heterocyclic aromatic organic compounds similar to benzene and pyridine, containing two nitrogen atoms at positions 1 and 3 of the six-member ring. They are one of the two types of nucleobases found in nucleic acids, the other being purines. The pyrimidine bases include cytosine (C) and thymine (T) in DNA, and uracil (U) in RNA, which pair with guanine (G) and adenine (A), respectively, through hydrogen bonding to form the double helix structure of nucleic acids. Pyrimidines are also found in many other biomolecules and have various roles in cellular metabolism and genetic regulation.

Lymph nodes are small, bean-shaped organs that are part of the immune system. They are found throughout the body, especially in the neck, armpits, groin, and abdomen. Lymph nodes filter lymph fluid, which carries waste and unwanted substances such as bacteria, viruses, and cancer cells. They contain white blood cells called lymphocytes that help fight infections and diseases by attacking and destroying the harmful substances found in the lymph fluid. When an infection or disease is present, lymph nodes may swell due to the increased number of immune cells and fluid accumulation as they work to fight off the invaders.

Gallbladder neoplasms refer to abnormal growths in the tissue of the gallbladder, which can be benign or malignant. Benign neoplasms are non-cancerous and typically do not spread to other parts of the body. Malignant neoplasms, also known as gallbladder cancer, can invade nearby tissues and organs and may metastasize (spread) to distant parts of the body. Gallbladder neoplasms can cause symptoms such as abdominal pain, jaundice, and nausea, but they are often asymptomatic until they have advanced to an advanced stage. The exact causes of gallbladder neoplasms are not fully understood, but risk factors include gallstones, chronic inflammation of the gallbladder, and certain inherited genetic conditions.

Cell adhesion refers to the binding of cells to extracellular matrices or to other cells, a process that is fundamental to the development, function, and maintenance of multicellular organisms. Cell adhesion is mediated by various cell surface receptors, such as integrins, cadherins, and immunoglobulin-like cell adhesion molecules (Ig-CAMs), which interact with specific ligands in the extracellular environment. These interactions lead to the formation of specialized junctions, such as tight junctions, adherens junctions, and desmosomes, that help to maintain tissue architecture and regulate various cellular processes, including proliferation, differentiation, migration, and survival. Disruptions in cell adhesion can contribute to a variety of diseases, including cancer, inflammation, and degenerative disorders.

Cell differentiation is the process by which a less specialized cell, or stem cell, becomes a more specialized cell type with specific functions and structures. This process involves changes in gene expression, which are regulated by various intracellular signaling pathways and transcription factors. Differentiation results in the development of distinct cell types that make up tissues and organs in multicellular organisms. It is a crucial aspect of embryonic development, tissue repair, and maintenance of homeostasis in the body.

Neurotransmitter receptors are specialized protein molecules found on the surface of neurons and other cells in the body. They play a crucial role in chemical communication within the nervous system by binding to specific neurotransmitters, which are chemicals that transmit signals across the synapse (the tiny gap between two neurons).

When a neurotransmitter binds to its corresponding receptor, it triggers a series of biochemical events that can either excite or inhibit the activity of the target neuron. This interaction helps regulate various physiological processes, including mood, cognition, movement, and sensation.

Neurotransmitter receptors can be classified into two main categories based on their mechanism of action: ionotropic and metabotropic receptors. Ionotropic receptors are ligand-gated ion channels that directly allow ions to flow through the cell membrane upon neurotransmitter binding, leading to rapid changes in neuronal excitability. In contrast, metabotropic receptors are linked to G proteins and second messenger systems, which modulate various intracellular signaling pathways more slowly.

Examples of neurotransmitters include glutamate, GABA (gamma-aminobutyric acid), dopamine, serotonin, acetylcholine, and norepinephrine, among others. Each neurotransmitter has its specific receptor types, which may have distinct functions and distributions within the nervous system. Understanding the roles of these receptors and their interactions with neurotransmitters is essential for developing therapeutic strategies to treat various neurological and psychiatric disorders.

Benzamides are a class of organic compounds that consist of a benzene ring (a aromatic hydrocarbon) attached to an amide functional group. The amide group can be bound to various substituents, leading to a variety of benzamide derivatives with different biological activities.

In a medical context, some benzamides have been developed as drugs for the treatment of various conditions. For example, danzol (a benzamide derivative) is used as a hormonal therapy for endometriosis and breast cancer. Additionally, other benzamides such as sulpiride and amisulpride are used as antipsychotic medications for the treatment of schizophrenia and related disorders.

It's important to note that while some benzamides have therapeutic uses, others may be toxic or have adverse effects, so they should only be used under the supervision of a medical professional.

The Ki-67 antigen is a cellular protein that is expressed in all active phases of the cell cycle (G1, S, G2, and M), but not in the resting phase (G0). It is often used as a marker for cell proliferation and can be found in high concentrations in rapidly dividing cells. Immunohistochemical staining for Ki-67 can help to determine the growth fraction of a group of cells, which can be useful in the diagnosis and prognosis of various malignancies, including cancer. The level of Ki-67 expression is often associated with the aggressiveness of the tumor and its response to treatment.

Laryngeal neoplasms refer to abnormal growths or tumors in the larynx, also known as the voice box. These growths can be benign (non-cancerous) or malignant (cancerous). Laryngeal neoplasms can affect any part of the larynx, including the vocal cords, epiglottis, and the area around the vocal cords called the ventricle.

Benign laryngeal neoplasms may include papillomas, hemangiomas, or polyps. Malignant laryngeal neoplasms are typically squamous cell carcinomas, which account for more than 95% of all malignant laryngeal tumors. Other types of malignant laryngeal neoplasms include adenocarcinoma, sarcoma, and lymphoma.

Risk factors for developing laryngeal neoplasms include smoking, alcohol consumption, exposure to industrial chemicals, and a history of acid reflux. Symptoms may include hoarseness, difficulty swallowing, sore throat, ear pain, or a lump in the neck. Treatment options depend on the type, size, location, and stage of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

Adjuvant radiotherapy is a type of cancer treatment that uses radiation therapy as an adjunct to a primary surgical procedure. The goal of adjuvant radiotherapy is to eliminate any remaining microscopic cancer cells that may be present in the surrounding tissues after surgery, thereby reducing the risk of local recurrence and improving the chances of cure.

Radiotherapy involves the use of high-energy radiation to destroy cancer cells and shrink tumors. In adjuvant radiotherapy, the radiation is usually delivered to the tumor bed and regional lymph nodes in order to target any potential sites of residual disease. The timing and dosing of adjuvant radiotherapy may vary depending on the type and stage of cancer being treated, as well as other factors such as patient age and overall health status.

Adjuvant radiotherapy is commonly used in the treatment of various types of cancer, including breast, colorectal, lung, head and neck, and gynecologic cancers. Its use has been shown to improve survival rates and reduce the risk of recurrence in many cases, making it an important component of comprehensive cancer care.

Drug repositioning, also known as drug repurposing or therapeutic switching, refers to the process of discovering new uses for approved or investigational drugs that are outside the scope of their original medical indication. This strategy leverages existing knowledge about a drug's safety, efficacy, and pharmacological properties to expedite development and reduce costs compared to de novo drug discovery. By finding new therapeutic applications for existing drugs, drug repositioning can provide faster and more cost-effective treatment options for various diseases, including neglected and rare disorders.

Membrane proteins are a type of protein that are embedded in the lipid bilayer of biological membranes, such as the plasma membrane of cells or the inner membrane of mitochondria. These proteins play crucial roles in various cellular processes, including:

1. Cell-cell recognition and signaling
2. Transport of molecules across the membrane (selective permeability)
3. Enzymatic reactions at the membrane surface
4. Energy transduction and conversion
5. Mechanosensation and signal transduction

Membrane proteins can be classified into two main categories: integral membrane proteins, which are permanently associated with the lipid bilayer, and peripheral membrane proteins, which are temporarily or loosely attached to the membrane surface. Integral membrane proteins can further be divided into three subcategories based on their topology:

1. Transmembrane proteins, which span the entire width of the lipid bilayer with one or more alpha-helices or beta-barrels.
2. Lipid-anchored proteins, which are covalently attached to lipids in the membrane via a glycosylphosphatidylinositol (GPI) anchor or other lipid modifications.
3. Monotopic proteins, which are partially embedded in the membrane and have one or more domains exposed to either side of the bilayer.

Membrane proteins are essential for maintaining cellular homeostasis and are targets for various therapeutic interventions, including drug development and gene therapy. However, their structural complexity and hydrophobicity make them challenging to study using traditional biochemical methods, requiring specialized techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and single-particle cryo-electron microscopy (cryo-EM).

Retinoblastoma Protein (pRb or RB1) is a tumor suppressor protein that plays a critical role in regulating the cell cycle and preventing uncontrolled cell growth. It is encoded by the RB1 gene, located on chromosome 13. The retinoblastoma protein functions as a regulatory checkpoint in the cell cycle, preventing cells from progressing into the S phase (DNA synthesis phase) until certain conditions are met.

When pRb is in its active state, it binds to and inhibits the activity of E2F transcription factors, which promote the expression of genes required for DNA replication and cell cycle progression. Phosphorylation of pRb by cyclin-dependent kinases (CDKs) leads to the release of E2F factors, allowing them to activate their target genes and drive the cell into S phase.

Mutations in the RB1 gene can result in the production of a nonfunctional or reduced amount of pRb protein, leading to uncontrolled cell growth and an increased risk of developing retinoblastoma, a rare form of eye cancer, as well as other types of tumors.

Epithelium is the tissue that covers the outer surface of the body, lines the internal cavities and organs, and forms various glands. It is composed of one or more layers of tightly packed cells that have a uniform shape and size, and rest on a basement membrane. Epithelial tissues are avascular, meaning they do not contain blood vessels, and are supplied with nutrients by diffusion from the underlying connective tissue.

Epithelial cells perform a variety of functions, including protection, secretion, absorption, excretion, and sensation. They can be classified based on their shape and the number of cell layers they contain. The main types of epithelium are:

1. Squamous epithelium: composed of flat, scalelike cells that fit together like tiles on a roof. It forms the lining of blood vessels, air sacs in the lungs, and the outermost layer of the skin.
2. Cuboidal epithelium: composed of cube-shaped cells with equal height and width. It is found in glands, tubules, and ducts.
3. Columnar epithelium: composed of tall, rectangular cells that are taller than they are wide. It lines the respiratory, digestive, and reproductive tracts.
4. Pseudostratified epithelium: appears stratified or layered but is actually made up of a single layer of cells that vary in height. The nuclei of these cells appear at different levels, giving the tissue a stratified appearance. It lines the respiratory and reproductive tracts.
5. Transitional epithelium: composed of several layers of cells that can stretch and change shape to accommodate changes in volume. It is found in the urinary bladder and ureters.

Epithelial tissue provides a barrier between the internal and external environments, protecting the body from physical, chemical, and biological damage. It also plays a crucial role in maintaining homeostasis by regulating the exchange of substances between the body and its environment.

Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.

Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.

Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.

There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.

Aclarubicin is an anthracycline antibiotic used in cancer chemotherapy. It works by interfering with the DNA in cancer cells, preventing them from dividing and growing. Aclarubicin is often used to treat acute leukemias, lymphomas, and solid tumors.

Like other anthracyclines, aclarubicin can cause significant side effects, including damage to the heart muscle, suppression of bone marrow function, and hair loss. It may also cause nausea, vomiting, and mouth sores. Aclarubicin is usually given by injection into a vein.

It's important to note that the use of aclarubicin should be under the supervision of a healthcare professional, as its administration requires careful monitoring due to potential toxicities.

Ras genes are a group of genes that encode for proteins involved in cell signaling pathways that regulate cell growth, differentiation, and survival. Mutations in Ras genes have been associated with various types of cancer, as well as other diseases such as developmental disorders and autoimmune diseases. The Ras protein family includes H-Ras, K-Ras, and N-Ras, which are activated by growth factor receptors and other signals to activate downstream effectors involved in cell proliferation and survival. Abnormal activation of Ras signaling due to mutations or dysregulation can contribute to tumor development and progression.

Polymerase Chain Reaction (PCR) is a laboratory technique used to amplify specific regions of DNA. It enables the production of thousands to millions of copies of a particular DNA sequence in a rapid and efficient manner, making it an essential tool in various fields such as molecular biology, medical diagnostics, forensic science, and research.

The PCR process involves repeated cycles of heating and cooling to separate the DNA strands, allow primers (short sequences of single-stranded DNA) to attach to the target regions, and extend these primers using an enzyme called Taq polymerase, resulting in the exponential amplification of the desired DNA segment.

In a medical context, PCR is often used for detecting and quantifying specific pathogens (viruses, bacteria, fungi, or parasites) in clinical samples, identifying genetic mutations or polymorphisms associated with diseases, monitoring disease progression, and evaluating treatment effectiveness.

Nogalamycin is not typically considered as a medical term, but it is a type of antibiotic that is used in research and microbiology. Here's the definition from a scientific perspective:

Nogalamycin is an anthracycline antitumor antibiotic produced by Streptomyces nogalater. It is a DNA-intercalating agent, which means it can insert itself between the base pairs of DNA and disrupt the structure and function of the genetic material in bacteria and cancer cells. Nogalamycin has been studied for its potential use as an anticancer drug, but its clinical use has been limited due to toxicity concerns.

Protein-Serine-Threonine Kinases (PSTKs) are a type of protein kinase that catalyzes the transfer of a phosphate group from ATP to the hydroxyl side chains of serine or threonine residues on target proteins. This phosphorylation process plays a crucial role in various cellular signaling pathways, including regulation of metabolism, gene expression, cell cycle progression, and apoptosis. PSTKs are involved in many physiological and pathological processes, and their dysregulation has been implicated in several diseases, such as cancer, diabetes, and neurodegenerative disorders.

Membrane glycoproteins are proteins that contain oligosaccharide chains (glycans) covalently attached to their polypeptide backbone. They are integral components of biological membranes, spanning the lipid bilayer and playing crucial roles in various cellular processes.

The glycosylation of these proteins occurs in the endoplasmic reticulum (ER) and Golgi apparatus during protein folding and trafficking. The attached glycans can vary in structure, length, and composition, which contributes to the diversity of membrane glycoproteins.

Membrane glycoproteins can be classified into two main types based on their orientation within the lipid bilayer:

1. Type I (N-linked): These glycoproteins have a single transmembrane domain and an extracellular N-terminus, where the oligosaccharides are predominantly attached via asparagine residues (Asn-X-Ser/Thr sequon).
2. Type II (C-linked): These glycoproteins possess two transmembrane domains and an intracellular C-terminus, with the oligosaccharides linked to tryptophan residues via a mannose moiety.

Membrane glycoproteins are involved in various cellular functions, such as:

* Cell adhesion and recognition
* Receptor-mediated signal transduction
* Enzymatic catalysis
* Transport of molecules across membranes
* Cell-cell communication
* Immunological responses

Some examples of membrane glycoproteins include cell surface receptors (e.g., growth factor receptors, cytokine receptors), adhesion molecules (e.g., integrins, cadherins), and transporters (e.g., ion channels, ABC transporters).

Neutropenia is a condition characterized by an abnormally low concentration (less than 1500 cells/mm3) of neutrophils, a type of white blood cell that plays a crucial role in fighting off bacterial and fungal infections. Neutrophils are essential components of the innate immune system, and their main function is to engulf and destroy microorganisms that can cause harm to the body.

Neutropenia can be classified as mild, moderate, or severe based on the severity of the neutrophil count reduction:

* Mild neutropenia: Neutrophil count between 1000-1500 cells/mm3
* Moderate neutropenia: Neutrophil count between 500-1000 cells/mm3
* Severe neutropenia: Neutrophil count below 500 cells/mm3

Severe neutropenia significantly increases the risk of developing infections, as the body's ability to fight off microorganisms is severely compromised. Common causes of neutropenia include viral infections, certain medications (such as chemotherapy or antibiotics), autoimmune disorders, and congenital conditions affecting bone marrow function. Treatment for neutropenia typically involves addressing the underlying cause, administering granulocyte-colony stimulating factors to boost neutrophil production, and providing appropriate antimicrobial therapy to prevent or treat infections.

... lung carcinomas are divided into 8 major taxa: Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma ... combined small cell carcinoma of the lung has been long classified as a subset of small cell carcinoma, and not as a subset of ... small cell lung carcinoma (SCLC), admixed with one (or more) components of any histological variant of non-small cell lung ... December 2007). "Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation". Lung Cancer. ...
... (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which ... 33% patients with small cell lung cancer are diagnosed with limited-stage small cell lung carcinoma when it is first found. ... can also be associated with small cell lung cancer. Unlike extensive-stage small cell lung cancer, limited-stage small cell ... Unlike extensive-stage small cell lung cancer, limited-stage small cell lung cancer is potentially curable. In limited small ...
Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC). It is the second most ... Early squamous-cell carcinoma of the lung (generally as squamous-cell carcinoma in situ) is asymptomatic and may only appear as ... for lung SCC. Lung squamous-cell carcinoma is the second most common histologic type of lung cancer after adenocarcinoma, ... Squamous-cell lung carcinoma share most of the signs and symptoms with other forms of lung cancer. These include worsening ...
It is currently considered to be a subtype of large-cell lung carcinoma. LCNEC is often generically grouped among the non-small ... Large-cell neuroendocrine carcinoma of the lung (LCNEC of the lung), or pulmonary large-cell neuroendocrine carcinoma (PLCNC), ... cell lung carcinomas. LCNECs often have inactivations of p53 and RB (~40%), or inactivation of TP53 and STK11 or KEAP1 (~40%). ... genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors". ...
Small-cell carcinoma Squamous cell carcinoma Adenocarcinoma Large-cell carcinoma Adenosquamous carcinoma Sarcomatoid carcinoma ... Giant-cell carcinoma of the lung (GCCL) is a rare histological form of large-cell lung carcinoma, a subtype of undifferentiated ... giant-cell carcinoma has the third-worst prognosis among 18 histological forms of lung cancer. (Only small-cell carcinoma and ... of all lung cancers. By the definition of "large-vs.-small-cell carcinoma", the diameter of GCCL cells must be considerably ...
... lung carcinomas are divided into 8 major taxa: Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma ... adenoid cystic carcinoma of the lung, epithelial-myoepithelial carcinoma of the lung, and other (even more rare) variants. Lung ... Salivary gland-like carcinomas of the lung generally refers a class of rare cancers that arise from the uncontrolled cell ... Rossi G, Marchioni A, Sartori1 G, Longo L, Piccinini S, Cavazza A (2007). "Histotype in non-small cell lung cancer therapy and ...
Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma Adenosquamous carcinoma Sarcomatoid carcinoma ... In the 1960s, small cell lung carcinoma (SCLC) was recognized as a unique form of lung cancer, based both on its appearance ( ... have based patient treatment decisions on a dichotomous division of lung cancers into SCLC and non-small cell lung carcinomas ( ... by volume each of squamous cell carcinoma (SqCC) and adenocarcinoma (AdC) cells. Lung cancers have been historically classified ...
LCC is categorized as a type of NSCLC (non-small-cell lung carcinoma) which originates from epithelial cells of the lung. ... large-cell carcinoma of the lung clear-cell carcinoma of the lung lymphoepithelioma-like carcinoma of the lung large-cell lung ... Large-cell lung carcinoma (LCLC), or large-cell carcinoma (LCC) in short, is a heterogeneous group of undifferentiated ... LCC is differentiated from small-cell lung carcinoma (SCLC) primarily by the larger size of the anaplastic cells, a higher ...
... is a type of rare lung tumour under the category of poorly differentiated Non-small-cell lung carcinoma ( ... Moran C, Saul S (2010). "Non Small Cell Carcinomas of the Lung". Tumors and Tumor-like Conditions of the Lung and Pleura. ... spindle cell carcinoma (almost completely consists of spindle cells), pleomorphic carcinoma (at least 10% spindle/giant cells ... it can be classified into giant cell carcinoma (almost completely consists of giant cells), ...
"Non-small cell lung cancer". www.cancer.gov. 2011-02-02. Retrieved 2023-04-09. "Small Cell Lung Carcinoma - MeSH - NCBI". www. ... Lung cancer can be classified into two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC ... adenocarcinoma and large cell carcinoma. SCLC is highly aggressive and consists of small ovoid cells. Surgical resection is ... "Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open- ...
Small cell lung carcinoma (SCLC) (FDA Oct 2007). As of 2016, experiments were under way for Neuroblastoma, Brainstem glioma, ... Topotecan is often given in combination with paclitaxel as first line treatment for extensive-stage small-cell lung cancer. ... "FDA Rubber-Stamps APP Pharma's Generic Topotecan for Small Cell Lung and Cervical Cancers". 30 Nov 2010. DNA Topoisomerases and ... In addition, topotecan is experimentally treating Non-small cell lung cancer, Colorectal Cancer, Breast cancer, Non-Hodgkin ...
Syrian hamsters are a model for researching Non-small-cell lung carcinoma, which is one of the types of human lung cancer. In ... "Current role of surgery in small cell lung carcinoma". Journal of Cardiothoracic Surgery. 4 (1): 30. doi:10.1186/1749-8090-4-30 ... Oral squamous-cell carcinoma is a common cancer in humans and difficult to treat. Scientists studying this disease broadly ... The scientist can take cell samples from the mouth of the hamster to measure the development of the cancer. This process has ...
... (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small- ... Non-Small Cell Lung Cancer at eMedicine "What Is Non-Small Cell Lung Cancer?". www.cancer.org. Archived from the original on 17 ... "Non-Small Cell Lung Cancer Signs and Symptoms". www.cancer.org. Retrieved 4 December 2017. "Non-small cell lung cancer". ... "Non-Small Cell Lung Cancer Treatment". National Cancer Institute. 1 January 1980. Retrieved 4 December 2017. "Non-small cell ...
"Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other ... Another reason is that lung cancer, particularly small cell lung cancer, is very aggressive with very low five-year survival ... is cell cycle-independent. TK1 is synthesized by the cell during the S phase of cell division. After cell division is completed ... "Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis". Cancer. 66 (4): 722- ...
In lung carcinoma, fibronectin expression is increased especially in non-small cell lung carcinoma. The adhesion of lung ... ISBN 978-0-387-97050-9. Han S, Khuri FR, Roman J (January 2006). "Fibronectin stimulates non-small cell lung carcinoma cell ... The RGD sequence (Arg-Gly-Asp) is located in III10 and is the site of cell attachment via α5β1 and αVβ3 integrins on the cell ... "Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma". Cancer Biology & Therapy ...
Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene. 2007 Feb;26(7):1046. Dierks C, Beigi R, ... Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature. 2003 Mar;422(6929):313. Yuan Z ... Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell ... small cell lung cancer, pancreatic cancer, intracranial meningioma, recurrent glioblastoma, and acute myeloid leukemia. ...
It was counterproductive in non-squamous non-small-cell lung carcinoma. International Nonproprietary Names for Pharmaceutical ... name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma ... Chustecka Z (2015-11-22). "Necitumumab (Portrazza) Approved for Lung Cancer in US". Medscape.com. Retrieved 2019-09-28. " ...
... small-cell lung cancer, ovarian cancer). It has been granted Orphan drug status for Merkel cell carcinoma. It has reported ... "ImmunoGen Announces Encouraging New Clinical Data With The Company's IMGN901 Compound In The Treatment Of Small-Cell Lung ... encouraging Phase II results for small-cell lung cancer. Dimond PF (9 March 2010). "Antibody-Drug Conjugates Stage a Comeback ... It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a ...
Increased expression of mir-126 inhibits cell proliferation of non-small cell lung carcinoma cells in vitro and prevents tumour ... "MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines". Biochem Biophys Res Commun. 373 (4): 607-12. doi: ... Sun Y, Bai Y, Zhang F, Wang Y, Guo Y, Guo L (2010). "miR-126 inhibits non-small cell lung cancer cells proliferation by ... This includes controlled cell death and responses to wounds. During apoptosis cell death, cells release apoptotic bodies ...
"Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies". Lancet. 341 (8836): 21-22. doi: ... which are cell-cell adhesion molecules found in desmosomes). Underlying cancer or irreversible system impairment, seen in acute ... Unlike a mass effect, it is not due to the local presence of cancer cells. Paraneoplastic syndromes are typical among middle- ... In this scenario, the body may produce antibodies to fight off the tumor by directly binding and destroying the tumor cell. ...
... -containing drugs Gefitinib for treatment of non-small-cell lung carcinoma. Lapatinib for treatment of advanced- ... "Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to ... Lapatinib eliminates the growth of breast cancer stem cells that cause tumor growth. The binding of lapatinib to the ATP- ... the cancer stem cell. Archived from the original on 2008-11-26. Nelson MH, Dolder CR (February 2006). "Lapatinib: a novel dual ...
... small cell lung carcinoma. Maksym Pashayev, 20, Ukrainian footballer, car accident. Amalia Solórzano, 97, Mexican First Lady ( ... Kenny Cox, 68, American jazz musician, lung cancer. Sir Bernard Crick, 79, British political theorist, cancer. Dock Ellis, 63, ... David Lieber, 83, Polish-born American biblical scholar, lung ailment. John W. Powell, 89, Chinese-born American journalist ... Ron Carey, 72, American labor leader (Teamsters), lung cancer. Robert Chandler, 80, American CBS executive, heart failure. Elie ...
Possible applications include non-small-cell lung carcinoma, hepatocellular carcinoma, and oesophageal cancer. In 2017, it was ... Tivantinib (ARQ197; by Arqule, Inc.) is an experimental small molecule anti-cancer drug. It is a bisindolylmaleimide that binds ... "ArQule Announces Commencement of Phase 3 Clinical Trial with Tivantinib in Hepatocellular Carcinoma by Partner Kyowa Hakko ... announced that a phase III clinical trial for advanced hepatocellular carcinoma had failed to meet the primary endpoint. ...
Trueman was diagnosed with small cell carcinoma of the lung in May 2006. He died of the disease on 1 July 2006 at Airedale ... This award was discontinued in 2004, two years before Trueman was diagnosed with lung cancer, because its organisers feared it ... Deaths from lung cancer in England, Derbyshire cricketers, England Test cricketers, English cricket commentators, English ...
... most oncologists tend to classify lung carcinomas into two major groups, namely small cell carcinoma (SCLC) and non-small cell ... It was not until 1962 that small cell lung carcinoma (SCLC), then called "oat cell carcinoma" was recognized for its unique ... Surgery is very rarely used in cases of stage 3b or stage 4 non-small cell lung carcinoma. In patients with stage 3 lung cancer ... cell lung cancer and was approved by the FDA in 2004 for second-line treatment of advanced non-small cell lung carcinoma. ...
... and non-small-cell lung carcinoma, which can be addicted to the gene EGFR. Oncogene addiction can be treated by using enzyme ... As a result, cancer cells rely on continuous signaling from these oncogenes for their survival. The term was coined in 2002 by ... Tulpule, Asmin; Bivona, Trever G. (2020). "Acquired Resistance in Lung Cancer". Annual Review of Cancer Biology. 4: 279-297. ... Articles with short description, Short description matches Wikidata, Cancer, Cell signaling). ...
In adults, most cases are associated with breast carcinoma or small-cell lung carcinoma. It is one of the few paraneoplastic ( ... and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes". Neurology. 62 (9): 1526-32. doi: ... possibly by expanding the memory B cell population. Studies have generally asserted that 70-80% of children with OMS will have ...
Shtivelman E (Jun 1997). "A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma". Oncogene ... Cell. Biol. 20 (2): 583-93. doi:10.1128/MCB.20.2.583-593.2000. PMC 85138. PMID 10611237. Xiao H, Palhan V, Yang Y, Roeder RG ( ... Cell. Biol. 24 (16): 7091-101. doi:10.1128/MCB.24.16.7091-7101.2004. PMC 479715. PMID 15282309. Suzuki Y, Yamashita R, Shirota ... NicAmhlaoibh R, Shtivelman E (2001). "Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro". ...
Middle mediastinum: lymphadenopathy, metastatic disease such as from small cell carcinoma from the lung. Posterior mediastinum ... It is surrounded by the chest wall in front, the lungs to the sides and the spine at the back. It extends from the sternum in ... "Cell Biology and Anatomy - School of Medicine - University of South Carolina". dba.med.sc.edu. "UAMS Department of Neurobiology ... It contains all the organs of the thorax except the lungs. It is continuous with the loose connective tissue of the neck. The ...
In contrast, non-small cell lung carcinomas (NSCLC's) are more likely to remain localized to the thorax during development, and ... Most small cell lung carcinomas (SCLC's) metastasize to distant organs early on in their course, rendering surgery ineffective ... While there have been no randomized clinical trials of targeted agents in combined small-cell lung carcinoma (c-SCLC),[citation ... Dempke WC, Suto T, Reck M (March 2010). "Targeted therapies for non-small cell lung cancer". Lung Cancer (Amsterdam, ...
... lung carcinomas are divided into 8 major taxa: Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma ... combined small cell carcinoma of the lung has been long classified as a subset of small cell carcinoma, and not as a subset of ... small cell lung carcinoma (SCLC), admixed with one (or more) components of any histological variant of non-small cell lung ... December 2007). "Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation". Lung Cancer. ...
... in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance ... Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas. May 5, 2010. ScienceBlog.com ... in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance ... Expression rate also associated more so with adenocarcinoma histology (39 percent) than in squamous cell carcinoma histology ( ...
... are effective therapeutic agents for the palliative treatment of metastatic non-small-cell lung cancer (NSCLC); the aim of our ... Non-small-cell lung carcinoma (NSCLC) constitutes approximately 85% of all lung cancer cases [2]. In the last decade, several ... Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint ... Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint ...
Response rates and median survival (MS; □) in small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC). Response ... Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. I. K. Demedts, K. Y. Vermaelen, J ... Klasa R, Murray N, Coldman A. Dose intensity (DI) analysis of chemotherapy in small cell carcinoma of the lung (SCCL). Proc Am ... Klasa R, Murray N, Coldman A. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin ...
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung ... Liver , Lung , Melanoma, skin , Other Female Genital. , Phase II. ...
His interests are in Non-small cell lung carcinoma, radiation induced lung injury and idiopathic pulmonary fibrosis. ... His interests are in Non-small cell lung carcinoma, radiation induced lung injury and idiopathic pulmonary fibrosis. ... Solomides, MD, Charalambos C., "Non Small Cell Carcinoma of the Lung- From Morphology to Molecular Profiling" (2011). Division ... Non Small Cell Carcinoma of the Lung- From Morphology to Molecular Profiling ...
... neoplastic cell; Non-Small-Cell Lung Carcinoma; Normal tissue morphology; novel; novel therapeutics; Nude Mice; Outcome; ... lung small cell carcinoma; Malignant - descriptor; malignant breast neoplasm; Malignant neoplasm of lung; Malignant Neoplasms; ... Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 Safety and Dose Escalation Studies. Award last edited on: 10/ ... In 2010, there were 222,520 new cases of lung cancer diagnosed in the US, 85% being non small cell lung cancer (NSCLC) and ...
Breast Carcinoma, Pancreatic Cancer, Advanced Non-small Cell Lung Carcinoma, and Others) - Global Industry Analysis, Size, ... 6.3.1. Ovarian Carcinoma *6.3.2. Breast Carcinoma *6.3.3. Pancreatic Cancer *6.3.4. Advanced Non-small Cell Lung Carcinoma *6.3 ... 9.2.1. Ovarian Carcinoma *9.2.2. Breast Carcinoma *9.2.3. Pancreatic Cancer *9.2.4. Advanced Non-small Cell Lung Carcinoma *9.2 ... 10.2.1. Ovarian Carcinoma *10.2.2. Breast Carcinoma *10.2.3. Pancreatic Cancer *10.2.4. Advanced Non-small Cell Lung Carcinoma ...
The epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small-cell lung carcinoma (NSCLC), and EGFR ... Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression ... Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression ... including squamous cell carcinoma (SCC; 89 patients) and non-SCC (94 patients) histologies. Protein expression was assessed by ...
It usually grows and spreads more slowly than small cell lung cancer. ... It usually grows and spreads more slowly than small cell lung cancer. ... Non-small cell lung cancer is the most common type of lung cancer. ... Non-small cell lung cancer is the most common type of lung cancer. ...
Susan GoodinJohns Hopkins cancerLung cancerLurie Cancer CenterNon-small-cell lung carcinomaPD-1PD-L1President Jimmy Carter ... adenocarcinomaCancerConditions and DiseasesLung cancerMetastasisNon-small-cell lung carcinomaRadiationRadiation therapy ... Tag Archives: Non-small-cell lung carcinoma cancer, immunotherapy New anti-PD-1 immunotherapies beating some cancers. September ... Non-small-cell lung carcinoma (Photo credit: Wikipedia). Months after shed received the treatment for early-stage ...
... to help efficiently distinguish lung carcinomas from other lung lesions, as well as how to stage and treat them. ... See Clinical Presentations of Lung Cancer: Slideshow, a Critical Images slideshow, ... The TNM classification for small cell lung cancer is provided below. ... encoded search term (Small Cell Lung Cancer Staging) and Small Cell Lung Cancer Staging What to Read Next on Medscape ...
Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. Most patients are diagnosed at an advanced stage ... Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin ... Carcinoma Pulmonar de Células não Pequenas/patologia Feminino Humanos Neoplasias Pulmonares/patologia Masculino Pessoa de Meia- ... Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico Neoplasias Pulmonares/tratamento farmacológico Paclitaxel/ ...
Search Keyword: Small Cell Lung Carcinoma The purpose of this study is to compare overall survival (OS) and progression free ... With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung ...
Human Non-Small Cell Lung Carcinoma (NSCLC) Peripheral Blood Mononuclear Cells (PBMCs) $660.00. - $955.00. ...
The reemergence of small cell carcinoma of the lung after a period of remission. ... Carcinoma*Lung carcinoma*Recurrent Lung Carcinoma*Recurrent Lung Small Cell Carcinoma*Recurrent Extensive Stage Lung Small Cell ... Recurrent Small Cell Lung Carcinoma; Relapsed Small Cell Carcinoma of Lung; Relapsed Small Cell Carcinoma of the Lung; Relapsed ... Recurrent Small Cell Carcinoma of Lung; Recurrent Small Cell Carcinoma of the Lung; Recurrent Small Cell Lung Cancer; ...
Non-small lung cancer dosing for Alimta, Pemfexy (pemetrexed), frequency-based adverse effects, comprehensive interactions, ... Nonsquamous Non-Small Cell Lung Carcinoma. Combination with pembrolizumab and platinum chemotherapy. *Indicated for initial ... Expert Consensus on Perioperative Immunotherapy for Local Advanced Non-Small Cell Lung Cancer ... an effect that may lead to a low number of blood cells such as red cells, white cells, and platelets. This effect can cause ...
... and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: Results of ... and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: Results of ... and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: Results of ... and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: Results of ...
Growth kinetics of small cell carcinoma of the lung. / Lenhard, Raymond E.; Woo, Kwang B.; Freund, Johns S. et al. In: European ... Growth kinetics of small cell carcinoma of the lung. In: European Journal of Cancer (1965). 1981 ; Vol. 17, No. 8. pp. 899-904. ... Growth kinetics of small cell carcinoma of the lung. European Journal of Cancer (1965). 1981 Aug;17(8):899-904. doi: 10.1016/ ... Lenhard, R. E., Woo, K. B., Freund, J. S., & Abeloff, M. D. (1981). Growth kinetics of small cell carcinoma of the lung. ...
Do you qualify for these Lung Non-Small Cell Squamous Carcinoma studies? Were researching treatments for 2023. ... Lung Non-Small Cell Squamous Carcinoma clinical trials at UCSD 2 in progress, 1 open to eligible people ... Our lead scientists for Lung Non-Small Cell Squamous Carcinoma research studies include Lyudmila A. Bazhenova. ... Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer ...
"Defining target volumes for non-small cell lung carcinoma",. abstract = "The definition of target volumes for non-small cell ... Defining target volumes for non-small cell lung carcinoma. / Senan, Suresh; Chapet, Olivier; Lagerwaard, Frank J. et al. In: ... Senan, S., Chapet, O., Lagerwaard, F. J., & Ten Haken, R. K. (2004). Defining target volumes for non-small cell lung carcinoma ... Defining target volumes for non-small cell lung carcinoma. Suresh Senan, Olivier Chapet, Frank J. Lagerwaard, Randall K. Ten ...
Find information about the best hospitals and centres in Europe for lung tumours on our website. ... Chemotherapy of small-cell lung carcinoma Radiation therapy of small-cell lung carcinoma ... Surgery of non-small cell carcinoma Chemotherapy of non-small cell lung carcinoma ... 9 hospitals and clinics found radiation therapy of small-cell lung carcinoma. ...
KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer ...
To cite: Boominathan, p53 target genes serve as biomarkers in non small cell lung carcinoma, 26/June/2013, 12.49, Genome-2-Bio- ... p53 target genes serve as biomarkers in non small cell lung carcinoma 26/June/2013 12.48. ...
Lung cancer is classified as small cell lung carcinomas (SCLCs) and non-small cell lung carcinomas (NSCLCs). SCLC comprises ... Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC), the major lung cancer ... Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11. ... an alternative pathway without PPARgamma activation in non-small cell lung carcinoma A549 cells. Prostaglandins & other lipid ...
The demonstration that small cell lung carcinoma cells can be lysed by cytolytic T lymphocytes, suggests that it will be ... However, a high level of lysis was observed when both stimulator and target small cell lung carcinoma cells were pretreated ... which increased considerably the expression of major histocompatibility class I molecules by these cells. ... Human lymphocytes stimulated in vitro by allogeneic small cell lung carcinoma cell lines did not show any significant cytolytic ...
Ultrasound-Guided Transbronchial Needle Aspiration Use for Subclassification and Genotyping of Lung Non-Small-Cell Carcinoma. ... A total of 6 to 10 passes were placed in a cell block. RESULTS:Sixty-nine samples from patients with non-small-cell lung cancer ... Ultrasound-Guided Transbronchial Needle Aspiration Use for Subclassification and Genotyping of Lung Non-Small-Cell Carcinoma. ... Ultrasound-Guided Transbronchial Needle Aspiration Use for Subclassification and Genotyping of Lung Non-Small-Cell Carcinoma. ...
Lung cancer can be caused by many risk factors other than smoking cigarettes. ... Adenocarcinomas and squamous cell carcinomas are two types of non-small cell lung cancer. A few (6% to 8%) are small cell lung ... are squamous cell carcinomas (cancer that forms in the thin, flat cells lining the inside of the lungs). ... cancer that begins in the cells that line the lungs tiny air sacs and make substances such as mucus). About 10% to 20% ...
Phase II trial of cisplatin in small cell carcinoma of the lung. / Levenson, R. M.; Ihde, D. C.; Huberman, M. S. et al. In: ... Phase II trial of cisplatin in small cell carcinoma of the lung. In: Cancer Treatment Reports. 1981 ; Vol. 65, No. 9-10. pp. ... Phase II trial of cisplatin in small cell carcinoma of the lung. Cancer Treatment Reports. 1981 Nov 6;65(9-10):905-907. ... Dive into the research topics of Phase II trial of cisplatin in small cell carcinoma of the lung. Together they form a unique ...
  • Combined small cell lung carcinoma (or c-SCLC) is a form of multiphasic lung cancer that is diagnosed by a pathologist when a malignant tumor, arising from transformed cells originating in lung tissue, contains a component of;small cell lung carcinoma (SCLC), admixed with one (or more) components of any histological variant of non-small cell lung carcinoma (NSCLC) in any relative proportion. (wikipedia.org)
  • In most cases of c-SCLC, genomic and immunohistochemical studies suggest that the morphological divergence of the separate components occurs when a SCLC-like cell is transformed into a cell with the potential to develop NSCLC variant characteristics, and not vice versa. (wikipedia.org)
  • The May edition of the Journal of Thoracic Oncology features a study aimed to clarify expression patterns of a novel cancer biomarker, CD24, in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance status, age, gender and prognostic significance. (scienceblog.com)
  • Recent data suggest that the tumour, node, metastasis classification traditionally reserved for the staging of nonsmall cell lung cancer (NSCLC) can also be applied for the staging of SCLC 3 . (ersjournals.com)
  • in small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC). (ersjournals.com)
  • In 2010, there were 222,520 new cases of lung cancer diagnosed in the US, 85% being non small cell lung cancer (NSCLC) and 157,300 lung cancer related deaths. (inknowvation.com)
  • The epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small-cell lung carcinoma (NSCLC), and EGFR inhibitors are promising new therapeutic agents. (nih.gov)
  • EGFR overexpression is frequent in NSCLC, is most prominent in SCC, and correlates with increased gene copy number per cell. (nih.gov)
  • Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer . (bvsalud.org)
  • Non-small cell lung cancer (NSCLC), the major lung cancer subtype, is characterized by high resistance to chemotherapy. (oncotarget.com)
  • Here we demonstrate that Tudor staphylococcal nuclease (SND1 or TSN) is overexpressed in NSCLC cell lines and tissues, and is important for maintaining NSCLC chemoresistance. (oncotarget.com)
  • Downregulation of TSN by RNAi in NSCLC cells led to strong potentiation of cell death in response to cisplatin. (oncotarget.com)
  • Downregulation of S100A11 by RNAi resulted in enhanced sensitivity of NSCLC cells to cisplatin, oxaliplatin and 5-fluouracil. (oncotarget.com)
  • NSCLC is divided into adeno-, squamous- and large cell lung carcinomas, accounting for about 40%, 30% and 10-15% of all lung cancer cases, respectively. (oncotarget.com)
  • There are two main types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). (medicalnewstoday.com)
  • This article outlines the prevalence of NSCLC compared with other lung cancers and over time. (medicalnewstoday.com)
  • Together, SCLC and NSCLC account for more than 95% of all lung cancers. (medicalnewstoday.com)
  • On its own, NSCLC accounts for up to 85% of all lung cancers in the United States. (medicalnewstoday.com)
  • This is the second most common type of NSCLC, accounting for about 25% of all lung cancer cases. (medicalnewstoday.com)
  • Most people with lung cancer who do not smoke develop NSCLC as opposed to SCLC. (medicalnewstoday.com)
  • METHODS: Discovery utilised Taqman Low Density Arrays (754 miRNAs) in 20 non-small cell lung cancer (NSCLC) tumour/normal pairs. (edgehill.ac.uk)
  • Here we developed and validated a prediction algorithm based on microRNA (miRNA) expression that can assist clinical diagnosis of lung cancer in minimal biopsy material to improve clinical management.METHODS: Discovery utilised Taqman Low Density Arrays (754 miRNAs) in 20 non-small cell lung cancer (NSCLC) tumour/normal pairs. (edgehill.ac.uk)
  • There are small cell and non-small cell lung cancers (NSCLC). (biomedcentral.com)
  • NSCLC are subdivided into adenocarcinomas (about 50%), squamous cell (about 20%), large cell (about 10%), and otherwise not defined carcinomas [ 1 ]. (biomedcentral.com)
  • The aim of the present study was to study the presence of pre-cachexia and cachexia in patients with stage III nonsmall-cell lung carcinoma (NSCLC) by using a cancer-specific framework and a general framework for cachexia, and to explore the prognostic value of pre-cachexia and cachexia. (edu.au)
  • In conclusion, pre-cachexia and cachexia are prevalent in this small population of patients at diagnosis of stage III NSCLC. (edu.au)
  • To determine how IPDA for pathologists' diagnoses of non-small cell lung carcinoma (NSCLC) is affected by the addition of a set of mucin and immunohistochemical (IHC) stains to hematoxylin-eosin (H&E) alone, by recent NSCLC reclassifications, by simplification of these classifications, and by pathologists' practice location, pulmonary pathology expertise, practice duration, and lung carcinoma case exposure. (duke.edu)
  • Higher IPDA is associated with use of mucin and IHC stains, with the 2015 NSCLC classification, and with pathologists' pulmonary pathology expertise, practice duration, and frequency of lung carcinoma cases. (duke.edu)
  • Eligible patients with previously untreated, metastatic squamous non-small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and paclitaxel/nab-paclitaxel once every 3 weeks for four cycles, followed by pembrolizumab or placebo for up to 35 cycles. (nih.gov)
  • Ryou Ishikawa Introduction: This study aimed to clarify the diagnostic structural features in cytology specimens that are useful in subtyping non-small cell lung carcinoma (NSCLC) into adenocarcinoma (ADC. (karger.com)
  • In order to ensure that patients receive the proper treatment, it is critical that the pathologist, when making a diagnosis of lung cancer, reports the finding of small cell carcinoma, regardless of other components, because small cell carcinoma is considered the most aggressive of all the lung cancer variants, and its treatment is normally radically different than the other forms of lung cancer (see below). (wikipedia.org)
  • Lung cancer is a large and exceptionally heterogeneous family of malignancies. (wikipedia.org)
  • Over 50 different histological variants are explicitly recognized within the 2004 revision of the World Health Organization (WHO) typing system ("WHO-2004"), currently the most widely used lung cancer classification scheme. (wikipedia.org)
  • However, since different forms of malignant tumors generally exhibit diverse genetic, biological, and clinical properties - including response to treatment - accurate classification of lung cancer cases are critical to assuring that patients with lung cancer receive optimum management. (wikipedia.org)
  • Under WHO-2004, lung carcinomas are divided into 8 major taxa: Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma Adenosquamous carcinoma Sarcomatoid carcinoma Carcinoid tumor Salivary gland-like carcinoma SCLC is generally considered to be the most aggressive of these major forms of lung cancer, with the worst long term prognosis and survival rates. (wikipedia.org)
  • It is currently thought that most cases of lung cancer probably occur after damage to genomic DNA causes malignant transformation of a single multipotent cell. (wikipedia.org)
  • This newly formed entity, sometimes referred to as a cancer stem cell, then begins to divide uncontrollably, giving rise to new daughter cancer cells in an exponential (or near exponential) fashion. (wikipedia.org)
  • The histogenesis of c-SCLC and other multiphasic forms of lung cancer appear to be complex and varied phenomena. (wikipedia.org)
  • The JTO is a prized resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer. (scienceblog.com)
  • The JTO is the official monthly journal of the International Association for the Study of Lung Cancer (IASLC.org) and emphasizes a multidisciplinary approach, including original research (clinical trials and translational or basic research), reviews and opinion pieces. (scienceblog.com)
  • Small cell lung cancer (SCLC) is an aggressive lung tumour strongly associated with cigarette smoking, with patients often presenting with metastatic disease at the time of diagnosis. (ersjournals.com)
  • Small cell lung cancer (SCLC) is an aggressive malignant disease, with the majority of patients presenting with distant metastasis at diagnosis. (ersjournals.com)
  • The International Association for the Study of Lung Cancer defines limited-stage SCLC (LS-SCLC) as: "disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and ipsilateral and contralateral supraclavicular nodes and should also include patients with ipsilateral pleural effusion independent of whether cytology is positive or negative" 2 . (ersjournals.com)
  • 2. Get familiar with new diagnostic and prognostic markers in lung cancer. (jefferson.edu)
  • Lung Cancer remains the leading cause of cancer and mortality for men and women worldwide. (inknowvation.com)
  • The development of novel therapy against target critical and specific to the cancer cells but not to the normal tissues is expected to be efficacious and minimize damage to healthy cells. (inknowvation.com)
  • The present application proposes feasibility studies to investigate if this agent can be inhibit lung cancer, particularly on small cell lung carcinoma. (inknowvation.com)
  • At the end of this phase I SBIR study, we will have established feasibility studies to develop novel therapies for lung cancer. (inknowvation.com)
  • Non-small cell lung cancer is the most common type of lung cancer . (medlineplus.gov)
  • It usually grows and spreads more slowly than small cell lung cancer . (medlineplus.gov)
  • There are more uncommon types of lung cancer that are also called non-small. (medlineplus.gov)
  • Smoking causes most cases (around 90%) of non-small cell lung cancer. (medlineplus.gov)
  • Being around the smoke from other people (secondhand smoke) also raises your risk of lung cancer. (medlineplus.gov)
  • But some people who have never smoked do develop lung cancer. (medlineplus.gov)
  • Research shows that smoking marijuana may help cancer cells grow. (medlineplus.gov)
  • But there is no direct link between smoking marijuana and developing lung cancer. (medlineplus.gov)
  • Constant exposure to high levels of air pollution and drinking water that has a high level of arsenic can increase your risk of lung cancer. (medlineplus.gov)
  • Working with or living near cancer-causing chemicals or materials can also increase the risk of developing lung cancer. (medlineplus.gov)
  • Early lung cancer may not cause any symptoms. (medlineplus.gov)
  • You will also be asked about other things that may have put you at risk of lung cancer, such as exposure to certain chemicals. (medlineplus.gov)
  • Stage 0 -- The cancer has not spread beyond the inner lining of the lung. (medlineplus.gov)
  • Stage I -- The cancer is small and has not spread to the lymph nodes. (medlineplus.gov)
  • Stage IV -- The cancer has spread to other organs of the body, such as the other lung, brain, or liver. (medlineplus.gov)
  • Chemotherapy uses drugs to kill cancer cells and stop new cells from growing. (medlineplus.gov)
  • Chemotherapy alone is often used when the cancer has spread outside the lung (stage IV). (medlineplus.gov)
  • Here's Boston's Dana-Farber Cancer Center's quick-and-dirty cartoon video about how the anti-PD-1 drug hooks up with the PD-L1 expression on the cancer cell (antigen). (biomednews.org)
  • Months after she'd received the treatment for early-stage adenocarcinoma, a type of non-small cell lung cancer, the woman came back suffering. (biomednews.org)
  • The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire was used in conjunction with its supplemental lung cancer -specific module in order to assess HRQoL . (bvsalud.org)
  • Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. (nih.gov)
  • Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. (nih.gov)
  • Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review. (nih.gov)
  • Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer. (nih.gov)
  • Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. (nih.gov)
  • Purpose: The combination of cisplatin, ifosfamide, and oral etoposide (PlEo) given concurrently with accelerated hyperfractionated thoracic radiation was studied in patients with limited small-cell lung cancer in a phase II trial to assess response, survival, and toxicity. (psu.edu)
  • The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. (oncotarget.com)
  • Lung cancer is the leading cause of cancer-related deaths worldwide. (oncotarget.com)
  • Lung cancer is classified as small cell lung carcinomas (SCLCs) and non-small cell lung carcinomas (NSCLCs). (oncotarget.com)
  • Despite improvements in the efficacy of therapeutics, the overall five-year survival rate for lung cancer still hovers around 15% [ 1 ]. (oncotarget.com)
  • OBJECTIVES:Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the primary method for the diagnosis and staging of lung cancer. (edu.lb)
  • RESULTS:Sixty-nine samples from patients with non-small-cell lung cancer were sent for molecular testing for epidermal growth factor receptor. (edu.lb)
  • You may not have symptoms," says Jackie, a lung cancer survivor who never smoked. (cdc.gov)
  • Lung cancer can be caused by risk factors other than smoking cigarettes, pipes, or cigars. (cdc.gov)
  • Examples include exposure to other people's smoke (called secondhand smoke), radon, air pollution, a family history of lung cancer, and asbestos. (cdc.gov)
  • What Are the Symptoms of Lung Cancer Among People Who Never Smoked? (cdc.gov)
  • Symptoms of lung cancer are the same, whether or not you have smoked. (cdc.gov)
  • How Can I Help Lower My Risk of Getting Lung Cancer? (cdc.gov)
  • You can help lower your risk of lung cancer by staying away from secondhand smoke, diesel exhaust, and other air pollution, as well as asbestos, arsenic, and some forms of silica and chromium. (cdc.gov)
  • Some risk factors, such as a personal or family history of lung cancer, can't be changed. (cdc.gov)
  • If lung cancer runs in your family, talk to your doctor about actions you can take stay healthy. (cdc.gov)
  • People with lung cancer who have never smoked may have a DNA mutation, such as a mutation in the epidermal growth factor receptor (EGFR) gene or other genes. (cdc.gov)
  • Is Lung Cancer Screening Recommended for People Who Never Smoked? (cdc.gov)
  • The U.S. Preventive Services Task Force does not recommend lung cancer screening for people who have never smoked. (cdc.gov)
  • That's because the possible harms of screening outweigh the possible benefit (finding lung cancer early) in this group. (cdc.gov)
  • What Types of Lung Cancer Are Diagnosed in People Who Never Smoked? (cdc.gov)
  • About 50% to 60% of lung cancers found in people who never smoked are adenocarcinomas (cancer that begins in the cells that line the lung's tiny air sacs and make substances such as mucus). (cdc.gov)
  • About 10% to 20% are squamous cell carcinomas (cancer that forms in the thin, flat cells lining the inside of the lungs). (cdc.gov)
  • Adenocarcinomas and squamous cell carcinomas are two types of non-small cell lung cancer. (cdc.gov)
  • A few (6% to 8%) are small cell lung cancers, and the rest are other types of lung cancer. (cdc.gov)
  • An aberrant miRNA expression could contribute to cancer development and progression [ 6 , 7 ] and could affect their target genes that are involved in many biological processes, such as cell differentiation, proliferation, apoptosis, metabolism, and development [ 8 ]. (hindawi.com)
  • Lung cancer is the second most common cancer and the leading cause of cancer-related death worldwide. (medicalnewstoday.com)
  • This is the most common type of primary lung cancer, accounting for around 40% of all lung cancer cases. (medicalnewstoday.com)
  • It is the leading cause of cancer death in the U.S., and it is the most common lung cancer among people who have never smoked. (medicalnewstoday.com)
  • This type accounts for approximately 10% of all lung cancer cases. (medicalnewstoday.com)
  • Black men have a 12% higher risk of developing lung cancer than white men. (medicalnewstoday.com)
  • Black women are 16% less likely to develop lung cancer than white women. (medicalnewstoday.com)
  • According to the Centers for Disease Control and Prevention (CDC), people who smoke are 15-30 times more likely to develop or die from lung cancer than people who have never smoked. (medicalnewstoday.com)
  • The CDC also notes that around 80-90% of deaths from lung cancer are linked to smoking. (medicalnewstoday.com)
  • Exposure to secondhand smoke accounts for around 15-35% of lung cancer cases among people who have never smoked. (medicalnewstoday.com)
  • Radon exposure is the leading cause of lung cancer among people who do not smoke. (medicalnewstoday.com)
  • Five-year survival rates vary according to lung cancer stage, which is the extent to which the cancer has spread. (medicalnewstoday.com)
  • This is cancer that has not spread outside the lungs. (medicalnewstoday.com)
  • This is cancer that has spread to nearby areas outside the lung. (medicalnewstoday.com)
  • Here we present an observational case report of a 49-year-old female, non-smoker, having a poor performance status with non-small-cell lung cancer and leptomeningeal carcinomatosis (LMC), who upon introduction of oral dichloroacetate (DCA) survived approximately 64 weeks (454 days) following palliative whole brain radiation without the need for chemotherapy or further targeted therapy to specifically address the LMC. (journalmc.org)
  • Further validation of the testing approach comes from NCCN: TMB analysis using an FDA-approved test is recommended ahead of second-line treatment decisions for cervical cancer , uterine sarcoma and endometrial carcinoma , vulvar cancer , bone cancer , and cancer of unknown primary . (genomeweb.com)
  • That mutation has been found in papillary thyroid carcinoma, colorectal cancer, melanoma, and non-small cell lung cancer. (news-medical.net)
  • What Is Lung Cancer? (webmd.com)
  • It's cancer that starts in your lungs and can spread to other parts of your body. (webmd.com)
  • There are more than 20 kinds of lung cancer . (webmd.com)
  • The two main types are non-small-cell lung cancer and small-cell lung cancer . (webmd.com)
  • It makes up 40% of lung cancer cases. (webmd.com)
  • It's also the No. 1 type of lung cancer among nonsmokers. (webmd.com)
  • Small-cell lung cancer makes up 10%-15% of lung cancers. (webmd.com)
  • The outlook for someone with lung cancer depends on a lot of things, including what type they have, their overall health, and how advanced the disease is when doctors find it. (webmd.com)
  • People who live with someone who smokes are 20% to 30% more likely to get lung cancer than those who live in a smoke-free home. (webmd.com)
  • People who work with asbestos or are exposed to uranium dust or the radioactive gas radon are more likely to get lung cancer, especially if they smoke. (webmd.com)
  • Treatment depends on what type of lung cancer you have and how advanced it is. (webmd.com)
  • If your lung cancer is advanced -- for instance, if it has spread to distant parts of your body -- there are still treatments that can control the disease and prevent further symptoms. (webmd.com)
  • Here we developed and validated a prediction algorithm based on microRNA (miRNA) expression that can assist clinical diagnosis of lung cancer in minimal biopsy material to improve clinical management. (edgehill.ac.uk)
  • CONCLUSION: The developed prediction algorithm is a valuable potential biomarker for assisting lung cancer diagnosis in minimal biopsy material. (edgehill.ac.uk)
  • 2 Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. (nih.gov)
  • Create healthcare diagrams like this example called Lung Cancer in minutes with SmartDraw. (smartdraw.com)
  • Lung cancer forms in tissues of the lung, usually in the cells lining air passages. (smartdraw.com)
  • Each type of lung cancer has different kinds of cancer cells. (smartdraw.com)
  • The cancer cells of each type grow and spread in different ways. (smartdraw.com)
  • Cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. (smartdraw.com)
  • Cancer that may begin in several types of large cells. (smartdraw.com)
  • Cancer that begins in the cells that line the alveoli and make substances such as mucus. (smartdraw.com)
  • We analyzed whole-genome sequencing data from 2,511 individuals in the Pan-Cancer Analysis of Whole Genomes (PCAWG) study as well as 489 individuals from four prospective cohorts and found distinct regional mutation type-specific frequencies in tissue and cell-free DNA from patients with cancer that were associated with replication timing and other chromatin features. (nature.com)
  • 90% of patients with lung cancer, including those with stage I and II disease. (nature.com)
  • For example, screening for lung cancer using low-dose computed tomography (LDCT) is recommended in the United States for adults aged 50-80 years who have smoked at least 20 pack years and currently smoke or have quit smoking within the last 15 years 3 . (nature.com)
  • Liquid biopsies may overcome these challenges and provide an attractive approach for the non-invasive detection of lung cancer and other malignancies. (nature.com)
  • Sequence alterations are abundant in cancer genomes but the proportion of fragments in cell-free DNA (cfDNA) that harbor tumor-specific (somatic) mutations is often low 8 , 9 , making it difficult to detect bona fide variants amidst background noise from sequence changes introduced in library construction and sequencing. (nature.com)
  • Lung cancer is the most common cause of global cancer-related mortality, leading to over a million deaths each year and adenocarcinoma is its most common histological type. (nature.com)
  • Other paraneoplastic syndromes are caused by cancer cells releasing hormones or other substances. (healthline.com)
  • Small cell lung cancer (SCLC) makes up about 15% of lung cancers in the United States. (healthline.com)
  • It is also one of the two main divisions of lung cancer along with non-small cell lung cancer. (healthline.com)
  • Others are caused by the production of hormones and other biologically active substances by cancer cells. (healthline.com)
  • Humoral hypercalcemia happens when cancer cells cause parathyroid hormone-related molecules to overproduce. (healthline.com)
  • Acromegaly is characterized by the abnormal secretion of growth hormone and insulin-like growth factor 1 by cancer cells. (healthline.com)
  • According to the National Cancer Registry, approximately two lakh (200,000) people are diagnosed with lung cancer every year in India. (cowurine.com)
  • Lung cancer is a type of cancer that begins in the cells of the lungs, typically in the cells that line the air passages. (cowurine.com)
  • The most common type of lung cancer is non-small cell lung cancer, which is further divided into different subtypes based on the specific cell type and stage of progression. (cowurine.com)
  • Jain's cow urine therapy helps to treat lung cancer by effectively increasing the anti-cancer cells and increasing immunity with reducing persistent cough, reduced chest pain, shortness of breath and wheezing, fatigue and weight loss, swelling on the neck and blood while coughing. (cowurine.com)
  • Along with glucosamine, alkaloids are known as gilo in, giloinin, gilosteral, and berberine, Giloy's residences destroy the most cancer cells in the body and smooth up the blood and cells. (cowurine.com)
  • Reactive oxygen species that ruin maximum cancer cells are produced through Ashwagandha. (cowurine.com)
  • A healthier and easier way of avoiding most cancer, Punarnavine, an anti-cancer drug, is an alkaloid known to prevent the improvement of most cancer cells. (cowurine.com)
  • A chemical compound discovered in Pippli Piperlongumine (PL) inhibits the majority of cancer cells and helps to avoid the extent of a tumor enzyme of lung cancer. (cowurine.com)
  • It is a powerful herb that prevents cancer cells from spreading in the body. (cowurine.com)
  • The natural molecules it contains inhibit the improvement of DNA molecules in most cancer cells. (cowurine.com)
  • Tulsi leaves have an element known to be eugenol, which is of very high quality when it comes to protecting most cells against cancer. (cowurine.com)
  • An enormous neem factor such as Neemaghan Satt acts as an antioxidant and anticarcinogenic property of the neem leaf that works to terminate most cancer cells in a person's body. (cowurine.com)
  • An immense amount of plumbagin, this herb's anti-cancer agent, has been used to cease the cancer-inflicting improvement of cancer cells. (cowurine.com)
  • Polyphenolic compounds are used powerfully in Kanghi with the sensitivity that maximally affects cancer cells. (cowurine.com)
  • Is the Subject Area "Non-small cell lung cancer" applicable to this article? (plos.org)
  • This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. (rush.edu)
  • However, intussusception due to a jejunal metastasis of combined lung cancer is extremely rare [ 3 ]. (hindawi.com)
  • Indeed, lung cancer metastasis to the bowel is uncommon, reported in less than 1% of patients [ 4 ]. (hindawi.com)
  • [ 5 ] An earlier report, in 1956, by Babolini and Blasi, described the same clinicopathological entity using the nomenclature, "The pleural form of primary cancer of the lung. (medscape.com)
  • To have been diagnosed before March 12, 2012 with: a) Lung cancer or b) Cancer (squamous cell carcinoma) of the throat, that is to say of the larynx, the oropharynx or the hypopharynx or c) Emphysema. (who.int)
  • Lung carcinoma is the leading cause of cancer-related death in men and women worldwide. (msdmanuals.com)
  • The risk of lung cancer increases with combined exposure to toxins and cigarette smoking. (msdmanuals.com)
  • The lung cancer risk associated with electronic nicotine delivery systems (eg, e-cigarettes) remains to be determined, although it is thought that the products of combustion of tobacco are the primary carcinogens. (msdmanuals.com)
  • About 15 to 20% of people who develop lung cancer have never smoked or have smoked minimally. (msdmanuals.com)
  • Chronic inflammation increases the risk of many cancers, including lung cancer. (msdmanuals.com)
  • See Small Cell Lung Cancer: Beating the Spread , a Critical Images slideshow, to help identify the key clinical and biologic characteristics of small cell lung cancer, the staging criteria, and the common sites of spread. (medscape.com)
  • Also, see Clinical Presentations of Lung Cancer: Slideshow to help efficiently distinguish lung carcinomas from other lung lesions, as well as how to stage and treat them. (medscape.com)
  • NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer V 2.2013. (medscape.com)
  • Patients and Methods Atezolizumab data from clinical trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. (medscape.com)
  • Lung neuroendocrine neoplasms (NEN) are a heterogeneous population of neoplasms with different pathology, clinical behavior, and prognosis compared to the more common lung cancers. (lu.se)
  • SFTs of the pleura are localized mesenchymal neoplasms composed of fibroblastlike cells believed to arise from the subpleural connective tissue. (medscape.com)
  • Expression rate also associated more so with adenocarcinoma histology (39 percent) than in squamous cell carcinoma histology (23 percent). (scienceblog.com)
  • The purpose of this study was to assess the yield of EBUS-TBNA in the subtyping and genotyping of lung adenocarcinoma. (edu.lb)
  • METHODS:Sixty-nine patients at Indiana University Hospital and Sidney and Lois Eskenazi Hospital with possible or confirmed lung adenocarcinoma underwent EBUS-TBNA using a 21-gauge Olympus needle without suction. (edu.lb)
  • CONCLUSIONS:EBUS-TBNA with a 21-gauge needle is appropriate for the analysis of multiple mutations and the genotyping of lung adenocarcinoma. (edu.lb)
  • They're rarer than adenocarcinoma or squamous cell carcinoma, making up 10%-15% of lung cancers. (webmd.com)
  • These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis. (nature.com)
  • Smoking is the major cause of lung adenocarcinoma but, as smoking rates decrease, proportionally more cases occur in never-smokers (defined as less than 100 cigarettes in a lifetime). (nature.com)
  • Our efforts focused on comprehensive, multiplatform analysis of lung adenocarcinoma, with attention towards pathobiology and clinically actionable events. (nature.com)
  • We analysed tumour and matched normal material from 230 previously untreated lung adenocarcinoma patients who provided informed consent ( Supplementary Table 1 ). (nature.com)
  • He underwent an en bloc resection, and pathological findings concluded to a metastasis of a pulmonary combined small cell carcinoma and adenocarcinoma. (hindawi.com)
  • In this present case, we report the observation of a patient who presented with an acute intestinal intussusception caused by a jejunal metastasis of pulmonary combined small cell carcinoma and adenocarcinoma and we present a review of the literature. (hindawi.com)
  • [ 3 , 4 ] The term "pseudomesotheliomatous carcinoma" was first applied by Harwood and colleagues in 1976 to 6 cases of peripheral lung adenocarcinoma that closely mimicked mesothelioma. (medscape.com)
  • As a result, it is recommended that all multiphasic malignant lung tumors (i.e. those with more than one histological pattern) that are found to contain any proportion of SCLC cells should be classified as c-SCLC, and not as combined forms of any of the other histological variants present in the tumor. (wikipedia.org)
  • In these instances, a minimum of 10% of the viable malignant cells present must be identified as LCLC before the tumor is considered to be a c-SCLC. (wikipedia.org)
  • Daughter cells of this transdifferentiated SCLC-like cell then repeatedly divide and, under both intrinsic genomic and extrinsic environmental influences, acquire additional mutations (a process known as tumor progression). (wikipedia.org)
  • In contrast, little progress has been made in the treatment of extensive-stage SCLC (ES-SCLC), apart from the recently documented survival gain by the addition of prophylactic cranial irradiation. (ersjournals.com)
  • Recently, prophylactic cranial irradiation (PCI) has been shown to improve outcome in patients with ES-SCLC 4 , but only small advances have been made otherwise. (ersjournals.com)
  • We have recently shown that staurosporine mediates the conversion of small cell lung carcinoma (SCLC) cells into a neuron-like process-bearing phenotype. (uni-luebeck.de)
  • Here, we have extended these studies to the staurosporine analogs K252a, lestaurtinib, PKC412, stauprimide, and UCN-01 and analyzed their influence on process extension, cell cycle distribution, and induction of polyploidy in four SCLC cell lines. (uni-luebeck.de)
  • In GLC-36 and SCLC-24H cells, only cell flattening was detectable. (uni-luebeck.de)
  • Fluorescence-activated cell sorting (FACS) and fluorescence in situ hybridization (FISH) analysis indicated the induction of polyploidy in all staurosporine and in two out of four stauprimide-treated SCLC cell lines. (uni-luebeck.de)
  • These data demonstrate that in SCLC cells, albeit a higher substrate specificity, staurosporine analogs can induce staurosporine-comparable effects. (uni-luebeck.de)
  • SCLC develops in neuroendocrine cells. (healthline.com)
  • Small cell lung carcinoma (SCLC) is not included in. (lu.se)
  • Small cell lung carcinoma (SCLC) is not included in these guidelines. (lu.se)
  • Approximately 99% of lung cancers are carcinoma, a term that indicates that the malignant neoplasm is composed of, or descended from, cells of epithelial lineage (i.e. derived from embryonic endoderm, as is the case in lung carcinomas, or from ectoderm), and/or that the malignant cells exhibit tissue architectural, cytological, or molecular features characteristically found in epithelial cells. (wikipedia.org)
  • The exact mechanisms and histogenesis of lung cancers are topics of intense interest and research. (wikipedia.org)
  • Approximately 98% of lung cancers are eventually diagnosed as a histological variant of carcinoma, a term that signifies that the tumor derives from transformed epithelial cells, or cells that have acquired epithelial characteristics as a result of cell differentiation. (wikipedia.org)
  • 3. Get familiar with microRNA profiling in lung cancers. (jefferson.edu)
  • Used alone and sometimes in combination with other drugs or modalities, the drugs are forcing a certain percentage of melanomas and smoking-induced lung cancers to yield. (biomednews.org)
  • In the United States, about 10% to 20% of lung cancers, or 20,000 to 40,000 lung cancers each year, happen in people who never smoked or smoked fewer than 100 cigarettes in their lifetime. (cdc.gov)
  • Researchers estimate that secondhand smoke contributes to about 7,300 and radon to about 2,900 of these lung cancers. (cdc.gov)
  • BRAF mutations are found in more than 80 percent of melanomas, but only 1-3 percent of lung cancers. (news-medical.net)
  • This type accounts for 30% of lung cancers, and it's more common in men and people who smoke. (webmd.com)
  • Large-cell carcinomas are a group of cancers with large cells that tend to start along the lungs' outer edges. (webmd.com)
  • Unless this runaway cell division process is checked, a clinically apparent tumor will eventually form as the mass reaches sufficient size to be detected clinically, or begins to cause signs or symptoms. (wikipedia.org)
  • Tumor volumes prior to initial therapy for 33 patients with small cell carcinoma of the lung were determined from serially measurable roentgenographic lesions. (johnshopkins.edu)
  • and cell differentiation ( SOX2 and TGFB3 ) as well as immunohistochemical assay for VEGFA, TP53, Bcl2, TGFB1, and Ki67 protein expression have been performed in 85 FFPE RCC tumor specimens. (hindawi.com)
  • This attack can lead to severe autoimmune damage to healthy cells that often exceeds the damage caused by the tumor. (healthline.com)
  • This occurs when tumor cells cause an overproduction of the hormone cortisol. (healthline.com)
  • Withaferin A is effective in killing the tumor-producing cells that are the ashwagandha-located compound. (cowurine.com)
  • The most significant factor of cytotoxicity that can prompt cytotoxicity (cellular-dying) in tumor cells is gallic acid, a high polyphenol placed in Baheda. (cowurine.com)
  • These Nordic guidelines summarize and update the Nordic Neuroendocrine Tumor Group's current view on how to diagnose and treat lung NEN-patients and are meant to be useful in the daily practice for clinicians handling these patients. (lu.se)
  • Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes. (rush.edu)
  • CT scan image of the right lung tumor (red arrow) extending to the three lobes with interbronchial lymph nodes. (hindawi.com)
  • Histological examination revealed a combined lung tumor appearance with a predominant component (80%) consisting of a small cell neuroendocrine carcinoma associated with a solid adenocarcinomatous component, with massive infiltration of the lung, rupture of the visceral pleura, and extension to parietal fat tissue but with free surgical margin at this level and without sarcomatoid component. (hindawi.com)
  • Immune-related response criteria (irRC) were developed based on experience with ipilimumab (anti-cytotoxic T-cell lymphocyte-4) in melanoma to better capture the response to CIT per changes in tumor biology and the long-termeffects of CITon solid tumors and to enable additional adaptations as the field evolved. (medscape.com)
  • Lung tissue that was scarred by a disease or infection, such as scleroderma or tuberculosis , becomes at risk for tumors in that tissue. (webmd.com)
  • Antibodies against the vascular-endothelial growth factor receptor (VEGFR) are efficient in non-squamous cell tumors [ 1 ]. (biomedcentral.com)
  • Is the Subject Area "Lung and intrathoracic tumors" applicable to this article? (plos.org)
  • Squamous cell carcinomas are usually found in the center of the lung next to an air tube (bronchus). (medlineplus.gov)
  • Eighteen patients with histologically documented small cell carcinoma of the lung who had failed initial combination chemotherapy regimens were treated with single-agent cisplatin in a dose of 100 mg/m 2 every 3 weeks, with mannitol and fluid diuresis. (elsevierpure.com)
  • However, most lung adenocarcinomas either lack an identifiable driver oncogene, or harbour mutations in KRAS and are therefore still treated with conventional chemotherapy. (nature.com)
  • 1. Get familiar with the new classification of lung adenocarcinomas. (jefferson.edu)
  • Adenocarcinomas are often found in an outer area of the lung. (medlineplus.gov)
  • Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. (nature.com)
  • Renal cell carcinoma (RCC) incidence has increased over the past two decades. (hindawi.com)
  • Renal cell carcinoma (RCC) accounts for approximately 3% of human malignancies, and its incidence appears to be increasing globally [ 1 ]. (hindawi.com)
  • although it is derived from cells of the renal tubular epithelium, it has several histological subtypes which differ in their clinical outcome and biological features. (hindawi.com)
  • His interests are in Non-small cell lung carcinoma, radiation induced lung injury and idiopathic pulmonary fibrosis. (jefferson.edu)
  • 4). Although some earlier studies failed to detect the with universal distribution and pulmonary tropism, and organism in postmortem lung samples or bronchoalveolar each species has a strong specificity for a given mam- samples from immunocompetent adults (20,21), a recent malian host species (3,4). (cdc.gov)
  • IPDA for H&E/mucin/IHC diagnoses with the 2015 World Health Organization classification is similar for community and academic pathologists, and is higher when pathologists have pulmonary pathology expertise, have more than 6 years of practice experience, or diagnose more than 100 new lung carcinoma cases per year. (duke.edu)
  • EBUS-GS is a useful method for collecting samples from peripheral pulmonary lesions, even those too small to be visualized under fluoroscopy. (nih.gov)
  • Squamous cell carcinoma can also spread to the lymph nodes, bones, and other organs such as the liver. (webmd.com)
  • A history of radiation therapy to the lungs can also increase risk. (medlineplus.gov)
  • Currently, the only exception to this recommendation occurs in cases where anaplastic large cell lung carcinoma (LCLC) is the second histological component. (wikipedia.org)
  • Treatment of recurrent small cell lung carcinoma with vindesine and cisplatin. (nih.gov)
  • The antitumor efficacy of high-dose cisplatin in heavily pretreated patients with small cell carcinoma of the lung appears to be marginal. (elsevierpure.com)
  • By definition, pseudomesotheliomatous carcinoma refers to an epithelial neoplasm that secondarily involves the pleura and encases the lung, thereby simulating the radiologic and macroscopic appearance of malignant mesothelioma. (medscape.com)
  • Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. (nih.gov)
  • High gene copy numbers per cell showed a trend toward poor prognosis. (nih.gov)
  • He presented with paraplegia due to spinal metastases of the bronchial carcinoma. (biomedcentral.com)
  • Here, we report the case of a 16-year-old boy with a non-small cell, squamous cell bronchial carcinoma T4N2M1 initially presenting with paraplegia due to spinal metastases. (biomedcentral.com)
  • Three cases of carcinomas, including a bronchial carcinoma, had been observed in grandparents and an aunt. (biomedcentral.com)
  • Other particles may be engulfed by epithelial cells, primarily in the vicinity of the bronchial-alveolar duct junctions, and retained for much longer periods, with gradual removal to lymph nodes. (cdc.gov)
  • Pathologic examination revealed a pT2 undifferentiated carcinoma with a sarcomatoid component involving all layers of the jejunum and expressing only cytokeratin 7. (hindawi.com)
  • Treating lung tumours at an early stage is crutial to prevent the disease from spreading to other thoracic areas. (mypremiumeurope.com)
  • Here, we show that genetic inactivation of Usp28 induced regression of established murine LSCC lung tumours. (ox.ac.uk)
  • We report on a 16-year-old Caucasian German boy with non-small cell lung carcinoma (squamous cell non-small cell lung carcinoma) stage IV, T4N2M1, without epidermal growth factor receptor overexpression and/or mutation or k-ras mutation. (biomedcentral.com)
  • Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel. (bvsalud.org)
  • RESEARCH patients with different chronic lung diseases (25,26). (cdc.gov)
  • A subsequent thoracic CT scan was performed to complete the extension report, which showed a polylobed mass extending to the three lobes of the right lung measuring 6 cm, with right interbronchial lymph nodes (Figure 2 ). (hindawi.com)
  • Mice homozygous for disruptions in this gene display abnormalities in cell:cell adhesion involving epithelial cells. (jax.org)
  • The diagnostic work-up and treatment of patients with lung- NEN has undergone major recent advances and new methods are currently being introduced into the clinic. (lu.se)
  • This review reflects our view of the current state of the art of diagnosis and treatment of patients with lung-NEN. (lu.se)
  • Thus, USP28 may represent a promising therapeutic target for the treatment of squamous cell lung carcinoma. (ox.ac.uk)
  • USP28 deletion and small molecule inhibition destabilises c-MYC and elicits regression of squamous cell lung carcinoma. (ox.ac.uk)
  • In most cases, a piece of tissue is removed from your lungs for examination under a microscope. (medlineplus.gov)
  • Lung squamous cell carcinoma (LSCC) is a considerable global health burden, with an incidence of over 600,000 cases per year. (ox.ac.uk)
  • Overlapping lung and pleural involvement in individual cases has given rise to the more inclusive term "pleuropulmonary" synovial sarcoma. (medscape.com)